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Summary 
N-arachidonoyletanolamine (AEA) and 2-arachidonoylglycerol (2-AG) are the most 
representative members of a class of endogenous ligands named endocannabinoid, 
which are able to activate cannabinoids receptors. The endocannabinoid 
neuromodulation plays important roles in various aspects of neural functions 
including learning and memory, anxiety, depression, appetite and feeding behavior, 
nociception, neuroprotection and movement control. Since 2-AG has been considered 
the true on-demand released endocannabinoid ligand for CB1 receptor, a promising 
way to explore and promote its therapeutic potential could be the selective inhibition 
of the monoacylglycerol lipase (MGL), the enzyme responsible of 2-AG degradation. 
Three critical residues of cysteine have been identified as regulatory gates for the 
activity of the enzyme: Cys242, within the active site close to the catalytic triad, Cys201 
and Cys208 located on the lid domain, a flexible solvent-exposed region that regulate 
the access of the substrate to the active site. Cys201 and Cys208 have been recently 
shown to be redox switches that regulate the activity of MGL by undergoing oxidation 
after oxidative stimulus induced by hydrogen peroxide. 
Despite the potential of MGL as target for 2-AG signaling modulation, few potent and 
selective MGL inhibitors are available until now. Recently two class of partially-
reversible MGL inhibitors has been reported: one is populated by covalent disulfide-
bond forming compounds such as isothiazol-3(2H)-one (ITZ) and benzo[d]isothiazol-
3(2H)-one (BTZ) derivatives, the second one is populated by triterpenes such as euphol 
and pristimerin. Both these classes of compounds interact with critical residues Cys201 
and Cys208 of MGL thus preserving the catalytic activity of the enzyme. The 
modulation of MGL activity by interaction with these critical cysteine residues is a 
crucial point to fine tune the 2-AG signaling avoiding behavioral side-effects 
associated to the total disruption of the catalytic activity of MGL exerted by inhibitors 
addressing the catalytic site. 
 
The research work reported in this PhD dissertation has been focused on the 
exploration of the structure-activity relationships (SAR) around the BTZ warhead in 
order to explore the pharmacophoric space around the targeted cysteines of MGL. 
  II 
The structure of the driver portion (blue labeled) of compounds sharing an identical 
warhead (red labeled) has been broadly changed. I 
investigated the effect of substituent groups with 
different steric demand and electronic inductive effects 
on the nitrogen atom and the substituents on the phenyl 
ring of BTZ.  
I performed the design and the synthesis of several compounds, applying different 
synthetic strategies.  
The inhibitory potency of synthesized BTZs on MGL and was evaluated and SAR of 
this class were described. We identified promising compounds with inhibitory potency 
on MGL in the low nanomolar range. Moreover, the lead compound emerged from 
this screening was subjected to mechanistic studies that revealed a behavior similar to 
that of hydrogen peroxide in inactivating MGL supporting the theory that BTZs mimic 
the effect of an endogenous oxidation stimulus. To further elucidate the role of critical 
Cys201 and Cys208 in MGL activity, site-directed mutagenesis studies were performed 
identifying both cysteines as possible counterpart in the interaction with BTZs. 
Moreover, in order to evaluate the stability and reactivity of these compounds towards 
biological thiols we investigated, trough analytical methods the effect of substituent 
groups with different steric hindrance and electronic effects on the sulfenamidic 
reactive core of BTZ. I investigated by means of NMR experiments the reactivity of 
selected BTZs with a model biological thiol, N-acetyl cysteine (NAC). These studies 
allowed us to define a structure-reactivity relationship landscape that further validated 
our biological results. 
 
To increse the knolewdge in the field of the terpene-based inhibitors of MGL, I 
synthesized 3 new compounds starting form commercially available celastrol: these 
scaffold modifications led to less active compounds than reference compound 
pristimerin thus discouraging the development of triperpene-based MGL inhibitors. 
 
Fibroblast growth factor-2 (FGF2) is a member of a large family of proteins that bind 
heparin and heparan sulfate and modulate the function of a wide range of cell types. 
FGF2 stimulates the growth and development of new blood vessels (angiogenesis) that 
contribute to the pathogenesis of several diseases (i.e. cancer, atherosclerosis), normal 
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wound healing and tissue development. FGF2 exerts its activity on endothelial cells by 
interacting with high affinity tyrosine-kinase FGF receptors (FGFRs) and low affinity 
heparan sulphate proteoglycans (HSPGs), leading to the formation of productive 
HSPG/FGF2/FGFR ternary complexes. Presta and coworkers identified, from a virtual 
screening study of an NCI library, a promising molecule NSC172288 able to inhibit 
FGF2-FGFR interactions. During my PhD research I designed and performed the 
synthesis of this compound not described in literature. The major challenge associated 
was the necessity of planning the synthesis on the base of a poorly described structure. 
A synthetic pathway for NSC172285 was setup and an efficient method for using HFA 
trihydrate as electrophilic partner in an aldol reaction, with standard laboratory 
equipment was developed. 
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Sommario 
N-arachidonoiletanolammina (AEA) e 2-arachidonoilglicerolo (2-AG) sono i membri 
più rappresentativi di una classe di ligandi endogeni chiamati endocannabinoidi in 
grado di attivare i recettori cannabinoidi. La neuromodulazione del sistema 
endocannabinoide regola numerose funzioni neurali che comprendono memoria e 
apprendimento, stati d’ansia, depressione, regolazione dell’appetito e di 
comportamenti legati alla nutrizione, nocicezione, neuroprotezione e controllo del 
movimento. Essendo il 2-AG il più abbondante tra i ligandi endocannabinoidi per il 
recettore CB1, una promettente strategia per esplorare e promuovere il suo potenziale 
terapeutico risiede nell’inibizione selettiva dell’enzima monoacilglicerol lipasi (MGL) 
deputato alla degradazione metabolica del 2-AG. MGL presenta tre cisteine regolatorie 
fondamentali per la sua attività: Cys242, all’interno del sito attivo vicina alla triade 
catalitica, Cys201 e Cys208 posizionate sul lid domain, una regione flessibile ed esposta 
al solvente che regola l’accesso del substrato al sito attivo. Inoltre, queste due cisteine 
sono state recentemente identificate come sensori redox in grado di regolare l’attività 
di MGL ossidandosi in risposta allo stimolo ossidativo esercitato dal perossido 
d’idrogeno. Nonostante il grande potenziale di MGL come target per la modulazione 
del segnale stimolatorio del 2-AG sui recettori cannabinoidi, pochi inibitori selettivi 
per MGL sono attualmente disponibili. Recentemente due classi di inibitori 
parzialmente-reversibili sono state identificate: la prima classe è popolata da composti 
in grado di formare ponti disolfuro generando addotti covalenti come iso- (ITZ) e 
bezisotiazolinoni (BTZ), mentre la seconda classe è popolata da triterpeni come eufolo 
e pristimerina. Entrambe queste classi interagiscono con le cisteine critiche 201 e 208 
dell’enima preservando quindi l’attività catalitica di MGL. La modulazione dell’attività 
di MGL utilizzando composti in grado di interagire con queste cisteine regolatorie è un 
punto cruciale per ottenere una fine regolazione dei livelli di 2-AG evitando gli effetti 
collaterali a livello comportamentale che si manifestano in seguito alla totale inibizione 
dell’attività catalitica di MGL tipica degli inibitori che colpiscono il sito attivo. 
 
Il lavoro di ricerca riportato in questa tesi di dottorato è stato focalizzato 
sull’esplorazione delle relazioni struttura-attività (SAR) intorno alla warhead a base 
benzisotiazolinonica in modo da esplorare lo spazio farmacoforico intorno alle cisteine 
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critiche di MGL. La struttura della driver portion (evidenziata in blu) è stata 
ampiamente modificata investigando l’effetto di 
sostituenti con diverse proprietà elettroniche e steriche 
sia sull’azoto sulfenamidico che sull’anello benzenico 
del nucleo benzisotiazolinonico.  
Ho ideato e sintetizzato numerosi composti applicando 
diverse strategie sintetiche. 
È stata quindi valutata la potenza inibitoria su MGL dei BTZs sintetizzati e sono state 
descritte le SAR per questa classe di composti. Abbiamo identificato composti 
promettenti in grado di inibire MGL con potenze nel range del basso nanomolare. 
Inoltre, il lead compound emerso da questo screening è stato sottoposto a dettagliati 
studi meccanicistici rivelando un comportamento inibitorio simile a quello esercitato 
dall’acqua ossigenata corroborando la teoria che questa classe di composti inibisca 
MGL mimando l’azione di uno stimolo ossidativo endogeno. Per chiarire meglio il 
ruolo delle cisteine critiche 201 e 208 sono stati eseguiti studi di mutagenesi sito- 
specifica che hanno mostrato come entrambe le cisteine siano coinvolte nel 
meccanismo di inibizione di questa classe di composti. 
Inoltre, per valutare la stabilità e la reattività di questi composti verso tioli di rilevanza 
biologica, abbiamo investigato con metodi analitici gli effetti dei diversi sostituenti 
sulla reattività del nucleo sulfenamidico. Per mezzo di esperimenti condotti all’NMR 
ho studiato la reattività di alcuni BTZs selezionati verso un tiolo biologico modello, la 
N-acetilcisteina (NAC) permettendo di definire una scala di relazione struttura-
reattività che ha ulteriormente validato i risultati biologici ottenuti . 
 
Durante il mio periodo di dottorato ho investigato la possibilità di apportare modifiche 
strutturali allo scaffold della pristimerina sintetizzando tre nuovi composti partendo 
dal prodotto commerciale celastrolo, in modo esplorare le SAR per questa classe di 
inibitori di MGL. I derivati sintetizzati sono risultati essere meno attivi del composto di 
riferimento, scoraggiando lo sviluppo di nuovi inibitori a base triterpenica. 
 
Il fattore di crescita 2 dei fibroblasti (FGF2) è un membro di una larga famiglia di 
proteine che legano l’eparina e l’eparan solfato e modulano le funzionalità di un ampio 
numero di cellule. FGF2 stimola la crescita e lo sviluppo di nuovi vasi sanguigni 
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(angiogenesi) che possono contribuire alla patogenesi di numerose disfunzioni (cancro, 
aterosclerosi), la normale guarigione delle ferite e lo sviluppo dei tessuti. FGF2 esercita 
la sua attività sulle cellule endoteliali interagendo con elevata affinità con recettori 
tirosin-chinasici (FGFRs) e con bassa affinità con proteogligani formando dei 
produttivi complessi ternari HSPG/FGF2/FGFR. Il gruppo di ricerca del Prof. Presta 
ha individuato, da un virtual screening di una libreria di composti NCI, un 
promettente inibitore NSC172285 in grado di bloccare l’interazione tra FGF2 e FGFR. 
Durante il periodo di ricerca ho pianificato e portato a termine la sintesi di questo 
composto finora mai descritta in letteratura. La maggiore difficoltà incontrata è stata 
quella di intraprendere una campagna sintetica sulla base di una formula di struttura 
del composto di riferimento non propriamente chiara. Il prodotto desiderato è stato 
sintetizzato utilizzando l’esafuoroacetone (HFA) triidrato come partner elettrofilo in 
una reazione aldolica, svuluppando un metodo efficace per la sua disidratazione e la 
generazione in situ di HFA allo stato gassoso. 
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Chapter 
1 
 
 
 
The endocannabinoid 
system 
 
 
Marijuana, or cannabis, is the most widely used illicit drug in Western societies and 
also the one with the longest recorded history of human use. The popularity of 
marijuana as a recreational drug is due to its ability to alter sensory perception and 
cause elation and euphoria, most vividly described by the 19th century French poet, 
Charles Baudelaire, in his book Les Paradis Artificiels1. However, the ability of extracts 
of the hemp plant (Cannabis sativa) to cause a variety of medicinal effects unrelated to 
its psychoactive properties had been recognized as early as the third millennium BC, 
when Chinese texts described its usefulness in the relief of pain and cramps2. In 
ancient India, the anxiety-relieving effect of bhang (the Indian term for marijuana 
ingested as food) had been recorded more than 3000 years ago. The use of cannabis or 
hashish as a psychoactive substance reached Europe and the Americas through the 
Arab world in the 19th century. During the same period, cannabis extracts had gained 
widespread use for medicinal purposes until 1937, when concern about the dangers of 
abuse led to the banning of marijuana for further medicinal use in the United States. 
The impediments to the development of cannabinoid medications has been the socially 
unacceptable psychoactive properties of plant-derived preparations and the, sometime 
misleading, information spread to block the diffusion of hemp for industrial 
applications. The rather turbulent history of marijuana and the recent resurgence of 
interest in its medicinal properties have been the subject of extensive researches. 
Added to this interest is the emergence of the endocannabinoid system (ECS), offering 
not only new insights into the mechanisms underlying the therapeutic actions of plant-
derived phytocannabinoids but also novel molecular targets for pharmacotherapy. 
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This chapter will provide a brief overview on the current state of knowledge of the 
endocannabinoid system as a target of pharmacotherapy3. 
 
 
1.1  Endocannabinoid system: the “early” view 
Up until the last two decades, marijuana research was a rather esoteric field, of interest 
to a small number of scientists. A contributory factor was the highly lipophilic nature 
of the biologically active ingredients, which led to the notion that marijuana elicits its 
effects non-specifically by perturbing membrane lipids 4 . The first important 
breakthrough in the discovery of its actual mechanism of action was the identification 
in 1964 by Gaoni and Mechoulam5 of the correct chemical structure of the main 
psychoactive ingredient of marijuana, Δ9-tetrahydrocannabinol (THC), and the 
subsequent demonstration that bioactivity resides in the L-stereoisomer of this 
compound6, which is one of the approximately 60 cannabinoids present in the plant7. 
Cannabinoid compounds isolated from the plant Cannabis sativa comprise a family of 
tricyclic ring structures characterized by a phenol ring having a 5-carbon alkyl chain 
meta to the hydroxyl, a central pyran ring, and a mono-unsaturated cyclohexyl ring8 
(Figure 1.1).  
 

Figure 1.1 The chemical structure and pharmacological activity of selected plant derived cannabinoids 
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Studies of the biological effects of THC and its synthetic analogs9,10 revealed strict 
structural selectivity as well as stereoselectivity 11, telltale signs of drug-receptor 
interactions and turned out to be of key importance in the subsequent identification of 
an orphan G protein-coupled receptor (GPCR) as the brain receptor for cannabinoids 
later named CB1 receptor. CB1 receptor was cloned in Tom Bonner’s laboratory in 
199012 and 3 years later Sean Murno discovered CB2 receptors13. These events were 
crucial steps for the definition of the ECS as a complex regulatory biochemical 
apparatus constituted by cannabinoid receptors, their endogenous ligands, and the 
catabolic and anabolic enzymes deputated to the regulation of endocannabinoids 
signaling. 
 
 
1.2 Cannabinoid receptors  
The cannabinoid receptor subtypes characterized so far, CB1 and CB2, belong to the 
superfamily of G-protein-coupled membrane receptors (GPCRs). The two cannabinoid 
receptors exhibit 48% amino acid sequence identity at the protein level or 68% in the 
trans-membrane domains, which are thought to contain the binding sites for 
cannabinoids. Both receptor types are coupled through G proteins to adenylyl cyclase 
and mitogen-activated protein kinase (see below). It was originally believed that the 
CB1 receptor was expressed mainly in the central nervous system (CNS), and hence it 
was considered a brain cannabinoid receptor. We are now aware that it is present in 
numerous peripheral organs, although in some of them the receptor levels are low. CB1 
receptors are among the most abundant GPCRs in the brain. The highest densities of 
CB1 receptors, in the rodent brain, are noted in the basal ganglia, substantia nigra, 
globus pallidus, cerebellum, and hippocampus, but not in the brainstem. CB1 receptors 
appear to be involved in γ- aminobutyric acid (GABA) and glutamate 
neurotransmission, as they are found on GABAergic and glutamatergic neurons. The 
CB1 receptors are found primarily on central and peripheral neurons in the 
presynapse. These locations facilitate their inhibition of neurotransmitter release, 
which is one of the major functions of the endocannabinoid system. 
The second cannabinoid GPCR, CB2, is expressed primarily in cells of the immune and 
hematopoietic systems but recently were found to be present in the CNS14, though at 
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lower levels than those of the CB1 receptors, in non-parenchymal cells of the cirrhotic 
liver 15 , in the endocrine pancreas 16 , and in bones 17 . Under some pathological 
conditions, CB2 receptor expression is enhanced in the CNS as well as in other tissues. 
It seems possible that the CB2 receptor is part of a general protective system (for a 
review, see Pacher & Mechoulam18).  
Functional stimulation of CB1/CB2 by endogenous or exogenous cannabinoids 
triggers, via activation of heterotrimeric Gi/o proteins, those intracellular signaling 
events that are normally coupled to these two GPCRs19. As a consequence of this 
preferential coupling, activation of cannabinoid receptors primarily leads to the 
inhibition of adenylyl cyclase and reductions in cAMP accumulation in most tissues 
and models. In addition, both the CB1 and CB2 cannabinoid receptors regulate the 
phosphorylation and activation of different members of the family of mitogen-
activated protein kinases (MAPKs), including extracellular signal-regulated kinase-1 
and -2 (ERK1/2), p38 MAPK and c-Jun N-terminal kinase (JNK). In addition, CB1 
cannabinoid receptors can negatively couple to N- and P/Q-type voltage-operated 
Ca2+ channels and positively couple to A-type and inwardly rectifying K+ channels. 
The CB1 cannabinoid receptor may also induce elevations in intracellular Ca2+ through 
G protein-dependent activation of phospholipase C- (PLC-)20 (Figure 1.2). The 
implication of MAPK cascades in the regulation of cell survival/death and glucose 
metabolism by cannabinoids, or the involvement of cannabinoid-controlled ionic 
currents in the regulation of neurotransmitter release are typical examples revealing 
that biological activities modulated by cannabinoid receptors are supported by 
complex signaling cascades. While the classical view of GPCR signaling was initially to 
describe these receptors as simple on/off switches for the multiple intracellular 
cascades, recent studies have clearly indicated that they are extremely versatile 
signaling molecules governing complex intracellular responses. Indeed, research over 
the past decade has led to growing evidence for additional, unrelated mechanisms 
increasing the repertoire and the complexity of GPCR-associated signaling pathways. 
These include: (i) the ability of the receptor to couple with distinct G proteins, (ii) the 
interaction with GPCR-modifier proteins or with lipid raft domains to control receptor 
signaling or trafficking, (iii) the variety of desensitization mechanisms to limit signal 
duration/amplitude, (iv) or the oligomerisation of GPCRs into organized novel 
signaling unit.  
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Figure 1.2 Complexity at cannabinoid receptor signaling 
 
Both CB1 and CB2 cannabinoid receptors are associated with Gαi/o-dependent inhibition of adenylyl cyclase 
activity and Gβγ-dependent activation of the different MAPK cascades (A). CB1 cannabinoid receptor 
negatively regulates voltage-gated Ca2+ channels, positively regulates inwardly rectifying K+ channels and 
induces elevation of intracellular free Ca2+ through Gβγ-dependent activation of PLC. Cross-talks between 
signaling pathways are illustrated by the variety of responses requiring cannabinoid-mediated inhibition of 
PKA. Reduction of PKA activity is related to a reduction of gene expression through decreasing cAMP 
response element (CRE) activity. Reduction of PKA activity leads to a decrease in constitutive inhibitory 
phosphorylation of c-Raf and a consecutive activation of ERK1/2. Similarly, reduction of voltage-
dependent K+ A channel and focal-adhesion kinase (pp125 FAK and FRNK) phosphorylation through 
inhibition of PKA lead to activation of these different effectors. Besides, it is now demonstrated that 
activation of CB1 cannabinoid receptors also leads to activation or Gs and Gq proteins (B). In addition the 
CB1 cannabinoid receptor also signals trough non-G protein partners such as the adaptor protein FAN. 
Preferential activation of different intracellular effectors by each G protein contributes to diversity and 
selectivity of responses regulated by cannabinoid receptors. 
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1.3 Endocannabinoids 
The existence of specific receptors in mammalian cells that recognize a plant-derived 
substance rekindled the question raised two decades earlier, after brain receptors for 
morphine had been first described, i.e., is there an endogenous ligand? A positive 
answer was provided in 1992 by the report by Devane et al.21 describing the isolation 
from porcine brain of the lipid arachidonoyl ethanolamide, named anandamide (AEA) 
(Figure 1.3), which binds the brain cannabinoid receptor with reasonably high affinity 
and mimics the behavioral actions of THC when injected into rodents. Three years 
later a second endocannabinoid, 2-arachidonoylglycerol (2-AG), was discovered 
independently by Mechoulam et al.22 and Sugiura et al.23. Since then, a number of 
related endogenous lipids with endocannabinoid-like activity have been reported 
(Figure 1.3), but follow-up studies about biosynthesis, cellular transport, metabolism, 
and biological function have focused on AEA and 2-AG, with much less information 
available about the other compounds with endocannabinoid-like properties.  
 
 
Figure 1.3 The chemical structure and pharmacological activity of endogenous cannabinoids 
 
AEA is a partial or full agonist at CB1 receptors, depending on the tissue and biological 
response measured. Although it also binds CB2 receptors, it has very low efficacy and 
may act as an antagonist. 2-AG exert its action as full agonist both at CB1 and CB2 
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receptors. Any molecule acting as an endogenous mediator of physiological and 
pathological responses needs mechanisms for its biosynthesis and, following its action 
on specific molecular targets, for its inactivation. Based on original observations 
carried out with AEA24, it was postulated that this endocannabinoid is not stored in 
resting cells but is, instead, synthesized and released “on demand” following 
physiological and pathological stimuli. This mechanism holds true also for 2-AG, 
which apart from being an endocannabinoid is also an intermediate in 
(phospho)glyceride metabolism. In general, pharmacological and electrophysiological 
data have shown that both Ca2+ influx and activation of some metabotropic receptors, 
either cooperatively or independently, can induce the formation of endocannabinoids 
acting as retrograde synaptic signals25. After their biosynthesis, AEA and 2-AG are 
immediately released into the extracellular milieu via a mechanism still unknown, 
which could be dependent on the same putative membrane transporter, proposed to 
underlie endocannabinoid cellular uptake (see below). Endocannabinoids such as AEA 
may also act on intracellular sites of ion channels, such as those of vanilloid TRPV1 
receptors and T-type Ca2+ channels.  
The termination of the action of the endocannabinoids on extracellular targets is 
achieved through their reuptake by cells, a process that can be facilitated by yet-to-be-
characterized membrane transporters, usually followed by one or more enzymatic 
reactions. 
 
 
1.3.1 Regulation of the endocannabinoid signal: formation 
The metabolic pathways of the class of lipids to which AEA belongs, the N-
acylethanolamines, have been investigated since the 1960s. Work performed by 
Schmid's group 26  had shown that these compounds are biosynthesized via a 
phospholipid-dependent pathway (Figure 1.4), that is the enzymatic hydrolysis of the 
corresponding N-acyl-phosphatidylethanolamines (NAPEs). The enzyme catalyzing 
this reaction is a phospholipase D (PLD) selective for NAPEs (NAPE-PLD) with low 
affinity for other membrane phospholipids. NAPEs, in turn, are produced through the 
acyl transfer from the sn-1 position of phospholipids to the N-position of 
phosphatidylethanolamine (PE), catalyzed by a Ca2+-dependent trans-acylase. Neither 
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the PLD nor the trans-acylase appeared to exhibit any selectivity for a particular fatty 
acid moiety. However there may be parallel pathways for the generation of 
anandamide from NAPE. A secretory PLA2 that can catalyze the hydrolysis of N-acyl-
PE to N-acyl-lysoPE, which is then acted on by a lysoPLD to generate N-acyl-
ethanolamides, including anandamide, was recently identified in the stomach 27 . 
Another route has been proposed for AEA biosynthesis, although only in cell-free 
systems, consisting of the ATP- and coenzyme A-independent condensation of free 
arachidonic acid and ethanolamine catalyzed by a “synthase”.  
The levels of 2-AG in unstimulated tissues and cells are usually much higher than 
those of AEA, and are sufficient in principle to permanently activate both cannabinoid 
receptor subtypes23,28. At any rate, the 2-AG found in cells and tissues is probably not 
uniquely used to stimulate cannabinoid receptors, as this compound is at the 
crossroads of several metabolic pathways, and is an important precursor and/or 
product of phospho-, di- and tri-glycerides, as well as of arachidonic acid. It is likely 
that a particular pool of 2-AG is produced via a special pathway only for the purpose 
of functioning as endocannabinoid. Of the several possible biosynthetic pathways 
known for 2-AG formation 29 , those routes leading to the synthesis of an 
endocannabinoid should be Ca2+ dependent since the de novo formation of 2-AG, like 
for AEA, is induced in neurons by membrane depolarization30. Several stimuli have 
been shown to lead to the formation of 2-AG in intact neuronal and non-neuronal 
cells31, but only seldom the pathways for 2-AG biosynthesis have been investigated. In 
most cases (Figure 1.4), 2-AG is produced from the hydrolysis of 2-arachidonate-
containing diacylglycerols (DAGs) catalyzed by an sn-1-selective DAG lipase (sn-1 
DAGL). DAGs serving as 2-AG precursors can be produced in turn from the 
hydrolysis of 2-arachidonate-containing phosphatidic acid (PA), catalyzed by a PA 
phosphohydrolase, or of phosphoinositides (PI), catalyzed by PI-selective 
phospholipase C (PI-PLC). Two sn-1 DAGL isozymes have been cloned and 
enzymatically characterized32. In summary, while a rather specific, albeit non-selective, 
pathway leads to AEA biosynthesis, several different mechanisms seem to underlie 2-
AG formation in cells. It is possible that only a minor part of the 2-AG produced by 
stimulated cells is used to activate cannabinoid receptors. 
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Figure 1.4 Biosynthetic pathways for anandamide and 2-arachidonyl glycerol.  
Dark grey panel: AEA biosynthesis. Light grey panel: 2-AG biosynthesis. 
 
 
1.3.2 Regulation of the endocannabinoid signal: inactivation 
The first step in the endocannabinoids inactivation consists of their being rapidly (t1/2 ≤ 
5 min) cleared away from their extracellular molecular targets. Being lipophilic in 
nature, endocannabinoids can diffuse through the plasma membrane if their amount in 
the extracellular milieu is higher than their intracellular concentration. This process is 
driven by trans-membrane concentration gradient, is saturable and temperature-
dependent, and does not require ATP or sodium ions. However, in order to be rapid, 
this process needs to be driven by controllable and selective mechanisms, such as 
either a membrane transporter protein, or an intracellular enzymatic process capable of 
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rapidly reducing the intracellular concentration of the two compounds, or both (Figure 
1.5). Indeed, AEA and 2-AG are taken up by cells via selective, saturable, temperature-
dependent and Na+-independent “facilitated transport” mechanisms, known as the 
endocannabinoids membrane transporter(s) (EMT)33. Once inside the cells, AEA and 2-
AG are immediately degraded to arachidonic acid and ethanolamine or glycerol, 
respectively, through the enzymatic hydrolysis of their amide/ester bonds34 (Figure 
1.5). The enzyme responsible for AEA hydrolysis, originally named “anandamide 
amidohydrolase” or “amidase” has been discovered by Daniele Piomelli 35  and  
thoroughly studied by Cravatt et al.36, who had purified and cloned the enzyme that 
was named “fatty acid amide hydrolase” (FAAH) in view of its ability to catalyze the 
hydrolysis of at least two distinct classes of bioactive fatty acid amides. FAAH has a 
molecular weight of ~ 65 kDa and a pH optimum of ~ 9 in vitro. Mutagenesis and 
chemical labeling studies, as well as the X-ray crystal structure have indicated that 
FAAH is a serine hydrolase with three catalytically essential amino acid residues 
Ser241/Ser217/Lys14237. Immunocytochemical studies in rat brain have revealed that 
FAAH is expressed at high levels in several brain regions, especially in the neurons of 
the hippocampus, cerebellum, neocortex and olfactory bulb38 . These same brain 
regions are also enriched with CB1 receptors. However, the CB1 receptors are mainly 
pre-synaptic, whereas FAAH localizes to dendrites of postsynaptic neurons. The 
unique role of FAAH in terminating signaling by AEA was indicated by the phenotype 
of FAAH knockout mice, which displayed 10 to 15 times elevated levels of AEA across 
the brain. Anandamide is also sometimes metabolized by other intracellular enzymes 
such as palmitoylethanolamide-preferring acid amidase (PAA), N-acylethanolamine 
acid amidase39 and type-2 fatty acid amide hydrolase40. Other enzymes that can 
metabolize AEA are cyclooxygenase-2, lipoxygenases, and cytochrome P45041.  
To date, four enzymes responsible of 2-AG hydrolysis have been characterized at the 
molecular level: FAAH (responsible of 2% of total 2-AG hydrolysis), 42  serine 
hydrolases ABHD12 and ABHD6 (responsible of 4% and 9% of total 2-AG hydrolysis, 
respectively)42,43 and monoacylglycerol lipase (MGL) considered as main actor in the 
degradation process of 2-AG44. 
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Figure 1.5 Catabolism of AEA and 2-AG. 
 
MGL is a cytosolic serine hydrolase that cleaves medium- and long-chain 
monoacyglicerols into fatty acids and glycerol, with the highest rate for arachidonic 
acid.45 MGL is 33 kDa protein belonging to α/β hydrolase family of enzymes46 that 
exerts its hydrolyzing activity through a Ser122/His269/Asp239 catalytic triad. MGL 
is abundant in brain regions with high cannabinoid CB1 receptor density, such as the 
hippocampus, but, unlike FAAH, it occurs in presynaptic neurons and is likely to be 
co-expressed with CB1 receptors47. MGL is the central topic of this PhD dissertation 
and will be exhaustively discussed in the next chapter (see Chapter 2). 
  
Several pathways may contribute to the inactivation of the two endocannabinoids once they have diffused 
through the cell membrane. Both hydrolysis of the amide bond and oxidation catalyzed by enzymes of the 
AA cascade have been proposed for anandamide. As to 2-AG, hydrolysis of the ester bond and esterification 
into phosphoglycerides or neutral glycerolipids have been found to occur in intact cells. FAAH plays a key 
role in the inactivation of both metabolites. AA produced from the hydrolysis of endocannabinoids is 
immediately reincorporated into membrane phospholipids. 
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1.4 The endocannabinoid system as therapeutic target 
The ECS might serve important regulatory functions in physiological processes; thus, 
cannabinoid agents might prove useful in the treatment of pathological conditions that 
are associated with such processes. 
The previous knowledge of THC pharmacology and, most importantly, recent studies 
carried out by using pharmacological, biochemical, analytical and genetic approaches 
are revealing several possible functions of endocannabinoid signaling under both 
physiological and pathological conditions. Modulating the activity of the ECS holds 
therapeutic promise for a broad range of diseases, including neurodegenerative, 
cardiovascular and inflammatory disorders, obesity/metabolic syndrome, cachexia, 
chemotherapy-induced nausea and vomiting and tissue injury and pain, amongst 
others (for reviews see ref. 3,48 and references therein). 
Despite the ubiquitous expression of the various components of the ECS, their genetic 
ablation or pharmacological blockade in normal, healthy animals has minimal 
functional consequences. On the other hand, an increase or decrease in ECS tone is 
associated with various pathological states, as a result of the altered expression of CB 
receptors, endocannabinoid metabolizing enzymes and/or synthetic pathways, in a 
tissue-specific and time-dependent manner. In some cases, altered ECS activity is 
transient and forms part of the body's compensatory response to a particular insult, 
thus reducing symptoms and/or slowing progression of the disease (e.g. in 
neuropathic pain); in other cases, activation of the ECS may be pathogenic (e.g. in 
various forms of shock or diabetic complications) or may reflect a deficiency (e.g. in 
various tumors) of unknown significance. 
Several pharmacological tools for the study of the endocannabinoid system have been 
developed49. These tools can be grouped functionally into five super-families, i.e.: (i) 
“indirect” cannabinoid receptor agonists (i.e. inhibitors of endocannabinoid 
inactivation), (ii) “direct” cannabinoid receptor agonists, (iii) “indirect” antagonists of 
cannabinoid receptors (i.e. inhibitors of endocannabinoid biosynthesis), (iv) 
cannabinoid receptor inverse agonists and antagonists, and (v) cannabinoid receptor 
allosteric modulators.  
Clinical trials with CB1 antagonists in obesity/metabolic syndrome, and other studies 
with peripherally-restricted CB1/2 agonists and inhibitors of the endocannabinoid 
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metabolizing enzyme in pain, have introduced unexpected complexities, suggesting 
that a better understanding of the pathophysiological role of the endocannabinoid 
system is required to devise clinically successful treatment strategies.  
 
 
Figure 1.6 Cannabinoid therapeutics: finding the right balance 
 
Among this complex scenario of modulating access points for the ECS, inhibitors of 
AEA and 2-AG degradation offer a potentially attractive alternative strategy compared 
to direct stimulation of cannabinoid receptors 50 . Indeed, despite the structural 
similarity shared by AEA and 2-AG, distinct enzymes inactivate these lipids and thus 
serve as key points of control over specific endocannabinoid signaling events in vivo. 
Pharmacological studies have revealed that selective FAAH and MGL inhibitors 
produce an intriguing subset of the behavioral effects observed with direct CB1 
agonists, including analgesia in multiple acute and chronic pain models51. Importantly, 
several findings indicate that selective blockade of FAAH or MAGL can disassociate 
some of the beneficial and undesirable effects of CB1 activation. 
The ECS is emerging as a key player in several physiological and pathological 
mechanisms, in both central and peripheral tissues. As such, this system is likely to 
lead in the future to the development of new therapeutic tools targeting disorders that 
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have been so far poorly managed in the clinical practice. Numerous examples exist of 
how “direct” or “indirect” activation of cannabinoid receptors can either counteract or 
contribute to the symptoms and/or progress of different pathologies. Furthermore, 
endocannabinoids seem sometimes to participate with opposing effects and, 
correspondingly, molecules that either reduce or enhance endocannabinoid tone both 
produce beneficial effects in different phases of the same disease. 
Therefore, the most challenging task for medicinal chemists and the pharmacologists 
will be to devise ways to target this pleiotropic and “plastic” system in a selective, and 
hence, safe way, thus obtaining therapeutic drugs with more and more favorable 
benefit-to-risk profiles. 
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The endocannabinoid system is involved in processes as diverse as control of appetite, 
perception of pain and the limitation of cancer cell growth and invasion (see Chapter 
1). The enzymes responsible for endocannabinoids breakdown are attractive 
pharmacological targets, and fatty acid amide hydrolase inhibitors, which potentiate 
the levels of AEA, are now undergoing pharmaceutical development. “Druggable” 
selective inhibitors of monoacylglycerol lipase, the key enzyme regulating the levels of 
the other main endocannabinoid, 2-AG, were however not identified until very 
recently. Their availability has resulted in a large expansion of the knowledge 
concerning the pharmacological consequences of monoacylglycerol lipase inhibition 
(MGL) and hence the role(s) played by the enzyme in the body. In this chapter, the 
pharmacology of MGL will be discussed, together with an analysis of the state of 
knowledge about MGL inhibitors and the therapeutic potential of this key enzyme of 
the endocannabinoid system1.  
 
 
2.1 Characterization of MGL 
 
2.1.1  Structure of MGL 
MGL was purified in 1975 for the first time from rat-adipocyte tissue, and its molecular 
weight was estimated to be 32.9 kDa2. Some 20 years later, MGL was cloned for the 
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first time from a mouse-adipocyte cDNA library, and it was determined to be 
composed of 302 amino acids, in accord with a molecular weight of ca. 33 kDa3. The 
primary sequence of MGL was found to contain two lipase motifs: an active-site serine 
GXSXG sequence and the HG dipeptide. MGL has also been cloned from human 
adipocytes and rat brain, and found to contain 303 amino acids4,5. MGL shares a high 
degree of homology in mouse-, rat-, and human-MGL amino acid sequence. Thus, at 
the amino acid level, human and mouse MGL are 84% identical, and mouse and rat 
MGL are 92% identical. The three-dimensional structure of MGL has been recently 
elucidated by X-ray crystallography, and the enzyme has been shown to be a dimeric 
molecule with amphitropic properties that can exist both in a soluble form and 
associated with the membrane lipid bilayers6. MGL belongs to the α/β hydrolase fold 
family. The α/β hydrolase fold is organized as a core domain constituted of a β-sheet 
made from 8 β-strands (one of which is antiparallel to the others) and surrounded by a 
series of α helices. This central domain contains the Ser122/His269/Asp239 catalytic 
triad, whose structural organization is well conserved. The nucleophilic serine is 
located at the top of the core in a typical sharp turn between α3 helix and β5 strand. 
This core domain is overhung by a much more variable domain termed cap, made of 
several α helices and loops that mediate structural information to provide the huge 
amount of α/β hydrolases family members with their specificity in both function and 
substrate profile. 
MGL structure reveals several key features of the enzyme, which are essential to 
explain its biological activity. It has been speculated that the cap domain in MGL 
serves as a lid domain that, once the proteins come into contact with lipid droplets or 
membranes containing 2-AG, allows the enzyme to unveil its otherwise unreachable 
hydrophobic active site (interfacial activation). This process should allow the enzyme 
to exist in two main conformation, a “closed” and an “open” form. Moreover, it has 
been suggested that the hydrophobic and flexible α4 helix of MGL cap domain may 
help the soluble cytosolic form of MGL either to get in close contact with or to anchor 
in the cytoplasmic membrane, in order to reach its lipophilic substrates. Despite this 
could explain why MGL was sometimes considered a cytosolic enzyme and sometimes 
a membrane-associated one,7,8 no interfacial activation has been described for MGL. 
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Beneath the MGL cap domain, a highly hydrophobic pocket connecting the MGL 
surface to its catalytic site, deeply buried in the protein, has been recognized. This 
cavity (25 Å in length and 8 Å in width) becomes wider as one moves away from the 
catalytic triad environment towards the surface of the protein and seems suitable for 
recognition and accommodation of the long and flexible chain of MGL substrates 
during their catalyzed hydrolysis process. Another narrow cavity (about 5 Å of 
diameter) was recognized to connect the active site to the outside of the protein. The 
architecture formed by loops connecting α4 to α5 and α5 to α6 helices, and the last 
portion of the α5 helix, is responsible of the formation of this narrow hole. This small 
channel lies perpendicularly to the trajectory that leads from the catalytic pocket to the 
membrane-binding site and might act as putative exit door for the glycerol moiety, 
released after 2-AG hydrolysis (Figure 2.1). 
 
A B  
Figure 2.1 Overall structure of hMGL monomer with catalytic triad  
represented as sticks, and cap domain colored magenta. (A) Side view (left) and top view (90° rotation), 
ribbons representation. (B) Top view, surface representation (nucleophilic Serine 122 colored in red) on top 
and transverse section highlighting the near environment of the nucleophilic serine lined in red (on bottom) 
 
Several studies have revealed that three cysteines (Cys201, Cys208, Cys242, short 
isoform numbering), which are conserved between the human, rat and mouse 
orthologs, can interfere with MGL catalytic activity9. Cys242 is located within the 
active site of MGL with its sulfur atom very closely positioned to catalytic Ser122 
whereas Cys201 and Cys208 were found quite far away from the catalytic serine. 
Cys201 and Cys208 were found solvent-exposed and located at the lipophilic tunnel's 
wide entrance or in the vicinity of the putative glycerol exit hole, respectively (Figure 
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2.2). While their functional role is still not fully understood, it is known from mass-
spectroscopy experiments that these residues are not involved in disulfide bridge 
formation10. On the other hand, in the first study mentioning the characterization of 
purified MGL, Tornqvist and Belfrage2 reported a more rapid loss of activity when the 
protein was incubated in absence of a reducing agent. Thus, there is a possibility that 
one or more of the cysteines play(s) a structural role in the stabilization of MGL active 
conformation in a redox-dependent manner. The role of these residues on the 
regulation of the enzyme activity will be further discussed in this chapter (see 
paragraph 2.3). 
 
Figure 2.2 Disposition of critical cysteines. Cys242 (orange) is located close to the catalytic triad  
(red labeled) while Cys201 and Cys208 (green) are solvent-exposed located on the lid domain  
(from PDB: 3HJU) 
 
 
2.1.2 Substrate selectivity 
MGL is unable to cleave either diacylglycerols or triacylglycerols. Moreover, it is 
inactive on cholesterol esters and prostaglandinglycerol esters, and despite its known 
homology with viral and bacterial lysophospholipases, the enzyme does not display 
any lysophospholipase activity for lysophosphatidylcholine2,11. Several authors have 
studied the impact of the length and the degree of unsaturation of the substrate acyl 
chain, by measuring either the rate of hydrolysis or the inhibitory potency of the 
compounds towards the hydrolysis of a known substrate (thus recording more the 
affinity for the enzyme than its capability to act as a substrate). MGL hydrolyzes 
efficiently substrates with various number of double bonds (C18:1, C18:2; C20:4) and 
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acyl chain length (from C8:0 to C18:0)12. However, the degree of unsaturation was 
reported to have a certain impact, with MGL displaying a preference for 
arachidonoylglycerol compared to palmitoylglycerol and, generally speaking, for 
unsaturated compared to saturated substrates (C16:0, C20:0)12b,13. By measuring the 
inhibitory potency of a series of trifluoromethylketone derivatives on the 2-AG 
hydrolase activity from a rat cerebellar cytosolic fraction, Ghafouri and colleagues also 
observed a marked preference for the arachidonyltrifuoromethylketone and 
oleoyltrifuoromethylketone compared to the palmitoyl analogue. It is noteworthy to 
mention that, in several of these studies, data analysis might have been complicated by 
the fact that protein homogenates are used as the source of enzyme activity, raising 
concerns about the exact identity of the enzyme whose activity is measured.  
 
 
2.1.3 Tissue localization of MGL 
Since its first identification in the adipose tissue12a, MGL localization has extended to 
many other tissues and is now known to constitute an ubiquitously expressed enzyme. 
In the rat, high levels of MGL mRNA are found in the adipose tissue, kidney and testis. 
Other organs include adrenal gland, brain, heart, lung, skeletal muscle, liver, ovary 
and spleen, in decreasing order of MGL mRNA abundance2. In the brain, MGL 
transcript is also present ubiquitously (cortex, hippocampus, cerebellum, thalamus, 
striatum) despite lower mRNA levels are found in the brainstem and hypothalamus4. 
In the adipocyte, MGL was found in large lipid-containing aggregates. Besides this, a 
concomitant distribution in membranes as well as in the cytosol has been reported. In 
fact, adenovirus-mediated MGL expression in HeLa cells led to immunoreactivity and 
lipase activity localized in both the cytosolic and plasma membranes/particulate 
fractions of the cells. Second, in the hippocampus, the ultra-structural distribution of 
the enzyme is homogenous and no compartmental preference is reported14. Third, 
using ABPP-MudPIT (Activity-Based Proteome Profiling with Multidimensional 
Protein Identification Technology), Blankman and colleagues identified MGL both in 
membrane and cytosolic mouse brain proteomes7. This dual MGL cellular localization 
may either suggest the intrinsic amphitropic nature of MGL or reflect putative post-
transcriptional/post-translational events regulating MGL expression and activity. 
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2.2 In vivo relevance of MGL:  
 biochemical and physiological roles 
 
MGL completes the hydrolysis of triacylglycerols in the adipocyte. It behaves as a 
selective 2-monoacylglycerol hydrolase, devoid of activity on other lipids. This 
observation turned out to be of utmost importance in the middle of the nineties, when 
the endocannabinoid system was brought to light. Indeed, besides its original role in 
the mobilization of fat in the adipocyte, which led to its discovery in the early sixties, 
the discovery of 2-arachidonoylglycerol as a key messenger of the endocannabinoid 
system marked a turning point in the study of MGL. Understanding of the metabolic 
and (patho)physiological roles of MGL, initially boosted by the selective inhibitor 
URB602,15 has been accelerated in recent years due to the synthesis of highly potent 
and selective in vivo efficacious inhibitors such as JZL184 (see below), as well as the 
development of MGL-deficient (−/−) mice.  
Pharmacological or genetic inactivation of MGL lowers 2-AG hydrolytic activity by 
> 80% in most tissues, including the brain. The remaining 20% of 2-AG hydrolytic 
activity in brain arises from the serine hydrolases α/β hydrolase domain 6 (ABHD6) 
and ABHD127,16. Although ABHD6 and ABHD12 may have roles in 2-AG hydrolysis in 
certain settings, both genetic inactivation and pharmacological inactivation of MGL 
lead to dramatic elevations in both bulk levels and depolarization-induced interstitial 
levels of 2-AG in the brain, confirming that MGL is indeed the primary enzyme 
involved in degrading 2-AG in vivo17,18. MGL blockade resulted in a ~90% inhibition of 
2-AG hydrolysis, with the brain showing the most dramatic elevations in 2-AG and 
peripheral tissues often showing greater changes in other monoacylglycerols, 
consistent with the lipolytic role of MGL as the final step of triglyceride hydrolysis in 
peripheral tissues19. 
One of the essential functions of cannabinoid receptors and endocannabinoids is to be 
involved in synaptic plasticity, as they modulate the signaling mediated by other 
transmitters20. Depolarization of the postsynaptic neuron, as well as the activation of 
Gq protein-coupled receptors, results in the activation of endocannabinoid biosynthesis 
pathways in the postsynaptic neuron.  
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Figure 2.3 The MGL modulates the 2-AG-dependent retrograde signaling in the presynaptic neuron. 
 
The newly synthesized endocannabinoid travels backward, crossing the synaptic space 
to bind presynaptic CB1 receptors, inhibiting calcium influx and decreasing the 
probability of presynaptic vesicle release. Overall, this chain of events leads to a 
temporary or more persistent dimming of inhibitory or excitatory currents at 
GABAergic and glutamatergic synapsis21, respectively (Figure 2.3). 
The subtlety of this modulation is further strengthened by the intervention of 
endocannabinoid catabolic pathways, and indeed growing evidence has emerged to 
assign a key role to MGL in the endocannabinoid-mediated retrograde signaling. In 
general, retrograde signaling can be investigated electro-physiologically in tissue slices 
by measurement of processes such as depolarization-induced suppression of excitation 
(DSE) or inhibition (DSI), with the EC component being demonstrated by the loss of 
the response in the presence of a CB1 receptor antagonist such as Rimonabant22. What 
was not initially clear, however, was whether AEA and 2-AG played separate roles in 
retrograde signaling pathways in different brain regions, or whether they acted simply 
as alternative signaling molecules within the same system. Histochemical studies in 
the rat hippocampus, cerebellum and amygdala indicated that MGL was mainly 
Following the on-demand 
synthesis of 2-AG, the 
endocannabinoid stimulates 
presynaptic CB1 receptor, 
thus decreasing the release 
of other neurotransmitters. 
MGL, which is exclusively 
located in the presynaptic 
neuron, modulates this 
inhibitory signal. In 
addition, in the 
postsynaptic neuron, the 
COX-2 appears to regulate 
part of the postsynaptic pool 
of 2-AG. 
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presynaptically localized, whereas FAAH was post-synaptic14 and a presynaptic 
localization of MGL in the human hippocampus has also been reported 23 . A 
presynaptic localization is more logical in terms of termination of the retrograde 
signaling molecule, and initial evidence favoring 2-AG over AEA was the finding that 
the selective FAAH inhibitor URB597 did not affect DSI in the hippocampus. By 
demonstrating that the selective MGL inhibitor JZL184 extends the duration of DSE in 
cerebellar neurons and DSE/DSI in hyppocampal pyramidal neurons, Straiker and 
Pan recently provided additional and convincing evidence for the predominance of the 
2-AG/MGL pathway over that involving AEA/FAAH in the DSI/DSE process24. 
MGL−/− mice have also been used to confirm 2-AG involvement in hippocampal DSI 
and cerebellar DSE25, although the down-regulation of CB1 receptors seen in these 
animals is a complicating factor, as is the ability of cyclooxygenase-2 to contribute to 
the metabolism of ECs in preparations used in electrophysiological experiments. 
 
 
2.3  Regulatory cysteines of MGL 
The evidence for a critical role of cysteines residues inside MGL, able to regulate the 
activity of the enzyme, came forty years ago when the first MGL inhibitors were 
described: among them several sulfhydryl-reacting compounds, such as p-
chloromercuribenzoate (pCMB), mercurichloride (HgCl2) and N-ethylmaleimide 
(NEM), are comprised2,26. Several studies were aimed at the identification of this 
regulatory cysteines and the elucidation of their role in the catalytic activity of MGL. 
There are six cysteine residues in rat and mouse MGL, four of which are conserved in 
their human ortholog. A homology model of MGL constructed using as a template the 
crystal structure of chloroperoxidase L from S. lividans (Figure 2.4) positioned Cys242 
in close proximity of a histidine residue that is part of the catalytic triad. Residues 
Cys201 and Cys208 were located within the lid domain, wherefrom they might be able 
to extend their sulfhydryl groups towards the substrate-binding site, while residues 
Cys32 and Cys55 were positioned in regions that could hardly interact with the 
catalytic site. While this computational model provided a first tentative explanation of 
the roles exerted by the three “regulatory” cysteines (Cys201, Cys208 and Cys242) on 
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MGL activity, the actual position of Cys201 and Cys208 within the lid domain was 
later revealed by crystal structures of human MGL.  
 
 
Figure 2.4 Computational three-dimensional model of rat MGL. The α/β core structure of the enzyme, shown 
in white, contains the catalytic triad. 2-AG is shown in orange. The lid domain is in magenta 
 
The role of Cys242 was further elucidated by the work of Saario et al.9, investigating 
maleimides as MGL inhibitors. This class of compounds revealed to be covalent 
inhibitors able to alkylate the enzyme through a Michael addiction reaction (for detail 
see paragraph 2.4.2). Zvonok et al.27 through a ligand-assisted MS-based approach 
demonstrated that MGL inhibition by maleimides involves covalent Michael addition 
to Cys208 and Cys242, while the adduct fragments with Cys32  or Cys201 were not 
found in human MGL. On the other hand, studies with mutants of rat MGL28 indicate 
that Cys201 could also be involved in the interaction with maleimides: the exact 
identity of cysteine residues targeted by this compounds is still debated. In the same 
studies, conducted by King and colleagues in 2009,28 a series of rat MGL mutants in 
which individual cysteines were replaced with glycines was generated to evaluate the 
impact of mutation on MGL activity. Wild-type (WT) and mutant proteins displayed 
comparable levels of heterologous expression. Nevertheless, the Cys242G mutation 
produced a striking reduction in MGL activity (Figure 2.5A), which was due to a 
decrease in maximal reaction velocity rather than a change in Michaelis constant, 
confirming the critical role of Cys242 on MGL activity. 
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A B  
Figure 2.5 Effects of cysteine mutations (to glycine) on MGL activity. (A) MGL activity in MGL mutants 
C242G, C32G, C55G and C301G. (B) MGL activity in MGL mutants C201G and C208G.  
Results are expressed in percentage of wild-type (WT) activity (50 mg protein) (mean _ SEM, n = 3) 
 
Mutations affecting Cys201 and Cys208 also caused significant decreases in enzyme 
activity, albeit smaller than that produced by Cys242G (Figure 2.5B). By contrast, 
mutations to cysteines located distal to the active site of MGL (Cys32G, Cys55G and 
Cys301G) had no effect on MGL activity. These results highlight the important 
functional role of cysteine residues proximal to the MGL active site, as previously 
suggested by computational and structural studies. 
 
 
2.3.1 Sensitivity of MGL to oxidizing agents 
Several studies have revealed the role of cysteines as redox-sensitive regulatory 
switches caused by the generation of reactive oxygen species (ROS) and the presence 
of oxidized thiols29. Oxidation of such cysteines is converted into signals that control 
cell regulatory pathways and induction of gene expression. A variety of proteins, 
including transcription factors, molecular chaperones and protein tyrosine 
phosphatases, are regulated via redox processes. Common mechanisms underlie the 
sensitivity of cysteines to redox, such as proximity to polar and charged groups, and 
signal transduction is exerted via conformational changes that are conferred by the 
formation of disulfide and cyclic sulfenamide covalent bonds, and sulfinic, sulfenic 
and sulfonic acids.  
Nitric oxide (NO) is recognized as one of the most important ROS and many enzymes 
with a reactive sulfhydryl group have been shown to be inhibited by NO reactive 
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species30. Saario and collagues9 determined the activity of MGL in the presence of NO 
donors S-nitrosoglutathione (GSNO), S-nitrosocysteine (CysNO), and sodium 
nitroprusside (SNP). However, no significant changes in the enzyme activity were 
shown by any of these NO species. This result suggests that MGL-like activity is not 
under NO regulation, a finding in agreement with the observation that inhibition of 
nitric oxide synthase by nitro L-arginine methyl ester and L-methylarginine has no 
effect on MGL activity in syn-aptoneurosomes31.  
Intensive research about the action of the second messenger hydrogen peroxide 
(H2O2) 32  on MGL have been recently conducted by Piomelli’s research group 
(University of Irvine, California) in collaboration with the research group where I 
spent my PhD period at the University of Parma. Data reported in this paragraph are 
strictly confidential and have been recently submitted for publication. H2O2 modifies 
protein function through reversible oxidation of cysteine thiol groups to sulfenic acid (-
SOH)33. To test the idea that peroxide-dependent cysteine sulfenylation might regulate 
MGL activity and 2-AG signaling, MGL was exposed to concentrations of H2O2 that 
modify protein function without causing irreversible oxidative damage 34 . H2O2 
inhibited MGL with an IC50 of 11.6±0.8 µM (Figure 2.6A). The inhibition displayed 
non-competitive kinetics (Figure 2.6B), and was reversible upon enzyme dilution 
(Figure 2.6D). Site-directed mutagenesis was helpful to determine whether regulatory 
cysteines contribute to peroxide-dependent MGL inhibition. Replacing either Cys201 
or Cys208 with alanine caused a rightward shift in H2O2 potency (Figure 2.6A). An 
even more pronounced shift was observed when both C201 and C208 were mutated, 
whereas replacing Cys242 with alanine or serine had no effect (Figure 2.6C). 
 
 
A B  
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C D  
 
Figure 2.6 Hydrogen peroxide inhibits MGL. (A) Effects of H2O2 on wild-type MGL (circles), MGL mutants 
C201A (diamonds), C208A (triangles) or C201/208A (empty squares) and DGL-α (full squares).  
(B) Michaelis-Menten kinetics of MGL inhibition by H2O2 (vehicle: open squares). (C) Effects of H2O2 on 
MGL (circles) or DGL-α (squares) activity. (D) Rapid dilution of MGL incubated with vehicle (circles), H2O2 
(squares; 10 µM final), or irreversible inhibitor methylarachidonylfluorophosphonate (triangles, 23 nM final) 
 
These findings suggest that H2O2 inhibits MGL through an allosteric reversible 
mechanism involving Cys201 and Cys208. To determine whether MGL is a substrate 
for sulfenylation, purified enzyme was incubated with H2O2 in the presence of 
dimedone, which reacts with short-lived sulfenic acid groups forming stable thioethers 
(Figure 2.7). Dimedone was exclusively bound to peptides containing Cys201 or 
Cys208 (after trypsin digestion and LC/MS analysis) identifying cysteines 201 and 208 
in MGL as targets for peroxide-dependent sulfenylation. 
 
 
Figure 2.7 Hydrogen peroxide sulfenylates MGL. Extracted-ion currents of native (black) and dimedone 
(DMD)-containing (red) peptides obtained by digestion of rat MGL exposed to H2O2 (10 µM, 1h) 
 
  
!
Chapter 2 – The monoacylglycerol lipase (MGL) 
!
! !
31 
Piomelli and coworkers performed experiments on rat cortical neurons to capture 
transient sulfenylation-dependent changes on MGL activity. Addiction of H2O2 
resulted in a decrease of MGL activity (Figure 2.8A) and in an elevation of 2-AG levels 
(Figure 2.8B). Additional evidence that redox status affects MGL activity was obtained 
by blocking glutathione biosynthesis with L-buthionine sulfoximine (BSO). Exposing 
cortical neurons to BSO depleted intracellular glutathione (Figure 2.8C), lowered MGL 
activity (Figure 2.8D) and increased 2-AG content (Figure 2.8E).  
 
 
A  B  
C   D     E  
 
Figure 2.8 Effects of H2O2 (filled bars) or vehicle (open bars) on (A) MGL activity, (B) 2-AG levels. Effects of 
BSO (filled bars) or vehicle (open bars) on (C) GSH levels, (D) MGL activity and (E) 2-AG levels in neurons. 
 
These evidences suggest that MGL activity is finely regulated by the redox status of 
the cell: the blockade of MGL catalysis results in an enhancement of 2-AG levels that 
could exert a neuroprotective action in response to oxidizing stress events. Further 
evidences confirmed this hypothesis displaying that MGL sulfenylation impairs 2-AG 
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degradation and also enhance 2-AG signaling. Neuro-2a cells were incubated with 
high levels of H2O2 and evaluation of cellular damage using LDH was assessed (Figure 
2.9). The toxic effect of hydrogen peroxide was heightened by MGL overexpression 
(Figure 2.9 - entry 2) and reduced by treatment with the MGL inhibitor JZL184 (Figure 
2.9 - entry 4) able to elevate 2-AG levels. Morover H2O2 toxicity was enhanced by CB1 
blockade using the selective antagonist Rimonabant, only when MGL was not 
overexpressed (Figure 2.9 - entry 3, Mock) or when it was inhibited by JZL184  (Figure 
2.9 - entry 6),  but not by CB2 blockade (antagonist AM630). These observations suggest 
that peroxide-dependent MGL deactivation enhances CB1-mediated 2-AG signaling 
and the possible neuroprotective role of 2-AG. 
 
 
 
 
Figure 2.9 Hydrogen peroxide enhances neuronal 2-AG signaling.  
Effects of H2O2 (300 µM), alone or combined with CB1 antagonist Rimonabant, CB2 antagonist AM630 or 
MGL inhibitor JZL-184 (1 µM), on LDH release 
 
In conclusion, three residues of cysteine are fundamental in the regulation of MGL 
activity. Cys242 influence directly the hydrolyzing activity of the enzyme by 
interacting with the catalytic triad. Cys201 and Cys208 instead, can be considered 
molecular switches that finely tune MGL catalytic activity by undergoing oxidation or 
reduction in response to the redox status of the cell.  
 
 
  
!
Chapter 2 – The monoacylglycerol lipase (MGL) 
!
! !
33 
2.4  MGL inhibition strategies 
The role of MGL as the key hydrolyzing enzyme of 2-AG in the endocannabinoid 
system has only recently been recognized. Therefore, the design and development of 
potent, selective MGL inhibitors is still in its infancy. Knowledge about the catalytic 
mechanism and substrate specificity are important factors to be taken into 
consideration, when designing new enzyme inhibitors. 
While the first selctive inhibitors of MGL were derivatives of the carbamate 
URB602,15,35 the most recent MGL inhibitors can be classified into three categories 
based on their mechanism of action:  
1. compounds targeting the catalytic serine: covalent modifiers able to interact 
with Ser122 within the active site; 
2. compounds targeting the critical cysteines: covalent modifiers able to interact 
with critical Cys242/Cys201/Cys208. These include iso- and 
benzisothiazolinones; 
3. triterpenoids: non-covalent binders of MGL able to interact with Cys201 and 
Cys208. 
 
To date, most MGL inhibitors are covalent binders able to generate an adduct with one 
of the nuclophilic residues of the target. Among them is it possible to identify 
miscellaneous reactive “warheads”, from carbamoylating to disulfide-forming reactive 
fragments. A classification of available covalent MGL inhibitors can be carried out 
considering the reversibility of established inhibitor-enzyme interaction that mainly 
depend from the chemical and biological stability of established covalent interactions. 
In this way, among described inhibitors, alkylating agents form the most stable 
covalent interaction and can be considered as irreversible inhibitors. Carbamoylating 
agents bind MGL forming middle-range stable covalent bonds and provide MGL 
inhibition that range from irreversible (at least from a pharmacological point of view) 
to partially reversible. Finally, despite disulfide bond forming agents and acylating 
agents should form the most easily breakable covalent interactions, the reversibility of 
their action can easily range from irreversible to completely reversible, depending on 
the macro- or micro-environment in which their respective covalent interactions take 
place.  
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Triterpenoids are way ahead from the rest of MGL inhibitors because their mechanism 
of action is exerted by formation of non covalent interaction involving lid domain 
cysteines and they represents therefore the first-class of non covalent modifiers of the 
enzyme. In the next paragraphs I will provide an exhaustive description of available 
MGL inhibitors. 
 
 
2.4.1 Targeting the catalytic serine 
This class of MGL inhibitors is represented by compounds able to covalently bind 
MGL catalytic Ser122, directly disrupting the MGL hydrolytic activity. Among them, 
despite these compounds provide the most effective MGL inhibition, only few 
derivatives have shown high selectivity for the desired target. 
For instance, highly reactive serine-binding fluorophosphonates or fluorosulphonates 
are able to block MGL activity36 with high potency but are also able to inhibit other 
serine-dependent enzyme inside and outside the endocannabinoid system with 
comparable efficiency: compounds including trifluoromethylketones 
(arachidonoyltrifluoromethylketone, ATFMK; oleoyltrifluoromethylketone; 
palmitoyltrifluoromethylketone) and the irreversible inhibitor 
methylarachidonylfluorophosphonate (MAFP) (Figure 2.10) were identified as MGL 
inhibitors. Despite the fact that the voluminous and lipophilic arachidonyl chain 
would be likely to provide MAFP and ATFMK an improved selectivity profile versus 
proteins belonging to other systems, these compounds also display several off-targets. 
MAFP was first reported as a phospholipase A2 inhibitor and inhibits FAAH and MGL 
with similar potencies, while ATFMK acts on MGL, FAAH and CB1 cannabinoid 
receptor37. This produces an undesirable complex pharmacological response from 
which is difficult to selectively define the 2-AG contribution to the observed biological 
effects. Furthermore, the ability of these fluorophosponate derivatives to inhibit 
multiple serine-dependent enzymes is often responsible to high off-target toxicity, 
sometimes so severe to kill the treated subject. Despite the low target selectivity shown 
by these labeling compounds does not allow their use as drugs and limit their use as 
pharmacological tools, their impressive MGL inhibitory potency have induced many 
scientists to develop more druggable and specific serine-trapping agents. 
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Nithipathikom developed a series of trifluoromethylketones with a β-thioether 
moiety38. A subset of these compounds, among which octylthiotrifluoropropan-2-one 
(OTFP) (Figure 2.10), increased 2-AG levels in prostate cancer cell lines revealing the 
anti-invasive effect of 2-AG. However, their inhibitory potency was only tested in 
crude cytosolic and membrane homogenates, and it is likely that these compounds 
unselectively target other esterases and probably the FAAH, since it is known that 
trifluoromethylketone scaffold constitutes a good template for FAAH inhibition39. 
 
 
Figure 2.10 Several MGL inhibitors targeting the nucleophilic serine (Ser122) 
 
Recently a series of carbamoyl tetrazoles and carbamates have been reported that have 
shown to covalently inhibit hMGL with high potency and with enhanced selectivity. 
Carbamoyl tetrazole LY2183240 (Figure 2.10) was first described as an inhibitor of 
anandamide transporter (IC50uptake = 15 nM)40. However, it has been subsequently 
reported that this property could result from its ability to potently and irreversibly 
inhibit FAAH as an off-target (IC50FAAH = 21 nM). LY2183240 was also shown to inhibit 
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other lipases such as MGL (IC50MGL = 5.3 nM)41. Indeed, as pointed out by Ortar and 
colleagues, the compound studied by Alexander and Cravatt likely represents a 
mixture of the 1,5- and 2,5-regioisomers of LY218324042. The authors thus synthesized 
and purified both isomers and other tetrazole derivatives, and measured their 
inhibitory potency on the MGL and the FAAH, as well as on the anandamide transport 
process. On the one hand, the 1,5-regioisomer only slightly inhibits MGL, whilst being 
a much more potent inhibitor of anandamide degradation and transport (IC50FAAH = 2.1 
nM; IC50uptake = 15 nM; IC50MGL = 8100 nM). On the other hand, the 2,5- isomer interacts 
with a much higher affinity with MGL, but unfortunately lacks selectivity versus 
FAAH (IC50FAAH = 33 nM; IC50uptake = 998 nM; IC50MGL = 20 nM). In a mass spectrometry 
analysis, the binding mode of the 2,5-regioisomer to recombinant human MGL was 
investigated.  
 
 
Figure 2.11 Mechanism of MGL inhibition exerted by LY2183240 2,5-regioisomer 
 
Inhibition occurs through the attack of the Ser122 hydroxyl group (Figure 2.11), which 
leads to the formation of a carbamoylation product containing the inhibitor 
dimethylamino group, as demonstrated by the +71 mass increment of the tryptic 
fragment containing this residue. The biphenylmethyl tetrazole moiety thus constitutes 
the leaving group during this reaction27. 
Following the success associated with the use of carbamates in the development of 
FAAH inhibitors, Hohmann and colleagues screened a library of O-biphenyl and N-
biphenyl carbamates and reported the development of URB602 (Figure 2.10) as the 
first selective inhibitor of 2-AG degradation, although its potency remained limited 
(IC50 = 28 µM and 223 µM on rat brain and pure recombinant rat MGL, respectively)43. 
Despite the fact that it was reported to inhibit FAAH and MGL with similar potencies 
in vitro,44 it was hown to lead to the selective accumulation of 2-AG (not AEA) in rat 
hippocampal slices or after injection in the periaqueductal gray.43 Nevertheless, 
URB602 was used to demonstrate the implication of the endocannabinoid system in 
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stress-induced analgesia, it exhibited CB2-dependent analgesic and anti-inflammatory 
properties in a model of inflammation45 and it showed significant protection from the 
long-term consequences of neonatal hypoxic-ischemic brain injury in rats.46 Other 
carbamates that led to MGL inhibition include SPB01403 (IC50 = 31 µM on rat cerebellar 
membranes)47, CAY10499 (IC50 = 0.5 µM to 20 nM on the pure human MGL, depending 
on the preincubation time)48, and 5-methoxy-3-(4-phenoxyphenyl)-3H-[1,3,4]oxadiazol-
2-one (IC50 = 78 nM)49 (Figure 2.10). However, SPB01403 also inactivates FAAH with a 
higher affinity (IC50 = 0.52 µM on rat brain homogenates), and the two latter 
compounds lack selectivity over FAAH and, at least for CAY10499, the hormone 
sensitive lipase. 
One of the most promising breakthroughs in the quest for selective MGL inhibitors 
came from the screening of a carbamate library and the development of a series of 
derivatives of this scaffold by Cravatt’s team17,50.  
This resulted in the low nanomolar inhibitor JZL184 (Figure 2.10), which exhibits a 
comfortable selectivity versus FAAH in vitro (IC50 = 6 nM and 4 µM for recombinant 
MGL and FAAH expressed in COS7 cells, respectively). The inhibition mechanism 
involves the carbamoylation of the Ser122, with p-nitrophenol as the leaving group 
(Figure 2.12).  
 
 
Figure 2.12 Mechanism of MGL inhibition exerted by JZL184 
 
Enzymatic assays performed on brain membrane proteome from JZL184-treated mice 
confirmed the nearly complete and rather selective inhibition of MGL and 2-AG 
hydrolysis (75% inhibition at 4 mg/kg). Note that, depending on the dose, FAAH was 
inhibited as well in vivo although incompletely and to a lesser extent than MGL. The 
compound displays an interesting interspecies selectivity, being ten times more potent 
on human and mouse MGL than on the rat ortholog. As expected, JZL184 
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administration resulted in a dramatic concentration-dependent increase of brain 2-AG 
levels. Accumulation of N-acylethanolamines (in particular AEA) did not occur, unless 
at the highest dose (40 mg/kg). Using microdialysis, the authors also measured the 
signaling-competent concentrations of endocannabinoids and found that JZL184 
enhances 2-AG pools in the synapsis, while leaving AEA levels unchanged. 
The accumulation of 2-AG in vivo is accompanied by a strong CB1-dependent analgesic 
effect in different models of nociception (tail immersion, phase I and II of the formalin 
test, as well as acetic acid-induced tail writhing). Another key finding of this study is 
the observation that JZL184 administration results in a subset of effects belonging to 
the classical “tetrad”, i.e. a CB1 dependent hypothermia and hypomotility (but not 
catalepsy), thus sharing common properties with direct cannabinoid agonists, and 
above all rising crucial question regarding the clinical use of MGL inhibitors. 
Di Marzo’s team reported the development of the micromolar inhibitor OMDM16951 
(Figure 2.10). Unlike several of the above-mentioned compounds, OMDM169 displays 
a good selectivity for 2-AG versus AEA degradation (IC50= 0.13-0.34 µM on 2-AG 
hydrolysis in rat brain and rat cerebellum preparations; IC50 = 3.0 µM on rat FAAH). 
Interestingly, OMDM169 is reversible and its inhibitory potency varies depending on 
the enzyme source and the species, as the compound inactivates 2-AG hydrolysis 
about ten times more strongly in rat than in mouse tissues (IC50 = 0.92 to 7.53 µM in 
mouse). Considering the multiple pathways that inactivate 2-AG in vitro, the authors 
also measured the ability of OMDM169 to inhibit pure recombinant human MGL (IC50 
= 0.89 µM). Despite the fact that the whole spectrum of off-targets has not yet been 
fully investigated, several enzymes may already be pointed out. Apart from these 
issues, OMDM169 was tested in vivo for its antinociceptive properties. In the formalin 
test, the compound (2.5-5 mg/kg, i.p.) promoted analgesia in the second phase of 
nociception. This effect was accompanied by an increase in 2-AG levels in the 
ipsilateral paw that received formalin injection.  Consistently, OMDM169 failed to 
elevate 2-AG level in untreated N18TG2 neuroblastoma in culture but increased its 
concentration when endocannabinoid biosynthesis was induced by ionomycin. This 
observation therefore supports the idea that inhibitors of endocannabinoid 
degradation could help to gain time or spatial selectivity over direct cannabinoid 
receptors agonists and avoid the central side effects associated with the use of the latter 
compounds. Unexpectedly enough given its in vivo pharmacological effects, 
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OMDM169 failed to produce a significant inhibition of 2-AG hydrolase activity in 
brain and paw skin from treated mice, reasons for this remaining unclear. 
 
 
2.4.2 Targeting critical cysteines 
The role of critical cysteines on MGL activity has been elucidated in this chapter (see 
paragraph 2.3). Several inhibitors affect MGL activity by interacting with these 
residues. 
As discussed before, Saario and colleagues9 synthesized a series of maleimide 
derivatives. N-arachidonylmaleimide (NAM) (Figure 2.13) was the most potent 
compound of the set, with an IC50 value of 0.14 µM on rat cerebellar membranes. The 
mechanism of inhibition exerted by NAM involves a Michael addition on one or more 
sulfhydryl residue(s) with a preference for Cys242 (Figure 2.14). Using ABPP, 
Blankman and colleagues confirmed the relative NAM selectivity for MGL, although a 
partial inhibition of FAAH and ABHD12 was also observed at higher doses. Hence, the 
compound was used as a pharmacological tool to unveil the consequences of a 
disruption of MGL activity and to elucidate the respective effects of 2-AG versus 
AEA52. However, given the fact that in vivo, NAM is likely to result in the covalent 
modification of a huge number of proteins, not necessarily in the active site, there is 
little chance that this compound would be a good candidate for drug development. 
 
 
 
Figure 2.13 Most representative examples of inhibitors targeting one or several cysteine residue(s) 
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Figure 2.14 Mechanism of MGL inhibition by NAM 
 
Noteworthy, other groups subsequently reported higher IC50 values for this class of 
compounds. Matuzsak et al. reported the synthesis of a series of maleimides53: among 
them 1-biphenyl-4-ylmethylmaleimide (Figure 2.13) inhibits pure human MGL with an 
IC50 of 790 nM, whilst being 2 orders of magnitude less potent on the FAAH. 
Disulfiram (Figure 2.13), a well known aldehyde dehydrogenase inhibitor used since 
decades to treat alcoholism, was reported to inhibit human MGL with micromolar 
affinity54. Recently, Kapanda and colleagues55 also reported the development of a 
series of MGL inhibitors based on this template. The most potent representative, bis(4-
methyl-1-piperazinylthiocarbonyl) disulfide (Figure 2.13), displayed an IC50 of 110 nM 
on the pure enzyme, and a more than 1000 selectivity ratio for MGL compared to 
FAAH. Using dithiothreitol and site-directed mutagenesis, the inhibition was shown to 
occur through an interaction with Cys242 and Cys208. 
While investigating a series of sulfhydryl-reactive agents, King and colleagues28 have 
reported the ability of iso- and benzisotiazolinones derivatives to inhibit rat MGL. 
Because of the central role of these two classes of MGL inhibitors in this PhD research 
project, they deserve a detailed statement provided in the next paragraph. 
 
 
2.4.3 Iso and Benzisothiazolinones as MGL inhibitors 
This inhibitor class, recently discovered by King and coworkers, is populated by 
disulfide-bond forming compounds such as isothiazol-3(2H)-one (ITZ) and 
benzo[d]isothiazol-3(2H)-one (BTZ) derivatives. These compounds were discovered as 
“hit compounds” during the screening of a short panel of cysteine trapping derivatives 
toward recombinant rat MGL. 2-octylisothiazolin-3-(2H)one (octhilinone) (Figure 2.15) 
was potent in inhibiting rat MGL, that is, IC50 in nM range (88 nM). Preliminary SAR 
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studies, which investigated the effects of select chemical modifications of octhilinone 
on MGL inhibition, revealed that substitution of the n-octyl group with a methyl group 
(2-methylisothiazol-3(2H)-one) resulted in a three-fold decrease in potency compared 
with the parent compound (IC50 = 249 nM). By contrast, introduction of a larger and 
more lipophilic oleoyl group at the same site ((Z)-2-(octadec-9-en-1-yl)isothiazol-3(2H)-
one) resulted in a two fold increase in potency (IC50 = 43 nM). Replacement of the 
isothiazolinone moiety with a benzisothiazolinone group (2-octylbenzo[d]isothiazol-
3(2H)-one) also yielded a potent inhibitor (IC50 = 59 nM) (Figure 2.15). 
 
 
Figure 2.15 Iso and benzisothiazolinones as MGL inhibitors 
 
Rapid dilution assay was performed to assess whether octhilinone inhibits MGL 
through a reversible or irreversible mechanism.  As shown in Figure 2.16A, the 
dilution produced a partial recovery of enzyme activity.  The partial reversibility of the 
effect of octhilinone is not consistent with the chemical reactivity of a Michael addition 
product, suggesting that octhilinone may form instead a disulfide bond with a cysteine 
residue in MGL (Figure 2.16B). Two findings support this possibility. First, the 
benzisothiazolinone, which cannot undergo Michael addition, was as potent as 
octhilinone at inhibiting MGL activity. Second, adding the reducing agent DTT (10 
mM) to the incubation mixture produced a 47-fold decrease in the inhibitory potency 
of octhilinone (Figure 2.16C) without affecting basal MGL activity. A glycine-based 
site-direct mutagenesis scanning revealed that octhilinone interacts with Cys208 
(Figure 2.17A) without interfering with other critical cysteines (Figure 2.17B). The 
interest for this chemical family was highlighted by the work of Matuszak and 
colleagues on human MGL56. They confirmed the mechanism of action, proposed by 
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King et al., on human MGL: after inhibition exerted by octhilinone or 2-
octylbenzo[d]isothiazol-3(2H)-one (Figure 2.15) the activity of the enzyme was restored 
with increasing DTT concentrations, confirming a redox-based mechanism of 
inhibition. 
 
 
Figure 2.16 Reversibility of (MGL) inhibition by octhilinone. (A) Rapid dilution assays of purified MGL in 
the presence of vehicle (squares), octhilinone (triangles) or MAFP (circles). (B) Scheme illustrating the 
formation of a disulphide adduct between octhilinone and cysteine. (C) Effects of dithiothreitol (DTT, 10 
mM) on inhibitory potency of octhilinone and MAFP towards purified MGL 
 
They confirmed the previous observations as the inhibitory potency of octhilinone was 
reduced when Cys208 was mutated to alanine, compared to wild-type MGL. 
Additionally, its potency was also reduced in the same fashion when Cys242 was 
mutated. For compound 2-octylbenzo[d]isothiazol-3(2H)-one (Figure 2.15) both Cys201 
and Cys242 mutations reduced its potency while the mutation of Cys208 did not seem 
to affect its inhibition properties. This results point out the classes of ITZ and BTZ as 
promising new partially-reversible, disulfide-forming inhibitors of MGL. 
 
 
Figure 2.17 Effect of cysteine mutations on MGL inhibition by octhilinone 
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2.4.4 Triterpenes as MGL inhibitors 
Triterpenoids are structurally diverse organic compounds, characterized by a basic 
backbone modified in multiple ways, allowing the formation of more than 20000 
naturally occurring triterpenoid varieties. Several triterpenoids, including ursolic and 
oleanolic acid, betulinic acid, celastrol, pristimerin, lupeol, euphol and avicins possess 
antitumor and anti-inflammatory properties. Among them, pristimerin and euphol 
(Figure 2.18A) have recently gained interest as new promising MGL inhibitors57. 
Pristimerin, a natural triterpenoid, elicits cellular responses closely resembling those 
elicited by proteasome inhibitors, such as the rapid induction of heat shock proteins 
(HSPs), activating transcription factor 3 (ATF3), and C/EBP homologous protein 
(CHOP). Pristimerin also inhibits NF-κB activation suppressing the activation of 
constitutive NF-κB in myeloma cells. Consistent with this, pristimerin has been shown 
to be potently and selectively lethal to primary myeloma cells (IC50 < 100 nM) and to 
inhibit xenografted plasmacytoma tumors in mice58. Pristimerin is also known as an 
antifungal, antimicrobial, and anti-inflammatory plant compound with an effect on the 
iNOS system in macrophages59. 
 
A B  
Figure 2.18 (A) Chemical structure of pristimerin and euphol. (B) Three dimensional superposition of euphol 
(gold) and pristimerin (green) 
 
The tetracyclic triterpene alcohol, euphol, is the main constituent in the sap of 
Euphorbia tirucalli. Previous studies have demonstrated that euphol exerts anti-
inflammatory effects associated with the inhibition of the activation of nuclear factor-
H
OMe
O
HO
O
pristimerin
HHO
H
euphol
  
!
Chapter 2 – The monoacylglycerol lipase (MGL) 
!
! !
44 
κB60, the down-regulation of tumor necrosis factor-α and cyclooxygenase-2 61. In 
addition to antiviral and anti-inflammatory effects, antitumor effects of euphol have 
also been observed62. Furthermore, recent studies also indicate that euphol has a 
systemic, spinal and supraspinal antinociception action: the antinociceptive effect of 
euphol depends largely on its ability to interact with cannabinoid system via both CB1 
and CB2 dependent mechanism63. 
From the screening of a chemical library, pristimerin emerged as inhibitor of purified 
MGL with a median effective concentration (IC50) of 93 nM. Enzyme assays showed 
that also euphol, having a 3D structure similar to that of pristimerin (Figure 2.18B), 
inhibits purified MGL with an IC50 of 315 nM. Rapid dilution assays of the MGL-
pristimerin and the MGL–euphol mixtures resulted in a virtually complete recovery of 
catalytic activity of the enzyme, with a reduction of VMAX, which is suggestive of a 
reversible non-competitive inhibition exerted by both compounds (Figure 2.19). 
 
 
A B  
Figure 2.19 Rapid dilution assays of HeLa-MGL in the presence of vehicle (squares, DMSO, final 
concentration 2%), pristimerin (A), euphol (B) or MAFP (circles) 
 
A glycine-based mutagenesis scanning revealed that the replacement of Cys208 caused 
a marked rightward shift in the concentration-response curve for pristimerin, whereas 
it had no effect on euphol (Figure 2.20). Conversely, a mutation affecting Cys201 
significantly reduced the inhibitory potency of euphol without affecting the potency of 
pristimerin. The structural and mechanistic similarities between pristimerin and 
euphol suggest that they could occupy a common hydrophobic pocket within the lid 
domain of MGL. Computational studies revealed the possibility of each inhibitor to 
engage interactions with adjacent cysteine residues, Cys201 and Cys208, which flank 
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this pocket. The limited overlap of the region occupied by pristimerin and euphol with 
the presumptive active site of MGL is consistent with the non-competitive kinetic 
behavior displayed by these inhibitors. However, there are other possible explanations 
for such behavior, including stabilization of a conformation of MGL that is inaccessible 
to the substrate. 
 
 
Figure 2.20 Effects of mutating Cys201 or Cys208 on MGL inhibition by pristimerin (A) and euphol (B) 
 
 
2.5 Therapeutic potential of MGL inhibition 
Given the roles of the endocannabinoid system in the regulation of many processes 
including pain, neuroprotection, appetite and even cancer diseases, enzymes involved 
in the endocannabinoid catabolism are potentially important targets for 
pharmaceutical development. Currently, the main focus has been upon fatty acid 
amide hydrolase (FAAH), which primarily hydrolyses AEA and related N-
acylethanolamines to their corresponding fatty acids. FAAH inhibitors are in 
pharmaceutical development, with pain as a major indication. MGL inhibitors have 
lagged behind, but have a potential advantage over FAAH inhibitors in terms of 
substrate specificity, given that the N-acylethanolamines are a class of compounds 
with multiple biological actions, and for the multiple possibilities of targeting, allowed 
by the complex regulation of MGL activity.  
A concern with the development of molecules affecting endocannabinoid metabolism 
is that they might produce cannabis-like effects, which would limit their usefulness. 
This concern was greatly reduced when the first selective FAAH inhibitor, URB597, 
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was found not to produce catalepsy, hypothermia or hyperphagia, responses that are 
seen with compounds activating central CB1 receptors 64 , and not to produce 
reinforcing effects in monkeys trained to self-administer Δ9-THC65. With respect to 
MGL inhibition, JZL184 was found to produce Rimonabant-sensitive thermal 
hypoalgesia and hypolocomotion in mice, but it did not produce any motor 
impairments and catalepsy, suggesting that the full gamut of behavioral responses that 
characterize a general activation of brain CB1 receptors is not seen17,19.  
Consistent with the role of MGL in modulating 2-AG-mediated endocannabinoid 
signaling, acute pharmacological blockade of MGL exerts CB1-dependent 
antinociceptive effects in mouse models of noxious chemical, inflammatory, thermal, 
and neuropathic pain66. MGL blockade reduces mechanical and acetone-induced cold 
allodynia in mice subjected to chronic constriction injury of the sciatic nerve. Recent 
studies have also shown that MGL blockade is protective in a mouse model of 
inflammatory bowel disease. MGL blockade by JZL184 reduces macroscopic and 
histological colon alterations and pro-inflammatory cytokines in a trinitrobenzene 
sulfonic acid-induced colitis model, and restores integrity of the intestinal barrier 
function resulting in reduced endotoxemia and peripheral and brain inflammation in a 
CB1 or CB2-dependent manner67. 
Genetic and pharmacological blockades of MGL also exhibit anti-inflammatory effects 
in the brain and neuroprotective effects in mouse models of Parkinson's disease and 
Alzheimer's disease (AD)18. Consistent with this anti-inflammatory effect, MGL 
blockade with JZL184 or MGL deficiency significantly protects against dopaminergic 
neurodegeneration and dopamine loss in an MPTP model of Parkinson's disease, 
concordant with suppression in pro-inflammatory eicosanoids. MGL inactivation 
lowers the pro-inflammatory eicosanoid levels in the AD mouse model, concordant 
with suppression of astrocyte and microglial activation and attenuation of pro-
inflammatory cytokines, leading to a substantial reduction in amyloid plaques. 
Collectively, MGL inhibitors exhibit antinociceptive and anti-inflammatory effects 
through simultaneously enhancing endocannabinoid and suppressing eicosanoid 
levels in the brain. These findings identify MGL as a distinct metabolic node that 
couples endocannabinoid to prostaglandin signaling networks in the nervous system 
and suggest that inhibition of this enzyme may be a new and potentially safer way to 
suppress the pro-inflammatory cascades that underlie neurodegenerative disorders. 
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MGL have a central role also in anxiety events. Multiple studies have shown that MGL 
blockade by JZL184 or URB602 also exert anxiolytic responses. In a marble burying 
model of repetitive and compulsive behavior inherent to anxiety disorders, MGL 
blockade reduced marble burying at doses that did not affect motility, on-par with the 
activity observed with FAAH inhibitor or tetrahydrocannabinol administration, in a 
CB1-dependent manner68. MGL blockade also exerts anxiolytic effects in an elevated 
plus maze paradigm for anxiety, showing increased percentage open arm time and 
number of open arm entries under high, but not low, levels of environmental 
aversiveness69. Sumislawski et al. showed that chronic MGL blockade prevented 
chronic stress-induced anxiety-like behavior and emergence of long-term depression of 
GABAergic transmission, indicating that enhanced endocannabinoid signaling 
prevents behavioral and synaptic adaptations to chronic stress that underlies the 
development and worsening of affective disorders70. Collectively, MGL inhibitors 
show promise, much like FAAH inhibitors or direct cannabinoid agonists, in reducing 
anxiety. 
Recently, the implication of the MGL in cancer pathogenesis has been demonstrated, 
raising new hopes for the development of original anticancer therapeutics based on 
MGL inhibition 71 . In their study, Nomura and colleagues found elevated MGL 
expression levels in aggressive versus non-aggressive human cancer cell lines. MGL 
overexpression increased the aggressiveness of non-aggressive cancer cell lines. On the 
other hand, genetic knockdown of MGL expression by interfering RNAs, as well as 
inhibition of the enzyme activity with an JZL184, affected the migration, invasion, cell 
survival and tumor growth in aggressive cancers. Importantly, exogenous fatty acids 
restored the loss of pathogenicity. Overall, it was shown that, in cancer cells, a panel of 
fatty acids and other lipids are produced following the stimulation of MGL activity to 
promote cell proliferation and cancer malignancy. 
In just a few years, the availability of selective MGL inhibitors has allowed for the 
identification of the roles played by 2-AG in the body, and provided preclinical data 
supporting potential indications for this class of compounds. Within the pain field, 
issues of tolerance and “cannabis-like” effects may present obstacles to drug 
development, but hopefully in vivo data with reversible inhibitors will be forthcoming 
to address these issues. Within the cancer field, it is early days and in vivo data with 
genetic and orthotopic cancer models would be most useful, as would combination 
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studies with standard drug regimes. Nonetheless, when it is remembered that prior to 
2005, no selective and “druggable” MGL inhibitors were available, the rapid progress 
in the field is impressive, and gives hope that the therapeutic potential of MGL as a 
target for drug development will be translated into a clinical reality.  
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Chapter 
3 
 
 
 
MGL inhibitors: 
results and discussion 
 
 
Monoacylglycerol lipase (MGL), as seen in the previous chapters, plays a key role in 
the inactivation of the stimulatory signal exerted by 2-AG, the main “on-demand” 
released endocannabinoid ligand for CB1 receptors. The role of MGL as new attractive 
therapeutic target for treatment of pain, neurodegenerative diseases, anxiety and 
cancer has been elucidated from several pharmacological studies (see Chapter 2). 
Targeting the enzyme involved to the catabolism of the major endocannabinoid is a 
promising approach to avoid side effects derived by direct stimulation of cannabinoid 
receptors. Molecular and crystallographic studies have provided a framework for the 
understanding of the structure and the mechanism of action of this enzyme: these 
informations led to the discovery of the first generation of selective MGL inhibitors. 
They revealed to be fundamental tools for a deep investigation of the physiological 
and therapeutic functions of MGL. The lack of potency, selectivity or the total 
disruption of the catalytic activity showed by these “early” inhibitors confined their 
development as potential drugs.  
The discovery of isothiazol-3(2H)-one (ITZ), benzo[d]isothiazol-3(2H)-one (BTZ) and 
triterpene derivatives as hit compounds for MGL inhibition has provided the 
fundamentals for the development of new potent MGL inhibitors with a novel 
mechanism. Therefore, there is a widespread interest of the scientific community in the 
development of allosteric inhibitors able to interact with the modulatory cysteines of 
MGL external to the active site, i.e. Cys201 and Cys208. The modulation of these 
critical residues is the access point for the comprehension of oxidation-depended 
inactivation of the enzyme (see Chapter 2). The design of redox-reversible inhibitors 
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targeting regulatory cysteines is a modern and powerful strategy to increase in a 
“physiological” way 2-AG signaling, avoiding side effects of a total and irreversible 
inhibition exerted by covalent modifiers of the catalytic triad. The major challenge of 
uncouple benefic and side effects of the endocannabinoid system stimulation requires 
the development of allosteric inhibitors of MGL. 
 
The research work discussed in this PhD thesis takes place within this overall picture. 
My work was aimed to the investigation of structure-activity relationships (SAR) of 
partially-reversible allosteric inhibitors of MGL, i.e. BTZ and triterpene derivatives, to 
increase the knowledge in a field still in its infancy. 
The results reported in this chapter are the outcome of an interdisciplinary research 
work involving different research area and groups. A comprehensive discussion of the 
role of BTZ and triterpenes derivatives as MGL inhibitors and the understanding of 
the workflow beyond the research process requires describing results not directly 
obtained from my own investigations. 
My work has been focused on the organic synthesis of BTZ and triterpene derivatives. 
Moreover, I performed reactivity studies on BTZ by means of NMR spectroscopy. 
Computational studies and reactivity analysis on BTZ by means of HPLC-UV and 
HPLC-ESI-MS have been performed from the computational and the bio-analytic part 
of the group where I spent my PhD period, respectively. Biological evaluation of the 
synthesized compounds on MGL was carried out by the research group of Prof. 
Piomelli (University of Irvine, California). 
 
 
3.1 BTZs as MGL inhibitors: results and discussion 
BTZs are characterized by the presence of a sulfenamide-based sulfhydryl-reactive 
warhead (red labeled) and driver groups R, R’ (blue labeled) necessary for a proper 
drug-target recognition and positioning and for the modulation of the warhead 
reactivity (Figure 3.1). The five–membered sulfenamide core is labile in a variety of 
ways. The sulfur atom tends to be the more electrophilic center of the S-N bond. 
Nucleophilic attack on sulfur can be taken by amines, by thiols, and by alkyl-
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magnesium halides, which leads to either new sulfenamide derivatives or compounds 
such as sulfides and disulfides. 
 
 
Figure 3.1 BTZ general structure: warhead portion (red labeled) and driver portion (blue labeled) 
 
Sanchez1 reported the synthesis of a series of unsymmetrical disulfides through a 
reaction involving a ring opening nucleophilic attack of a thiol on BTZs, confirming 
the high reactivity of these compounds toward sulfur-based nucleophiles. The 
reactivity of the sulfur atom to nucleophilic addictions leading to a disulfide bond is, 
as seen in the previous chapter, at the base of the mechanism of inhibition on MGL. 
Moreover, BTZ are very sensitive to reducing agents: the S-N bond can be easily 
disrupted from common reducing agents (H2, hydrides) leading to the formation of 
the ring-opened sulfhydryl derivative. The sulfhydryl form is very susceptible to 
oxidation: air oxygen is sufficient to generate the symmetric disulfide.  
 
 
Scheme 3.1 Proposed route of degradation of I in aqueous solution, leading to formation of 
benzisothiazolinone II and sulfhydryl III 
 
Phillips et al.2 reported an interesting degradation reaction occurring in aqueous media 
for 2,2’-dithiobis[N-isoleucylbenzamide] I (Scheme 3.1), which can dismutate into its 
sulfhydryl monomer III and benzisothiazolinone II. BTZs, in aqueous environment, 
can be generated from disproportion of disulfides and they establish a dynamic 
equilibrium as outlined in Scheme 3.1. 
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Several methods have been reported for the synthesis of the BTZ scaffold3.  Most of 
these methods are based on an oxidative cyclization in the presence of chlorine, 
chlorinating agents or iodine with a nucleophilic attack exerted from the nitrogen 
atom on the activated sulfur atom.  
BTZs are compounds well known as additives in cosmetic preparations, paints and 
glues and as industrial biocides4. The biological properties of this class have been 
deeply investigated. BTZs showed antibacterial, antifungal, antimicrobial and 
genotoxic activities5. N-phenylbenzisothiazolones have been investigated as inhibitors 
of the tautomerase activity of the proinflammatory cytokine MIF (macrophage 
migration inhibitory factor): several BTZ-based compounds were found to possess 
antagonist activity in the low micromolar range6. BTZs were recently reported as 
promising caspase-3 7 , histone acetyltransferase 8  and blood platelet aggregation 
inhibitors 9. In a recent study conducted by Dahl and coworkers10 on the properties of a 
series of BTZs as inhibitors of the phosphomannose isomerase, the most promising 
compounds were profiled for bioavailability parameters, including metabolic stability, 
plasma stability, and permeability. The pharmacokinetic profile of a representative of 
this series was also assessed demonstrating the potential of these compounds for in 
vivo efficacy when dosed orally in disease models. 
 
The high inhibitory potency of BTZ compound 1 (Figure 3.2) on MGL showing a IC50 
of 59 nM, reported in the milestone work of King and colleagues11, represented a 
promising starting point to set up a structure-activity relationships (SAR) study. 
 
 
Figure 3.2 Structure of 2-octylbenzo[d]isothiazol-3(2H)-one 
 
The establishment of a covalent bond between MGL and BTZs allows to freely expand 
the diversity of decorating groups around the warhead core with reduced risk of 
binding loss. However, the driver portion of BTZ should be designed to assure a good 
basal affinity for MGL. This portion is also designed to modulate the reactivity of 
S
N
O
1
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sulfenamidic warhead through a differential contribution to its electronic distribution. 
The possibility of a double modulation of the driver portion by insertion of 
substituents at nitrogen (R) and modulatory groups on the benzene ring (R’) (Figure 
3.1) was a crucial criteria for the choice of BTZ over ITZ core as lead structure. 
The diversity of decorating group around the BTZ warhead was expanded in order to: 
1. explore the pharmacophoric space around the targeted Cys201/Cys208 in 
order to get crucial information about the drug-target interaction; 
2. modulate the reactivity of the sulfenamidic warhead to optimize their 
druggability; 
3. achieve a better activity-stability balance; 
Beside the biological evaluation of the newly synthesized BTZ derivatives on MGL, the 
modifications performed were aimed to increase the knowledge about the reactivity of 
this chemical class toward biological thiols in order to define a structure-reactivity 
landscape for BTZs. 
To accomplish these purposes 3 clusters of BTZs have been synthesized, as outlined in 
Table 3.1. 
 
Table 3.1. Overview of scaffold modifications around the BTZ core 
 
 
Cluster 1 Cluster 2 Cluster 3 
X R R’ X R R’ X R R’ 
CH2 
H 
Alkyl 
Alkylaryl 
H CH2 Benzyl 
Nitro 
Hydroxy 
Alkyloxy 
Alkyl 
N-H 
N-
Me 
Alkylaryl 
 
 
H 
 
Compounds variously substituted on the sulfenamidic nitrogen with alkyl or alkylaryl 
substituents populate Cluster 1. Starting from the reference compound 1, the influence 
of lipophilicity, shape and steric hindrance of the lateral chain were explored. 
Compounds belonging to Cluster 2 were synthesized to evaluate the influence of 
substituents with different electronic and steric properties on the benzene ring of BTZ 
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warhead. We tried to achieve a modulation of inhibitory potency on MGL by affecting 
the reactivity of the sulfenamidic warhead. Cluster 3 is populated by 2-aminoalkylaryl 
derivatives and bidentate ligands. 
 
 
3.1.1 Chemistry 
For the synthesis of compounds belonging to Cluster 1, outlined in Scheme 3.2, 
different strategies were applied. Final products 3 and 5 were obtained via nucleophilic 
substitution from commercially available compounds 2, treated with potassium 
carbonate and a proper electrophilic side chain. This reaction was carried out 
activating the benzo[d]isothiazol-3(2H)-one 2 in basic conditions to obtain in situ the 
activated nucleophilic benzo[d]isothiazol-3-olate salt.  
 
 
Scheme 3.2 Synthesis of BTZs and ITZ belonging to Cluster 1. Reagents and conditions: a) K2CO3, alkyl halide, 
MeCN, r.t., 16h; b) K2CO3, KI, MeCN, 60° C, 16h; c) SOCl2, reflux, 6h; d) Cl2, CCl4, r.t., 2h; e) amine, dry TEA, 
r.t., 16h f) 2-phenylethanamine, dry TEA, dry DCE, r.t., 2h; g) SO2Cl2, dry DCE, 0° C, 2h. 
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Compound 4, an intermediate with a terminal chlorine atom in the side chain, was 
converted to final product 5 by a simple displacement of the chlorine using piperidine 
as nucleophilic species. Since a basic environment is required to deprotonate the 
nitrogen of benzo[d]isothiazol-3(2H)-one, the occurrence of elimination side reactions 
made this synthetic strategy not suitable to obtain final compounds in which aliphatic 
side chains were joined to the heterocyclic warhead by a secondary carbon. In order to 
move around to this side reactions occurrence and to achieve a good synthetic 
methodology for the preparation of N-alkylaryl and N-alkyl derivatives, other 
synthetic routes were carried out. Compounds 9-12 were synthesized in a 3-step 
sequence starting from dithiosalicylic acid 6 converted into the corresponding acyl 
chloride by reaction with SOCl2 and oxidized in presence of bubbling gaseous chlorine 
to generate intermediate 8 that, after reaction with the proper amine, led to the 
formation of compounds 9-12 in modest to good yields. To Cluster 1 belongs also the 
isothiazolinone 16 that was synthesized with a similar procedure: acyl chloride 14 was 
firstly reacted with 2-phenethylamine and the isolated amide 15 was then subjected to 
oxidative cyclization exerted by SO2Cl2. 
Phenyl-substituted BTZs 23-30 belonging to Cluster 2 were synthesized with a 
common procedure as outlined in Scheme 3.3. The strategy used for synthesis of 
Cluster 1-BTZs was not exploitable due to the lack of commercially available properly 
substituted dithiosalicylic derivatives. The key step of the synthetic procedure 
employed is the insertion of the sulfur atom on the phenyl ring that was accomplished 
through the Newman-Kwart rearrangement (NKR). The NKR allows access to 
thiophenols from phenols, as O-thiocarbamates are readily prepared and hydrolysis of 
S-thiocarbamates can readily be achieved. Indeed, intramolecular aryl migration of O-
thiocarbamates (19a-e) at high temperatures led to S-thiocarbamates (20a-e). As the 
NKR requires elevated temperatures, several side reactions can occur, and these can be 
catalyzed by trace impurities. The use of N,N-dimethylthiocarbamates has a major 
advantage in that these compounds tend to crystallize more easily and can therefore 
be easily purified. The accepted mechanism for the NKR, confirmed by kinetics 
experiments, is depicted in Scheme 3.4. The reaction exhibits the first-order kinetics 
typical for intramolecular reactions together with a large and negative entropy of 
activation. The driving force is the thermodynamically favorable conversion of a C=S 
into a C=O bond (ΔH ~ 13 kcal mol-1). Typically for aromatic nucleophilic substitution 
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reactions, electron-withdrawing groups in the para- and ortho-positions show a 
substantial activating effect. 
 
 
Scheme 3.3 Synthesis of BTZs belonging to Cluster 2. Reagents and conditions: a) conc. H2SO4, super-dry 
MeOH, reflux; b) DABCO or NaH, N,N-dithiocarbamoylchloride, dry DMF; c) MW, diphenylether; d) 
NaOH, MeOH/H2O 2:1, reflux; e) SOCl2, reflux, 6h; f) 2-phenylethanamine, dry TEA then I2, dry THF, 0°C to 
r.t., 20h; g) BBr3, dry benzene 0°C to reflux, 3h; h) K2CO3, EtBr, dry MeCN, 0° C to 30° C, 25h 
 
 
Scheme 3.4 Mechanism of NKR 
 
The use of a pressure-proof microwave oven allowed discarding the classical heating 
conditions that led to destruction of the substrate and to formation of side products on 
prolonged contact with the hot reaction vessel walls. The microwave-assisted 
procedure provided a significant reduction of the reaction times and a slightly increase 
in yields. 
The properly substituted 2-hydroxy methylbenzoate 18a-e was reacted with N,N-
dithiocarbamoyl chloride in presence of a base in dimethylformamide (DMF). The 
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choice of the base was influenced by the acidity of the hydroxyl group. The basic 
catalysis exerted by 1,4-diazabicyclo[2.2.2]octane (DABCO) was sufficient to obtain 
compounds 18a-b in good yield while resulted ineffective for compounds 18c-e. The 
latters required the use a stronger base such as sodium hydride (NaH) to reach 
appreciable conversions. After the NKR, S-thiocarmates 20a-e were hydrolyzed by 
exposure to NaOH, leading to the formation of 2-mercaptobenzoic acids 21a-e. 
Hydrolytic conditions were not effective for compound 20e, indeed, product 21e was 
not isolated, while the product of hydrolysis of 20e showed the intact thiocarbate 
moiety; this intermediate (methyl 2-((dimethylcarbamoyl)thio)-3-methylbenzoate) was 
used for the next reaction step exploiting the thiocarbate moiety as leaving group. 
Substituted benzoic acids 21a-d and the aforementioned product of 20e hydrolysis 
were then treated with SOCl2 to generate acyl chlorides 22a-e that were isolated and 
used without any further purification. The highly reactive acyl chlorides were finally 
subjected to a one-pot oxidative cyclization with 2-phenethylamine in anhydrous THF 
in presence of iodine, to generate final products 23-27 in good yields. Compounds 25 
and 26 were used to synthesize final products 28 and 29, respectively, through a 
demethylation reaction exerted by boron tribromide in benzene. Compound 30 was 
synthesized from product 29 via nucleophilic substitution with ethyl bromide in 
presence of potassium carbonate.  
The synthesis of BTZs belonging to Cluster 3 required the investigation of various 
synthetic pathways, outlined in Scheme 3.5. Strategy A was centered on the oxidative 
cyclization between dithiosalicylic chloride 7 and the preformed hydrazine IV. Results 
were not fully satisfactory due to the formation of a mixture of the 5-membered 
desired product V and the undesired 6-membered derivative VI.  
Strategy B was based on a classical reductive amination. BTZ VII was reacted with the 
proper aldehyde and after isolation of the imine derivative IX the reduction step was 
performed. As expected, classical imine reduction conditions (H2, Pd/C or NaBCNH3) 
led to ring opening of the BTZ core confirming the instability of the sulfenamidic 
moiety to reductive conditions. 
Synthesis of BTZs belonging to Cluster 3 was accomplished following Strategy C. Boc-
protected BTZ 31 was reacted, in presence of a base, with the proper lateral chain 
fragment XI functionalized with a leaving group (halide), following a SN2 mechanism. 
The subsequent cleavage of the protecting group allowed obtaining desired product V. 
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Scheme 3.5 Overview of synthetic strategies applied for the synthesis of BTZs belonging to Cluster 3 
 
This strategy revealed to be solid and versatile and was applied for the synthesis of a 
wide range of compounds. The choice of the proper base was fundamental to avoid 
elimination side-reactions and to increase the yield of the process. Potassium 
bis(trimethylsilyl)amide (KHMDS), a very hindered base, was chosen for its high basic 
properties and its low nucleophilic character thus avoiding the formation of undesired 
side-products. Intermediate 31 (Scheme 3.6) was generated, through the consolidated 
oxidative cyclization exerted by iodine, from compound 7 and tert-butyl 
hydrazinecarboxylate and was used as starting material for the synthesis of the final 
products. Compound 31, in a two-step reaction process according to Strategy C, was 
firstly treated with KHMDS and the proper alkyl halide and subsequently oxidized by 
means of iodine to generate intermediates 32a-d and 37a-b. In the second step, acidic 
cleavage of the Boc group by exposure to an equivolume mixture of trifluoroacetic 
acid and dichloromethane, afforded final products 33-36, 38 and 39. Compound 40 was 
obtained by methylation of final product 33 with methyl iodide and a nucleophilic 
weak base such as imidazole. 
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Scheme 3.6 Synthesis of BTZs belonging to Cluster 3. Reagents and conditions: a) tert-butyl 
hydrazinecarboxylate, dry TEA dry THF, 0°C to r.t., 16h then I2, r.t., 4h; b) KHMDS, alkyl halide, dry DMF, 
0° C to r.t., 16h; c) TFA, DCM, 0° C to r.t., 4h; d) MeI, imidazole, r.t., 16h 
 
 
3.1.2 Biological evaluation of BTZ derivatives on MGL 
The synthesized BTZ compounds were evaluated for their ability to inhibit 
recombinant purified rat MGL overexpressed in E. Coli. At first we investigated the 
influence of substituents on the nitrogen atom of the warhead core evaluating the role 
of lipophilicity and steric hindrance of the lateral chain. The IC50 values for BTZs 
belonging to Cluster 1 are reported in Table 3.2 along with that of the reference 
compound 1. Replacing the n-octyl group with an hydrogen atom (2) resulted in a 
significant decrease of the inhibitory potency (IC50 = 306.5 nM), witch was recovered 
with the introduction of a methyl substituent on the nitrogen atom (3 - IC50 = 59.5 nM). 
The lack of a N-substituent probably decreases the activity of compound 2 on MGL 
because of the existence of a prototropic equilibrium between the nitrogen and the 
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oxygen atoms of non-substituted isothiazol-3-one12. This hydrogen transfer induces 
the isothiazol-3-onic system aromatization and produces a fully aromatized 3-
hydroxybenzisothiazole (Scheme 3.7).  
 
Scheme 3.7 Prototropic equilibrium of compound 2 
 
In this form, the sulfenamidic system is not present, precluding any reactivity toward 
nucleophiles. Indeed, the S-N bond cleavage induced by a nucleophilic attack on 3-
hydroxybenzisothiazole sulfur atom is unfavored because it should lead to the 
disruption of heterocyclic system aromaticity. 
 
Table 3.2 Inhibition of purified recombinant rat MGL by BTZs and ITZ belonging to Cluster 1. 
 
Compound R IC50 (nM)a 
1 n-octyl 59 ± 7 
2 H 306.5 ± 32.7 
3 Me 59.5 ± 5.8 
12 
 
55.5 ± 7.4 
4 
 
195.2 ± 12.3 
9 
 
34.1 ± 2.0 
10 
 
21.8 ± 5.2 
11 
 
54.2 ± 15.7 
Compound Structure IC50 (nM) a 
16 
 
758.6 ± 49.8 
a Reported are Means ± SEM (n = 3-4) 
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The similar activity of compounds 1 (ClogP: 5.2) and 3 (ClogP: 1.5) suggests that the 
enzyme can tolerate broad modification of the N-side chain both in term of steric bulk 
and lipophilicity. This also suggests that an increase in lipophilicity does not bring to a 
parallel increase of potency in the BTZ series, differently to what had been observed 
for the less lipophilic isothiazolinone series (Chapter 2) The first hypothesis was 
confirmed by compound 12, bearing a cyclohexyl side chain that have intermediate 
properties in terms of ClogP (ClogP: 3.5) but a significant difference in terms of shape 
compared to the n-octyl group of reference compound 1. This shape variance, 
however, had no impact on potency, indeed, compounds 1 and 12 showed comparable 
IC50 values. The introduction of a side chain with a basic terminal pyperidine (4) 
brought a significant decrease of activity (IC50 = 195.2 nM) suggesting that protonation 
of the side chain could be detrimental because a certain level of lipophilicity is 
required to achieve good inhibitory potency on MGL. 
Compound 9, bearing a 2-phenethyl group that confers a lipophilicity within the 
“allowed” range (ClogP: 3.6), showed a slightly increment in the inhibitory potency 
(IC50 = 34.1 nM), revealing the profitable insertion of an aromatic portion in the side 
chain. With compounds 10 and 11 we explored the possibility to increase the aromatic 
portion with an α- and β-naphthyle group, respectively. Both these compounds 
showed high inhibitory potency on MGL with IC50 in the low nanomolar range 
appointing N-alkylaryl BTZ as the most promising hits. The slightly drop of potency of 
compound 11 compared to 10 suggests that the bent shape of the α-naphthyle group is 
better tolerated. Eventually, we synthesized for comparison the homologous ITZ 16 of 
leading compound 9 that showed a IC50 of 758.6 nM on MGL. 
Despite this result seems to point out BTZs as a more potent class of MGL inhibitors, is 
not appropriate to compare the inhibitory potency of BTZs and ITZs. This because the 
two classes have different SAR, indeed, previous studies on the ITZ octhilinone, 
revealed that increasing lipophilicity of the N-side chain enhanced activity on MGL11, 
while this finding is not found for the BTZ class. Moreover, site-direct mutagenesis 
studies in which individual regulatory Cys201 and Cys208 were replaced with 
alanines and the mutants were expressed in HeLa cells, had indicated different 
preferential target cysteines for the two classes. We examined how cysteine mutations 
influence the ability of compounds 9 and 16 to inhibit MGL.  
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Table 3.3 Inhibition of purified recombinant rat MGL by compounds 9 and 16 
with selective mutation of Cys201 and Cys208 
Cpd Structure 
IC50 (nM)a 
Wt C201A C208A C201-208A 
Cys Index 
(C201-208A/Wt) 
9 
 
34.1 
± 2.0 
242.9 
± 18.0 
72.6 
± 30.3 
604.7 
± 10.2 
17.7 
16 
 
758.6 
± 49.8 
461.5 
± 59.5 
1239.9  
± 20.4 
1968.9 
± 59.6 
2.6 
a Reported are Means ± SEM (n = 3-4) 
 
As outlined in Table 3.3, IC50 of compound 9 dropped to 242.9 nM when Cys201 was 
converted to alanine and to 72.6 nM on Cys208A MGL mutant. Conversely, compound 
16 showed a higher, yet limited, loss of potency when Cys208 was muted to alanine 
(IC50 = 1239.9), compared to wild-type MGL. These outcomes, in agreement with 
previous studies performed by Matuszak et al. on human MGL 13 , display the 
preferential interaction of BTZs with Cys201 while Cys208 seems to be the favorite 
target residue for ITZs. Evaluation of activity of compounds 9 and 16 on double 
mutants (C201/208A) MGL resulted in a significant decrease of inhibitory potency 
with IC50 of 604.7 nM and 1968.9 nM, respectively. This additive effect observed on the 
double mutant enzyme suggests that both Cys201 and Cys208 may be involved in the 
inhibition process exerted by BTZs and ITZs. A Cys index, calculated as the ratio 
between IC50 values on double mutant and wild type MGL, expresses the specificity of 
thiol-reactive inhibitors for the two cysteines Cys201 and Cys208. A high Cys index, as 
observed for compound 9, means that the inhibitor is much less potent in inhibiting 
MGL laking both the cysteines on the lid domain, so it is probably acting at one of 
these (or both). A small Cys index suggests that the inhibitor has other mechanisms, 
that could be, e.g., interaction with Cys242. 
 
We next conducted a deep study about the mechanism of action of lead compound 9 
and its MGL inhibitory effect on 2-AG signaling. We utilized a rapid dilution assay to 
assess whether compound 9 inhibits MGL through a reversible or irreversible 
mechanism. Purified MGL was first preincubated with a concentration of compound 9 
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that was 10-fold higher than its IC50 value, and then diluted 100-fold (to 10% of its IC50 
value). As shown in Figure 3.3B, the dilution produced a total recovery of enzyme 
activity. By contrast, when MGL was incubated with the irreversible serine-reacting 
probe MAFP, MGL activity did not recover after dilution. The restoration of the 
catalytic activity of the enzyme upon dilution revealed the reversible inhibitory 
mechanism of compound 9, consolidating previous findings reported for this class of 
compounds11,13. 
 
A B  
C D  
Figure 3.3 (A) Effects of compound 9 on wild-type MGL (circles), MGL mutants C201A, C208A or 
C201/208A. (B). Rapid dilution of MGL incubated with vehicle, compound 9 (10 µM final), or MAFP (23 nM 
final) (C) Effects of H2O2 (300 µM), alone or combined with CB1 antagonist Rimonabant, CB2 antagonist 
AM630, MGL inhibitor JZL-184 (1 µM) or compound 9 (1 µM), on LDH release.  
(D) Effect of compound 9 (30 mg/Kg i.p.) on 2-AG levels in rat brain 
 
Mutagenesis studies (Table 3.3, Figure 3.3A) and rapid dilution assay showed an 
H2O2-like behavior of compound 9 on MGL (see Chapter 2). To evaluate the ability of 
our compound to modulate 2-AG levels, in vitro and in vivo experiments were 
 
Chapter 3 – MGL inhibitors: results and discussion  
 
  
 
 70 
performed. Neuro-2a cells were incubated with high levels of H2O2 and evaluation of 
cellular damage using LDH was assessed (Figure 3.3C). The toxic effect of hydrogen 
peroxide (Figure 3.3C - entry 2) was heightened by CB1 blockade using the selective 
antagonist Rimonabant (Figure 3.3C - entry 3) but not by CB2 blockade (antagonist 
AM630, Figure 3.3C - entry 4). Conversely, LDH release was reduced by treatment 
with the irreversible MGL inhibitor JZL184 (Figure 3.3C - entry 5). Administration of 
compound 9 combined with H2O2 resulted in a reduction of cellular damage (Figure 
3.3C - entry 6) comparable with that of JZL184. These results display that blockade of 
MGL activity, and the consequent increase of 2-AG levels, reduces cellular damage 
elucidating the CB1-mediated neuroprotective role of 2-AG, and that compound 9 has 
the same ability as JZL184 to exert this blockade on Neuro-2a cells, when added at the 
same concentration. Moreover, administration of compound 9 in animal models with a 
dose of 30 mg/kg resulted in an increase of 2-AG levels in rat brain after 2 hours 
(Figure 3.3D). These outcomes display the ability of tested BTZ 9 to selective inhibit 
MGL catalytic activity and to modulate 2-AG signaling both in vitro and in vivo. 
 
The structure-activity relationships for BTZs belonging to Cluster 1 revealed the role of 
the side chain lipophilicity and the good tolerance of the enzyme to steric modification 
of the N-substituents, possibly due to the surface-exposed position of Cys201 and 
Cys208 that allows diversified accommodations of the lateral chain. We next 
investigated, through the introduction on the benzene ring in positions conjugated to 
the sulfur atom or to the carbonyl moiety, the effect of substituents with different 
electronic properties on the inhibitory potency of BTZs. We also evaluated the 
influence of a steric hindering group inserted close to the reactive sulfur atom. These 
scaffold modifications were aimed at modulating the reactivity of the sulfenamidic 
warhead. We synthesized compounds 23-30 (Cluster 2) keeping fixed the 2-phenethyl 
side chain of the lead compound 9. We inserted a polar electron-withdrawing group 
such as -nitro (23, 24), hydrophilic (-hydroxy 28, 29) and lipophilic (-methoxy and -
ethoxy 25, 26, 30) electron-donor groups at position 5 and 6 of the benzene ring. 
Evaluation of potency of Cluster 2-BTZs on rat MGL was assessed and the results, 
outlined in Table 3.4, revealed a general loss of potency. The most considerable 
decrease of potency was registered for compounds 29 and 27 with IC50 of 2.5 and 13.1 
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µM, respectively. No clear influence of the electronic effects on inhibitory potency 
emerged from BTZs belonging to this set.  
 
 
Table 3.4 Inhibition of purified recombinant rat MGL by BTZs belonging to Cluster 2 
 
 
 
Compound R IC50 (nM)a 
9 H 34.1 ± 2.0 
23 5-NO2 163.4 ± 2.8 
28 5-OH 135.0 ± 3.8 
25 5-OMe 568.0 ± 55.3 
24 6- NO2 237.9 ± 10.3 
29 6-OH 2547.0 ± 879.7 
26 6-OMe 512.2 ± 64.4 
30 6-OEt 208.4 ± 10.6 
27 7-Me 13069.5 ± 523.9 
a Reported are Means ± SEM (n = 3-4) 
 
 
On the other hand, the role of steric hindrance was evidenced with compound 27 (IC50 
= 13069.5 nM), which displayed the negative influence of a bulky group in position 7 
close to the reactive core of the molecule. The steric hindrance of the methyl group 
could reduce the reactivity of the warhead hampering the sulfur atom and reducing 
the rate of the nucleophilic attack by the thiol group of the targeted cysteine.  
 
The results obtained suggest that insertion of substituents on the benzene ring of BTZ 
is poorly tolerated and forced us to continue our SAR investigation focusing on the 
lateral chain that appeared to be the only fragment of the molecule susceptible to 
profitable modifications. To design new compounds for further SAR exploration, 
computational studies were performed. In order to evaluate the conformations of BTZ 
derivatives covalently bound to Cys201, as suggested by mutagenesis studies, the 
crystal structure of human MGL 3HJU was selected as model structure and it was used 
for covalent docking studies. Binding modes obtained for compounds 9 are 
represented in Figure 3.4A (orange carbons). The covalent adduct of compound 9 
showed a polar interaction between the sulfenamidic nitrogen and the backbone 
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oxygen of Pro198, which can stabilize the binding mode. Compound 33, bearing a 
nitrogen atom at the α-position of the sulfenamidic core, assumed a comparable 
conformation, but the polar interaction with the backbone carbonyl was taken by the 
peripheral (formerly exocyclic) NH group as depicted in Figure 3.4A (deep-teal 
carbons). Notably, the exocyclic nitrogen could enhance the water solubility of this 
derivative. It could be protonated under acidic conditions, thus increasing the 
electron-withdrawal effect of the exocyclic nitrogen on sulfenamidic system.  
 
 
Figure 3.4 (A) Covalently bound compounds 9 (orange carbons) and 33 (deep-teal carbons) assume a very 
similar binding mode, which is strengthened by the formation of hydrogen bonds (yellow dashes) with the 
backbone oxygen of Pro198. (B) The introduction of the N-methyl group in compound 40 (light cyan 
carbons) prevents the formation of polar contacts between the ligand and the protein 
 
Compound 33 showed a high inhibitory potency on MGL with a IC50 of 19.5 nM 
(Table 3.5), supporting our model. This encouraging result led us to explore SAR for 
this new cluster, populated by 2-amino derivatives. 
Compound 33, the most potent BTZ synthesized, was subjected to detailed studies on 
mutant enzymes. The results, outlined in Table 3.6, showed comparable potency on 
single mutants with a IC50 of 54.4 nM on C201A mutant and 44.9 nM on C208A MGL. 
This data revealed a different behavior from compound 9 with a loss of selectivity for 
Cys201. The additive effect of double mutation on inhibitory potency of compound 33 
was observed with a IC50 on C201-208A mutant of 782.0 nM.  
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The introduction of a methyl substituent on the exocyclic nitrogen yielded to 
compound 40. The results of binding modes obtained for compound 40, showing the 
influence of the methyl group that hamper the formation of any polar interaction 
(Figure 3.4B), were reflected by the 10-fold loss of activity observed for this compound 
(IC50 = 189.4 nM). 
 
Table 3.5 Inhibition of purified recombinant rat MGL by BTZs belonging to Cluster 3 
 
 
Compound Structure IC50 (nM) a 
9 
 
34.1 ± 2.0 
33 
 
19.5 ± 0.8 
40 
 
189.4 ± 39.7 
35 
 
277.7 ± 1.9 
34 
 
93.9 ± 5.5 
36 
 
322.1 ± 18.7 
38 
 
22.3 ± 3.7 
39 
 
21.0 ± 0.3 
a Reported are Means ± SEM (n = 3-4) 
 
The introduction of an acid group (35) in position 4 of the benzylamino side chain was 
devised to allow the formation of hydrogen bonds with Lys206 and Glu86, which were 
involved in an intramolecular saline bond in the crystal structure of the enzyme. 
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Hypothetical covalent adducts of MGL with compounds 35 and 34 are represented in 
Figure 3.5. 
 
Table 3.6 Inhibition of purified recombinant rat MGL by compound 33  
with selective mutation of Cys201 and Cys208 
Cpd Structure 
IC50 (nM) a 
Wt C201A C208A C201-208A 
Cys Index 
(C201-208A/Wt) 
33 
 
19.5 
± 0.8 
54.4 
± 4.1 
44.9 
± 8.7 
782.0 
± 77.5 
40.1 
a Reported are Means ± SEM (n = 3-4) 
 
These possible interactions, hypothesized by docking studies, are not sufficient to 
generate a specific in vitro enhancement of inhibitory potency, indeed, IC50 of 
compounds 35 and 34 on purified MGL are 277.7 nM and 93.9 nM, respectively. The 
introduction of a second phenyl ring in position 4 of the benzylamino side chain 
resulted in a loss of activity as well, with a IC50 for compound 36 of 322.1 nM. 
 
 
Figure 3.5 (A) Binding modes for compound 35 show the interaction of the acid group with Lys206 and 
Glu86. (B) Docking results for compound 34 gave binding modes comparable to that obtained for 35 
showing polar interactions with Lys206 
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As the modulation of the lateral chain of compound 33 always led to less active 
compounds, we next focused our attention on the investigation of bidentate ligands. 
Mutagenesis studies revealed that mutating both Cys201 and Cys208 to alanine 
reduced the inhibitory potency of BTZs, compared to WT MGL, supporting the design 
of compounds able to concurrently interact with both cysteines generating a 
synergistic inhibitory effect. To test this hypothesis an Induced Fit Docking study was 
performed in order to evaluate the binding mode of symmetric ligands, based on 
compound 33 scaffold, looking for the optimal linker length to reach both Cys201 and 
Cys208. The results of the Induced Fit Docking Study are represented in Figure 3.6.  
 
 
Figure 3.6 Both compounds 38 (blue carbons) and 39 (pink carbons) occupy the region separating CYS201 
from CYS208; orange dashes indicate the distance between the cysteines thiol groups and the benzo[d] 
isothiazol-3(2H)-one moieties of the symmetric compounds 
 
The flexible alkyl chain of both compounds 38 and 39 occupy the region situated 
between Cys201 and Cys208, while the sulfur atoms of the BTZ groups reside nearby 
the cysteines thiol groups, suggesting that both the pentyl and the hexyl linker 
represent suitable spacers. Compounds 38 and 39 showed IC50 of 11.6 and 16.8 nM, 
respectively, on purified rat MGL. To evaluate if these results are ascribable to a 
simultaneous interaction with both cysteines, compounds 38 and 39 were tested on 
mutant MGL. As reported in Table 3.7 compound 38 showed a 20-fold decrease in 
potency on both C201A and C208A single mutant. This result is consistent with a 
inhibitory mechanism that involves the simultaneous covalent reaction with both 
cysteines. This hypothesis is supported by the high values of IC50 on double mutant 
MGL (1460.7) and Cys Index. Compound 39 showed a minor loss of potency on single 
mutants, especially on C208A MGL (IC50 = 82.7 nM), and a 120-fold decrease of 
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inhibitory potency on double mutant with a Cys Index comparable to that of 
compound 39. 
 
Table 3.7 Inhibition of purified recombinant rat MGL by compound 38 and 39  
with selective mutation of Cys201 and Cys208 
Cpd Structure 
IC50 (nM)a 
Wt C201A C208A C201-208A 
Cys Index 
(C201-208A/Wt) 
38 
 
11.5  
± 1.5 
229.8  
± 69.0 
219.8  
± 33.9 
1460.7  
± 465.0 
127.0 
39 
 
16.8  
± 0.4 
114.3  
± 8.9 
82.7  
± 11.6 
2079.6  
± 40.0 
129.3 
a Reported are Means ± SEM (n = 3-4) 
 
 
3.1.3 Reactivity studies on BTZ derivatives 
To better understand the chemical properties of BTZ class and to evaluate the behavior 
of these compounds in presence of thiols of biological relevance, we performed 
detailed studies on their reactivity. The experimental reactivity of BTZs in the presence 
of thiols was studied by means of HPLC-UV and HPLC-ESI-MS analysis, monitoring 
the decreasing concentration of BTZ and the formation of new species as the reaction 
proceeded. Reactions were performed mimicking physiological conditions (PBS buffer, 
pH 7.4, 37° C) and choosing as reactive counterpart of BTZ the most abundant thiol in 
cells, glutathione (GSH). To minimize the potential interference of atmospheric oxygen 
on this elaborate ox-redox system, we performed reactions under argon atmosphere 
with degassed solvents. The first attempts were conducted using equimolar 
concentrations of BTZ and GSH, trying to measure the rate of the nucleophilic 
substitution of GSH on the sulfur atom of BTZs. However, reaction occurred in 
seconds and rate was impossible to be measured, as, for the majority of tested BTZs, at 
the first time point (i.e. t ∼ 30 s) BTZ had almost totally reacted with GSH. Moreover, 
the HPLC chromatogram revealed the formation of different reaction species, whose 
relative amounts were not reproducible from one experiment to another (data not 
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shown). Therefore, we decided to investigate the reactions of BTZ in presence of two 
equivalents of GSH and to monitor the time-course of reaction species in solution. We 
observed that at two different reaction time-points, t=60 and t =120 min, a condition of 
pseudo-equilibrium among reaction species was reached. t = 60 min was therefore 
chosen as appropriate reaction time to investigate the identity of unknown species in 
solution by HPLC-ESI-MS/MS analysis.  
 
 
Figure 3.7 HPLC-MS extracted ion chromatograms showing reaction species identified after a 60 min 
incubation of BTZ with two equivalents of GSH. 
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In Figure 3.7, the extracted ion chromatograms from a HR-MS full scan analysis (m/z = 
150-750 amu) in positive ion mode of a 60-min incubation of BTZ 9 with GSH are 
presented. At m/z = 308.09, Retention Time (RT) = 2.73 min a peak of monoprotonated 
molecular ion [M+H]+ corresponding to unreacted GSH was present (See LC/MS 
Trace #1). At m/z = 256.08 and RT = 22.49 min a small peak of unreacted BTZ is present 
(Trace #4). The other peak at RT = 24.48 min is the product ion from another species, 
the symmetric disulfide of BTZ, in solution (see below). 
At RT = 18.95 min, and at m/z = 563.16 (Trace 3) a peak was present, which 
corresponded to the BTZ conjugate with GSH. This conjugate BTZ-GSH was formed 
by a 1:1 reaction of BTZ with GSH (Scheme 3.8A).  
 
 
Scheme 3.8 A Reaction pathway of BTZ in presence of 2-fold excess of GSH B Disproportion of mixed and 
symmetric disulfides in aqueous media leading to formation of the native BTZ and the corresponding 
sulfhydryl monomer 
 
In presence of another equivalent of GSH, the BTZ-GSH conjugate was prone to 
further react generating a substituted thiosalicylamide BTZ-SH (m/z = 258.08, RT = 
21.35 min, Trace #5) and oxidized glutathione (GSSG, m/z = 613.16, RT = 4.18 min, 
Trace #2). Thiosalicylamide could react as a thiolic nucleophile able to attack both 
native BTZ and BTZ-GSH conjugate in order to generate symmetric disulfide (m/z = 
513.17, RT = 24.48 min, Trace #6), which in turn is susceptible of a new nucleophilic 
attack by GSH. On the other hand, the disproportion reaction of disulfides in aqueous 
media leading to restoration of BTZ and to the corresponding sulfhydryl compound 
(BTZ-SH or GSH) is well known in literature2 (Scheme 3.8B).  
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In our attempt to build a reactivity scale among the selected set of BTZs, we focused 
our attention on the measurement of the concentrations of unreacted GSH, of oxidized 
glutathione disulfide (GSSG) and on the formation of the mixed disulfide BTZ-GSH. 
Moreover, we monitored the concentration of BTZ still present under pseudo-
equilibrium conditions that could reveal the capability of BTZ to be regenerated in the 
ox-redox process and, therefore, to be available for further reactions with nucleophiles.  
As already stated, we aimed to modulate the reactivity of the BTZ nucleus vs. thiol 
nucleophiles by different substitution at positions 5 and 6 of the BTZ ring with groups 
endowed with opposite electronic properties. Substitution at position 7 was explored 
with the aim to evaluate the effect of an increased steric hindrance at this position on 
BTZ reactivity. In Table 3.8 are reported the results obtained for our set of BTZs after a 
60-min incubation time during which 200 µM GSH reacted with 100 µM BTZ. Due to 
the absence of an adequate calibration standard, we couldn’t quantify the BTZ-GSH 
conjugate present and we therefore reported in Table 3.8 the difference between initial 
concentration of GSH (200 µM) and the sum of final GSH + 2*GSSG concentrations. 
Peak areas derived from HPLC/UV runs were lower than the detection limits for 
compounds 24 and 27. The same was observed for compound 23, for which the 
estimated BTZ-GSH concentration was close to the standard deviation of the GSH 
concentrations measured. For the reference compound 9 no intact BTZ was detected, 
with a small amount of mixed disulfide, while GSH and GSSG were approximately 
equimolar. For the nitro derivatives 23 and 24 no BTZ nor BTZ-GSH were detected, 
which allows to simplify the complex scheme of reactions traced above to two half-cell 
reactions, consisting of GSH oxidation and BTZ reduction to a mixture of salicylamide 
and symmetrical dithiosalicylate. This is probably due to the fact that the electron 
withdrawing effect on the benzene rings destabilizes the mixed disulfide BTZ-GSH. In 
this context, the 5-nitro derivative 23 resulted a stronger oxidant than the 6-nitro, 
giving a significantly higher ratio GSSG/GSH, which is consistent with its conjugation 
to the sulfur atom. Compounds substituted with the electron-donating methoxy group 
gave significant residual concentrations of the mixed disulfide, more evident for the 5-
methoxy derivative 25, which also showed a small, yet detectable concentration of 
intact BTZ. Compared to the reference compound 9, the pseudo-equilibrium 
concentrations of reduced GSH did not show highly significant differences, pointing 
out a limited effect of this substituent on redox potential. The hydroxyl substituent 
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also caused a stabilization of the mixed disulfides BTZ-GSH, as evidenced by mass 
balance calculation and the highest peak areas observed by UV-HPLC (not shown). As 
all compounds 23-29 were less potent than 9 as MGL inhibitors, the relevance of 
electronic properties on this activity is not clear. On the other hand, this study clearly 
indicated that a substitution hindering the free access to the ring sulfur, as in the 7-
methyl derivative 27, strongly reduces the ability of the BTZ to react with the thiol 
group of free GSH. In parallel, compound 27 was much less potent than other 
compounds as a MGL inhibitor. 
 
Table 3.8 Reactivity of substituted BTZs with glutathione in PBS at pH 7.4. Concentrations of reaction 
species under equilibrium conditions (t = 60 min) 
 
 
Cpd R X 
[GSH]  
(µM)a 
[GSSG] 
(µM)a 
[BTZ] 
(µM)a 
Estimated 
[BTZ-GSH] 
(µM)a 
9 H CH2 73.4 ± 4.7 59.3 ± 1.1 < LOD 8.0 
23 5-NO2 CH2 32.1 ± 9.5 78.3 ± 4.8 < LOD 11.3 
24 6-NO2 CH2 105.1 ± 7.5 46.9 ± 1.3 < LOD 1.1 
25 5-OMe CH2 80.9 ± 3.8 40.7 ± 2.5 1.2 ± 0.5 37.7 
26 6-OMe CH2 66.1 ± 4.2 58.4 ± 3.5 < LOD 17.1 
28 5-OH CH2 83.1 ± 2.3 53.4 ± 0.7 < LOD 10.1  
29 6-OH CH2   30.7 ± 10.9 69.9 ± 4.1 1.3 ± 0.4 29.5  
27 7-Me CH2 186.6 ± 4.5 7.6 ± 0.2 99.3 ± 5.4 0.0 
33 H NH 23.8 ± 1.0 64.2 ± 7.8 2.5 ± 0.3 47.8 
a Reported are Means ± SD (n = 3); b LOD = limit of detection 
 
In principle, a good cysteine-addressed inhibitor should be able to react with target 
cysteines forming a stable disulfide adduct. From this point of view, 
benzisothiazolinone is a highly reactive warhead, and a significant reduction of its 
reactivity leads to a loss of potency. On the other hand, its ability to maintain (or 
regenerate at equilibrium) a significant concentration of intact warhead in the presence 
of high concentrations of competing thiols (e.g. reduced GSH within a cell) could be 
useful for in vitro and in vivo activity. Interestingly, the 2-amino derivative 33 showed 
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both the ability to react with GSH, forming a rather stable mixed disulfide, and the 
highest concentration of intact BTZ after 1 hour. 
 
While these experiments gave indications on the behavior of BTZs at longer times, to 
get information about the kinetics of this warhead with thiols we setup a new series of 
experiments based on 1H-NMR spectroscopy.  
As the reactive counterpart of BTZs we chose N-acetyl cysteine (NAC) in order to have 
a structural accessible thiol easy to be monitored by NMR spectroscopy. Equimolar 
concentration of BTZ and NAC were dissolved separately in a deuterated solvent with 
a final concentration of 80 mM and they were rapidly mixed in a NMR tube at 25° C. 
The first monodimensional proton spectra was recorded after 4 minutes (technical 
time necessary to set up the experiment) and than spectra were collected every 2 
minutes until reaction was complete. We monitored the variation of signals intensity 
corresponding to BTZ and NAC and the appearance of new resonance peaks 
belonging to new species generated after the reaction between the substrates. The 
choice of the proper deuterated solvent was fundamental for the success of the 
experiments. First attempts were conducted in PBS-deuterated water (PBS-D2O) in 
order to mimic physiological conditions and to obtain results that could be compared 
to reactivity studies with GSH. The lack of sensitivity of NMR methodology forced us 
to use high concentration of the reactive partners, which generated solubility 
problems. Moreover, the reaction in PBS-D2O was complete at first checkpoint (t = 4 
min) with formation of different species that generated complex spectra, confirming 
results obtained during the reactivity studies with GSH. The use of deuterated 
methanol (MeOD) solved solubility problems and decreased the rate of reaction 
allowing monitoring the time-course of the first step of the reaction.  
Nucleophilic attack of thiol group of NAC on sulfenamidic sulfur of BTZ leads to the 
formation of an adduct BTZ-NAC, that in these conditions is stable and not susceptible 
to side reaction or disproportion events, generating readable spectra in which is 
possible to easily identify BTZ, NAC and the adduct signals. In particular, in the 1H-
NMR spectra of the reaction mixture, we monitored the singlet corresponding to the 
acetyl group of NAC (2.0 ppm) and the one belonging to BTZ-NAC adduct that is 
shifted at higher magnetic fields (∼ 1.9 ppm). Other significant signals are the 
methylenic hydrogens of NAC in α position to the sulfhydryl group, which generate a 
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double quartet at 2.9 ppm. In the BTZ-NAC adduct the two methylenic protons 
become diastereotopic generating an AB system with two distinct doublet of doublets 
at ∼ 3.0 and ∼ 3.2 ppm.  
 
A  
B  
Figure 3.8 1H-NMR of reaction between compound 2 and NAC.  
Spectra registered at 4 min (A) and 40 min (B). 
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In Figure 3.8 are reported, as an example, NMR spectra of compound 2 reacting with 
NAC. The two spectra registered at 4 min (A) and 40 min (B) reveal clearly the time 
course of reaction with decrease of BTZ and NAC peaks (blue and green respectively) 
and the concomitant proportional appearance of BTZ-NAC signals (magenta). 
Quantification of reaction species in solution was afforded trough integration of 
significant peaks, proportional to the relative concentrations. Kinetic traces of reaction 
between BTZ and NAC were obtained plotting concentrations, expressed as molar 
fraction (Xi), over time. In Figure 3.9A is reported as example the time course of 
reaction between compound 2 and NAC showing the progressive disappearance of 
NAC (red trace) and the proportional appearance of the BTZ-NAC adduct (light blue 
trace).  
 
A B  
Figure 3.9 Kinetic traces for the reaction of compound 2 with NAC. Concentrations were determined by 1H-
NMR. (A) The disappearance of NAC (red trace) and the appearance of BTZ-NAC adduct (light blue trace) 
vs. time. (B) Plot of 1/xNAC vs. time shows a linear trend up to 70% of conversion (second-order reaction) 
 
The determination of the reaction order was fundamental to calculate parameter such 
as the rate constant (κ) and the half-life (t1/2) of species involved and, therefore, to 
obtain crucial information about the rate of the transformation. Interaction between 
BTZ and NAC (eq. 1) gives a second-order reaction with a rate law described by eq. 2. 
The integrated rate law (eq. 3) shows that the plot of reciprocal of NAC concentration 
vs. time should be a straight line. In Figure 3.9B we report the plot on 1/xNAC vs. time 
for compound 2.  
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eq. 2: !! = !− !!! !"#!"# = !!! !!" ! 
eq. 3:  1!"# ! − 1!"# ! = !!" 
 
Reaction of 2 with NAC follows a second order rate law (linear plot) between 0 and 30 
min corresponding to 70% of NAC reacted, while it deviates from a linear trend in last 
part of the interaction. This behavior could be ascribed to diffusion problems that 
reduced the rate of reaction when the concentration of the reactants decreased. 
Therefore, we proceeded to calculate the rate constant of reaction (κ) for the liner part 
of the plot, represented by the slope of the straight line and, through eq. 4, the t1/2 of 
NAC resulting in 9.95 min (Table 3.9). 
 
eq. 4: !! ! = ! 1! !"# ! 
 
We next tested compounds 9, 33, 23, 29 in the same experimental conditions. The 
results are outlined in Table 3.9. Compounds 9 and 29 showed the same behavior of 
compound 2: up to 70% of conversion, data were fitted by a linear trend according to a 
second-order reaction. For these compounds, it was possible to calculate NAC half-
time, that was of 3.56 minutes for 9 and 10.78 minutes for 29. Reaction of compounds 
33 and 23 was complete at first checkpoint (t = 4 min) and was impossible to determine 
NAC half-time, that was, therefore, lower than 2 minutes. The results obtained by this 
kinetic investigation can be correlated to the in vitro potency of BTZ. Compounds 
showing the highest NAC half-live values (2 and 29) are the less potent on MGL, 
conversely compounds 9 and 33 that show a fast rate of reaction with NAC are very 
potent on the enzyme confirming the hypothesis that inhibition exerted by BTZ on 
MGL is strictly dependent from their inner warhead reactivity toward thiol 
nucleophiles. Comparing the last data with those obtained with GSH in water, it can 
be speculated that more different requirements must be fulfilled to have a potent MGL 
inhibitor addressing exposed cysteines. Thus, while compound 29 had shown 
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favorable features in the first test (formation of stable disulfide adduct, presence of a 
small quote of intact BTZ), its lower reaction rate is probably the reason of low 
inhibitory potency. On the other hand, the nitro-derivative 23 has a good reaction rate, 
but its lack of ability to form stable adducts can explain its lower potency, compared to 
compound 33. 
 
Table 3.9 Calculation of NAC half-time by 1H-NMR 
Compound Structure NAC t½ (min)a 
2 
 
9.95 ± 0.28 
9 
 
3.56 ± 0.49 
33 
 
<2b 
23 
 
<2b 
29 
 
10.78 ± 0.57 
a Reported are Means ± SD (n = 3); b Reaction complete at first checkpoint (t = 4 min) 
 
 
3.2 Triterpenes as MGL inhibitors: results and discussion 
As anticipated in Chapter 2, from the screening of a chemical library, King and 
coworkers14 reported pristimerin 42 (Figure 3.10) as a potent inhibitor of purified MGL 
with a median effective concentration (IC50) of 93 nM. Enzyme assays showed that also 
euphol, a bioisoster of pristimerin, inhibits purified MGL with an IC50 of 315 nM.  
SAR studies were conducted by King and colleagues on friedelane-based pentacyclic 
triterpenoids including celastrol 41, dihydrocelastrol 43 and pristimerol 44 (Figure 
3.10). The inhibitory potencies of these compounds appeared to be particularly 
sensitive to chemical modifications at the two opposite ends of their rigid terpenoid 
scaffold: the esterification of the carboxyl group at carbon 29, which increased 
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inhibitory activity, and the reduction of the quinone methide ring, which decreased 
such activity. During my PhD research I investigated SAR for this class of terpenoids. 
The crystal structure of human MGL 3HJU was selected as model structure and it was 
used for docking studies. Binding modes obtained for pristimerin showed the 
triterpene can be placed at the entrance of the substrate cavity, thus affecting lid 
domain flexibility and the access of the substrate to the catalytic pocket (Figure 3.11A). 
 
 
Figure 3.10 Structures of friedelane-based pentacyclic triterpenoids 
 
A B  
Figure 3.11 A Binding modes for pristimerin 42 show the blockade of the lid domain (red) and the 
occupancy of the substrate cavity. B Detail of the interaction with a backbone carbonyl 
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In the docked pose, the ester group of pristimerin pointed toward a backbone carbonyl 
of MGL (Figure 3.11B). This model can explain the loss of potency of celastrol 41 
observed by King et al. (IC50 = 1.6 µM), ascribing it to electrostatic repulsion between 
the carboxilate anion of celastrol and the backbone carbonyl. In the same docking pose, 
the methyl group linked to the pristimerin ester lined a loop of the lid domain, taking 
hydrophobic interactions. This loop is just above the region of the lid domain that 
includes Cys201 and Cys208. We tested this hypothesis by increasing the lipophilicity 
of the ester group to assess possible hydrophobic interactions with the lid domain. 
Furthermore, the ester moiety was replaced with an amide group to test the possibility 
of an hydrogen bond interaction with a backbone carbonyl. 
 
 
3.2.1 Chemistry 
Synthesis of triterpenoids derivatives was accomplished starting from the 
commercially available carboxilic acid 41 (celastrol) as outlined in Scheme 3.9. Ester 
derivatives 42 and 45 were synthesized by treatment of celastrol 41 with a mild base 
such as NaHCO3 in order to ensure deprotonation of the acidic group without 
interfering with the quinone-methide hydroxyl group. Subsequent substitution 
reaction of the preformed celastrol carboxylate on methyle iodide or 2-bromoethyl 
benzene afforded the desired products 42 and 45 in high yields.  
 
 
Scheme 3.9 Synthesis of celastrol derivatives. Reagents and conditions: a) NaHCO3, MeI or 2-bromoethyl 
benzene, dry DMF, r.t., 20h; b) HATU, DIPEA, methylamine or 2-phenylethanamine, dry DMF 0° C to r.t., 
20h. 
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The synthesis of the amide derivatives of celastrol 46 and 47 was successfully achieved 
through the use of the coupling agent 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU).  
In the first step (Scheme 3.10) the carboxylate anion, formed by deprotonation exerted 
by the Hunig’s base DIPEA, attacks HATU to form the unstable O-
acyl(tetramethyl)isouronium salt. The generated anion rapidly attacks the isouronium 
salt, affording the activated ester and giving a stoichiometric quantity of 
tetramethylurea. Addition of the nucleophilic amine, methylamine or 2- 
phenylethanamine, to the activated ester resulted in the acylation of the carboxylic 
moiety leading to formation of final compounds 46 and 47. 
 
 
Scheme 3.10 Mechanism of action of coupling agent HATU 
 
 
3.2.2 Biological evaluation of celastrol derivatives on MGL 
Synthesized triterpenes were incubated with non-purified rat MGL (cell lysates of 
MGL-transfected HeLa cells) to evaluate their inhibitory potency and the results are 
outlined in Table 3.10. Re-synthesized pristimerin 42 was re-tested on MGL and 
revealed a IC50 of 568 nM. The difference with previous data that reported a IC50 of 93 
nM can be ascribed to a dissimilarity in the protocol used during the in vitro test 
(purified vs. non-purified MGL). The replacement of the methyl group of the ester 
functionality (compound 42) with a more bulky and lipophilic substituent such as the 
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2-phenethyl group (compound 45) didn’t result in enhancement of potency as 
expected from computational studies. However, only a small increase of IC50 (796 nM, 
1.5x) was observed, which suggests that hindered lipophilic groups are tolerated. In 
spite of the lack of additional hydrophobic interactions, this is not in open contrast 
with the proposed docking pose, where solvent, instead of lining the hydrophobic lid 
domain, could also surround the phenethyl group.  
 
Table 3.10 Inhibition of non-purified rat MGL by triterpenes derivatives 
 
Compound X R IC50 (nM) 
42 O Me 568  
45 O 
 
796 
46 NH Me 1478 
47 NH 
 
1437 
 
On the other hand, the amide-based compounds 46 and 47 showed a marked decrease 
of inhibitory potency on MGL, which is inconsistent with the possibility to take an 
attractive polar interaction with the backbone carbonyl pointed out by the docking 
study. These controversial results could be due to the fact that lid-domain flexibility 
has a negative impact on the predictivity of static docking models. However, the 
present results, although based on limited exploration of the chemical space, 
discourage the aim of improving the MGL-inhibitor potency of pristimerin derivatives 
through simple modifications at the ester functionality. 
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3.3 Conclusions 
The role of MGL as key enzyme of the ECS has been thoroughly discussed in this PhD 
dissertation. The discovery of partially-reversible modulators (ITZs and BTZs) of this 
enzyme has been an extraordinary step forward in the field of MGL inhibitors. This 
class to regulates the activity of the enzyme through an allosteric modulation of the 
cysteines 201 and 208, preserving the integrity of the catalytic site. This approach has 
some potential advantages, or at least differences, with respect to known active-site 
directed (ASD) covalent inhibitors: (i) although non-competitive, MGL inhibition by 
cysteine-trapping agents is reversible, avoiding both competition with high 
concentrations of substrate (which would reduce activity) and prolonged inhibition of 
MGL function; (ii) the analogy between their effect on wild type and Cys-mutated 
MGL and that of hydrogen peroxyde suggests that, while MGL inhibition could be a 
way fro the cell to stimulate antioxidant defenses in the presence of increasing levels of 
ROS, BTZs could mimic the same stimulation while avoiding the damages due to 
oxidation; (iii) MGL inhibition by these compounds is redox-sensitive: this could lead 
to selective activation of the endocannabinoid system, possibly avoiding the 
cannabinoid-like effects observed for active site inhibitors. While these potential 
advantages still need to be confirmed by in vivo studies, structural optimization of 
BTZ inhibitors, comprehension of the role of their interaction with thiols and SAR 
exploration was a prerequisite for these studies. 
During my PhD research a deep SAR study for BTZs as MGL inhibitors has been 
performed. As a result of the SAR investigation, we identified promising lead 
compounds 9 and 33 with IC50 of 34 and 19 nM and bidentate ligands 38 and 39 with 
IC50 of 11 and 16 nM on the purified enzyme, respectively, improving the potency of 
reference compound 1.  
SAR gathered for BTZ derivatives point out how the recognition portion, able to 
establish non-covalent interaction with the target enzyme, plays a marginal role in the 
inhibition process exerted by BTZs suggesting that their relatively high inhibitory 
potency on MGL is likely due to the reactivity of the sulfenamidic fragment toward 
thiol-based nucleophiles.  
Kinetic experiments and reactivity studies performed in presence of biological thiols 
supports this finding. Indeed, kinetic experiment with NAC outlined a significant 
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correlation between the in vitro potency of BTZ and their experimental reactivity, i.e. 
the compounds revealing the highest reaction rates are the ones most potent on MGL. 
Moreover, reactivity studies with GSH revealed the complex behavior of the BTZ class 
if exposed to biological thiols in physiological conditions. BTZs instantly react with 
GSH establishing a pseudo-equilibrium condition among different oxidized species. 
The modulation of the BTZ core reactivity by introduction of electronically diversified 
substituents, didn’t afford valuable results. Only with the introduction of a bulky 
group close to reactive sulfur atom, a decrease of reactivity can be achieved resulting, 
unfortunately, in an undesired loss of potency. Although BTZs can be depleted by 
intracellular GSH, the discovery of compounds able to be restored during the ox-redox 
process is a promising outcome. 
The recent findings about the sensitivity of MGL to oxidation stimuli are an important 
breakthrough in the knowledge of the biological relevance of this enzyme. These 
studies, developed from collaboration between the research group where I spent my 
PhD period and the research group of Professor Piomelli (University of Irvine, 
California) revealed the inhibitory effect of hydrogen peroxide exerted through 
oxidative sulfenylation of critical cysteines 201 and 208.  
The major achievement of our research work was to characterize the mechanism of 
action and SAR of a class of MGL inhibitors, BTZs, able to mimic the physiological 
inactivation exerted by H2O2. We speculate that BTZs mimic the oxidative action of 
hydrogen peroxide acting on key cysteine residues 201 and 208 of MGL, uncoupling 
the damage suffered from all cellular compartments after oxidative stress from the 
physiological “protective” inactivation of MGL. This hypothesis is corroborated by the 
in vitro and in vivo studies performed on compound 9 showing that blockade of MGL 
activity reduces cellular damage exerted by hydrogen peroxide and increase 2-AG 
content in rats brain. Compound 9 revealed to be a valuable tool for elucidating the 
neuroprotective role of 2-AG in response to oxidative stress events. These findings 
appoint BTZs as promising inhibitors with a potential application as neuroprotective 
agents. 
However, the molecular mechanism at the basis of the inhibition exerted by H2O2 and 
BTZs still need to be elucidated. Our hypothesis is centered around the flexibility of 
the lid domain, that can generate an “open” or a “closed” conformation of MGL, as 
supported by crystallographic data, allowing or blocking the access of the substrate to 
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the catalytic site. Hydrogen peroxide and BTZs, acting on the peroxidatic cysteines 
located on the lid domain, could induce and/or stabilize the structural “closed” 
conformation associated with a low catalytic activity of MGL. Metadynamics and 
molecular modeling studies have been performed to explore the conformational space 
of MGL with particular focus on the lid domain flexibility. Preliminary evidences, 
which need to be further validated, showed that metadynamics of MGL modeled from 
the crystal structure assume a stable “open“ conformation corresponding to a free 
energy minimum (Figure 3.12A). When models simulating oxidation of Cys201 by 
sulfenylation (mimicking the hydrogen peroxide action) or by formation of a disulfide 
bond (mimicking the inhibition of BTZs) were explored, a switch from the “open” to 
the “closed” conformation, thus blocking the recruitment of the substrate, was 
observed (Figure 3.12B,C).  
The understanding of the molecular mechanism of inhibitions exerted by BTZs is a 
fundamental tool to proceed the investigation of these promising inhibitors.  
 
The SAR investigation performed on celastrol-based triterpenes reveal the 
troublesome development of this class of compounds as exploitable MGL inhibitors. 
The rigid scaffold of the molecule allows few structural modification: the exploration 
of the quinone methide ring and the carboxyl group at carbon 29 have been reported 
in the present and in previous studies leading always to less active compounds 
compared to the reference inhibitor pristimerin. While this is not sufficient to rule out 
the possibility that MGL-inhibitor potency of triterpenes could be improved by 
chemical modification, at the moment we conclude that, among the classes of 
compounds interacting with the regulatory function of cysteines within the lid 
domain, BTZ derivatives appear more promising for further chemical development. 
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A  
B C  
Figure 3.12 Well-tempered Metadynamics on MGL. The distances between CA of selected residues (D1 and 
D2, red arrows) on the lid domain rims have been used as collective variables describing the lid domain 
motions. (A) Metadynamics simulation of MGL modeled from the crystal structure (grey cartoon) shows an 
energy minimum corresponding to an “open” conformation of the lid domain (orange cartoon). (B, C) 
Metadynamics simulations of MGL modeled with C201 oxidized to sulfenic acid (red cartoon) and MGL 
modeled with compound 9 covalently bound to C201 (green cartoon) show free energy minima 
corresponding to “closed” conformations of the lid domain. 
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Chapter 
4 
 
 
 
Synthesis of NSC172285: 
a stereochemistry issue 
 
 
4.1 Introduction 
Fibroblast growth factor-2 (FGF2) is a member of a large family of structurally related 
proteins that affect the growth, differentiation, migration and survival of a wide 
variety of cell types1. FGF2 and other members of the FGF family bind to heparin and 
heparan sulfate, linear sulfated polysaccharides known as glycosaminoglycans2. The 
binding of FGF2 to heparan sulfate has been demonstrated to reflect a complex 
biochemical regulatory mechanism for this growth factor. The interaction of FGF2 with 
heparin protects FGF2 against heat or acid denaturation and protease cleavage. While 
heparin is only synthesized by connective tissue mast cells, heparan sulfate is widely 
distributed throughout all mammalian tissues and organs attached to core proteins as 
heparan sulfate proteoglycans (HSPG). HSPGs are a functionally diverse class of 
molecules found on cell surfaces and in the extracellular matrix where they have been 
demonstrated to interact with FGF2 and modulate its distribution and function3. FGF2 
interacts with specific cell surface receptor proteins derived from four separate genes 
(FGFR1–4)4. A number of splice variants exist for each receptor type resulting in 
differing ligand binding domains. The splice variants confer specificity in signaling in 
response to the various FGF family members. FGF2 has been proposed to have two 
separate receptor binding sites, which might allow a single FGF2 to bind to two 
receptors or to interact with a single receptor in two separate positions5. HSPGs can 
increase the affinity of FGF2 for its receptors6 and potentially act as a bridge to 
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facilitate the dimerization of receptors leading to the formation of productive 
HSPG/FGF2/FGFR ternary complexes7 (Figure 4.1).  
 
 
Figure 4.1 Schematic of FGF2 signaling pathways 
 
FGF2 plays key roles in development, remodeling and disease states in almost every 
organ system1. One of the best characterized activities of FGF2 is its ability to regulate 
the growth, chemotaxis and function of vascular cells such as endothelial and smooth 
muscle cells 8. In vivo, FGF2 shows angiogenic activity in different experimental 
models 9  and modulates neovascularization during wound healing, inflammation, 
atherosclerosis and tumor growth10, thus representing a possible target for anti-
angiogenic therapies11.  
Natural and synthetic molecules able to interfere with HSPG/FGF2/FGFR interaction 
may act as angiogenesis inhibitors. To this respect, structural analysis of FGFR ligands 
and screening of random phage epitope libraries have led to the design of synthetic 
peptides able to target FGFRs and compete for ligand binding, thus inhibiting the 
FGF2 activates a number of 
intracellular signaling pathways. The 
binding of FGF2 to its receptors is 
enhanced by cell surface HSPG and 
leads to activation of 
autophosphorylation of the FGFR on 
several tyrosine residues. The specific 
signaling pathways depend on the 
particular FGFR type activated. 
Signaling directly from cell surface 
HSPGs, as well as direct actions of 
intracellular and nuclear FGF2 might 
also be important in determining the 
cellular response. As a result of this 
complexity, FGF2 activation of various 
cell types can lead to a number of end-
point biological responses such as 
stimulation of cell proliferation and 
migration, and either stimulation or 
inhibition of the expression of a 
particular differentiated phenotype 
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biological activity of FGF212. Similarly, FGF2-binding peptides have been identified as 
in vitro and/or in vivo FGF2 antagonists.  
 
Presta and coworkers at the University of Brescia have recently discovered from a 
virtual screening campaign of a National Cancer Institute (NCI) library, a promising 
new inhibitor of the FGF2-FGFR interaction. The steroid-based compound NSC172285 
emerged from this screening was found to bind the FGF2 portion involved in the 
interaction with FGFR thus blocking the formation of the ternary complex 
HSPG/FGF2/FGFR necessary for the correct signaling pathway. NSC172285 was 
tested in vitro on multiple human myeloma cells and revealed to inhibit cell 
proliferation with a IC50 of 3.6 µM (Figure 4.2A). Moreover, in addiction to the 
antiproliferative activity it showed a promising cytotoxic effect on myeloma cells: at 6 
µM cell death for apoptosis was found to be almost 80% while at 10 µM cell death was 
100% (Figure 4.2B). This preliminary in vitro studies displayed promising 
antiproliferative and citotoxic properties of this FGF2 inhibitor. Therefore further 
analyses were required to evaluate its therapeutic properties. 
 
A B  
Figure 4.2 NSC172285 effects in vitro. (A) In vitro anti-proliferative effect on KMS11 human multiple 
myeloma cells treated with increasing doses of NSC172285 (IC50: ~ 3.6). (B) Induction of cell death (reported 
as percent of PI+ cells) was assessed in KMS11 cells treated with increasing concentrations of NSC172285. 
 
Compound NSC172285 was furnished to the research group of Prof. Presta from the 
NCI Chemotherapeutic Agents Repository in milligrams amounts, inadequate for a 
complete and deep investigation of its inhibitory properties. The collaboration between 
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the research group of Prof. Presta and Prof. Mor, where I spent my PhD period, 
resulted in a joint effort to pursue the investigation on NSC172285 as FGF2-FGFR 
inhibitor. The first step to be made was for sure the re-synthesis of the NCI compound 
with an eye turned to future modification of the scaffold in order to explore structure 
activity-relationships (SAR). Therefore, during my PhD research I designed and 
performed the synthesis of NSC172285. 
 
 
4.2  Retrosynthetic approach and preliminary 
considerations 
The synthesis of compound NSC172285 was not reported in literature. Unexpectedly, 
the first challenge we faced was the decoding of the unclear structure furnished by the 
NCI (Figure 4.3A) and a printout of an sdf file from the Presta group (Figure 4.3B). 
Two major inconsistencies were immediately individuated: 
1. the stereochemistry of the junction between cycles B and C in the sdf file was 
not consistent with a classical steroidal scaffold; 
2. the stereochemistry of C20 was not defined in the NCI formula. 
 
A B  
C  
Figure 4.3 (A-B) Structural characterization of compound NSC172285 furnished by NCI. (C) Correct 
structure of the target molecule with proper atom numbering and ring lettering. 
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In the structure of NSC172285 is clearly recognizable a steroidal scaffold. We speculate 
that in the chemical formula present in the printout of the sdf file, presumably 
automatically generated by a software, the cis-junction between cycles B and C was the 
outcome of a genuine mistake. 
Our hypothesis was supported by the lack of reports in the literature about steroidal 
skeletons with cis-junctions between the B and C rings. In the target molecule a 3,3-
di(trifluoromethyl)propane-1,3-diol motif is also identifiable. 1,3-diols can be prepared 
by, inter alia, the reaction between an alkene and formaldehyde (the Prins reaction). A 
common strategy to obtain substituted 1,3-diols is the aldol reaction between ketones 
and either aldehydes (to obtain β-keto secondary alcohols) or another ketone (to obtain 
β-keto tertiary alcohols). Subsequent reduction of the carbonyl moiety leads to the 
formation of the 1,3-diol. The retrosynthetic rationalization (Scheme 4.1) applied to our 
target molecule involved the reduction of the aforementioned β-keto tertiary alcohol, 
in turn obtained from the aldol reaction between the steroid-based methyl ketone and 
hexafluoroacetone (HFA). We anticipated condensing in an aldol fashion a 
pregnenolone derivative (3β-hydroxypregn-5-en-20-one), a steroid hormone.  
 
 
Scheme 4.1 Retrosynthetic approach for NCS172285.  
 
The reduction step is crucial because of the formation of a new stereogenic center at 
C20. The trigonal planar sp2-hybridized carbonyl is converted to a sp3-hybridized chiral 
center upon addition to the re or si face of the keto group. The influence of neighboring 
chiral centers, as well as the nature of the reducing agent employed in the reaction 
could in principle affect the stereochemistry of the newly generated stereocenter. It is 
worth remembering the lack of a clear stereochemistry attribution for C20 of 
NCS172285. As a first hypothesis, we assumed that the compound in the NCI library 
could have been generated under conditions favoring the product in line with several 
literature precedents.  
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Midland and Kwon13 deeply investigated the reduction of pregnenolone. Typical 
nucleophilic reducing agents such as NaBH4 and LiAlH4 provided the 20R product, 
and hindered trialkylborohydrides provided nearly 99% epimeric purity. Borane-
based reducing agents such as borane-dimethyl sulfide (BMS) or 9-BBN were reported 
to give the 20R alcohol as well. The stereochemistry of nucleophilic addition to ketones 
has been postulated by Ahn to occur from a conformation that places the entering 
group in an antiperiplanar arrangement with the largest group at the adjacent chiral 
center. The trajectory of nucleophilic addition to pregnenolone C20 carbonyl then 
brings the nucleophile over the smallest group as depicted in Scheme 4.2.  
 
 
Scheme 4.2 Mechanistic rationalization for the attack of a generic nucleophile Nu (blue) on the C20 of 
pregnenolone. Felkin-Ahn model (on top) reveal the preference for a nucleophilic attack on the si face  
 
Felkin-Ahn model shows the disposition of smallest S (H), medium M and large L 
groups (5-memberd D ring of the steroid) and the favored attack on the si face of the 
ketone leading to the formation of the Cram product. A decisive contribution to the 
nucleophile trajectory is exerted by the steric hindrance of the methyl group which 
hampers the attack on the re face. If the entering group is a low priority substituent (as 
in the case of a reduction reaction where Nu = H) the attack on the si face leads 
therefore to the formation of the R diastereoisomer.  
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4.3 Results and discussion 
4.3.1 Chemistry 
According to our retrosynthetic analysis (Scheme 4.1) the first step required the aldol 
reaction between pregnenolone and HFA. HFA comes in the form of a colorless, 
hygroscopic, non-flammable, highly reactive gas characterized by a musty odor. It is 
known to react with metal enolates derived from a variety of carbonyl compounds and 
to obtain aldols and related derivatives14. Moreover, HFA reacts with silyl enol ethers 
in presence of a Lewis acid and the product can be easily dehydrated under very mild 
conditions15. Although these encouraging reported applications of HFA in aldol 
condensations, the main disadvantage we had to overcome was the lack of suppliers of 
gaseous HFA. The commercially available form of this substance is hexafluoroacetone 
trihydrate (3.0 H2O), in which one molecule of water is incorporated in the form of a 
geminal diol. Most aldol condensation protocols requires strictly anhydrous reaction 
conditions due to air and moisture sensitivity of the reactive partners involved; 
therefore, the direct use of hydrate HFA is strongly discouraged, as only one sixth of 
the enolate reagent could engage in the aldol process, the rest being destroyed by 
water. On the other hand, organocatalytic16 and Mukaiyama-type17 aldol reactions 
have been recently developed to work efficiently even in aqueous solvent systems. We 
therefore pursued this route and planned to perform the aldol reaction using HFA 
trihydrate in a water-tolerant methodology. Pregnenolone was purchased in the form 
of its cheap precursor pregnenolone acetate 48, with the protection of the hydroxyl 
functionality at C3 as an acetate ester already coming with the commercially available 
material. This was considered to avoid side reactions during the synthetic pathway.  
The first attempts were performed following an organocatalytic protocol. Entry 1 and 
entry 2 (Table 4.1) show the results obtained with pyrrolidine and L-proline as 
catalysts respectively, using as reactive partners pregnenolone acetate 48 and 
trihydrate HFA. In both cases conversion of starting material into the desired product 
was not observed and compound 48 was fully recovered after work-up. Given the 
unsatisfactory results we desisted from the organocatalytic methodology and we 
applied a canonical aldol reaction. 
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Table 4.1 Screening results for the aldol reaction between pregnenolone 49 or derivatives 48, 50 and HFA 
 
 
Entry 
Reactive 
partners 
Conditions 
Yielda 
(%) 
Comments 
1 48 + HFA (l) Pyrrolidine, DMF, r.t. - no conversion 
2 48 + HFA (l) L-proline, DMSO, r.t. - no conversion 
3 48 + HFA (l) KOHc, TBAC, DCE/H2O, r.t. - deacetylation product 
4 49 + HFA (l)  1. TIPS-OTf
d, TEA, DCM 
2. TMS-OTf, DCE/H2O 
- undesired product 
5 50 + HFA (g) BuLi, DIPEA, dry THF, -78°C 20  LDA impurities 
6 50 + HFA (g) KHMDS, dry THF, -78°C work-up: NH4Cl sat. solution 30 
partially dehydration 
of desired product 
7 50 + HFA (g) KHMDS, dry THF, -78°C work-up: NH4Cl 5%sol. 48  
8 50 + HFA (g) KHMDS, dry THF, -78°C work-up: Acetic acid 5% sol. 67  
a isolated yield 
c 3.0 eq. of KOH were used 
d 2.2 eq of TIPS-OTf were used 
 
A first attempt (Table 4.1 - entry 3) was carried out with KOH as base in a solvent 
mixture of dichloroethane (DCE) and water using tetrabutylammonium chloride 
(TBCA) as phase transfer catalyst. An excess of KOH (3 eq.) was employed in order to 
assure the enolization of the α-carbonyl position. Conversion of the starting material 
was incomplete and the formed product revealed to be the undesired deacetylated 
product i.e. pregnenolone 49. We next tried to apply a Mukaiyama methodology 
(Table 4.1 - entry 4). A manipulation of the hydroxyl protecting group was at this 
point required: we removed the acetyl group by exposure to KOH (Scheme 4.3) to 
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obtain pregnenolone 49 that was reacted with triisopropylsilyl 
trifluoromethanesulfonate (TIPS-OTf) in presence of triethylamine (TEA).  
 
 
Scheme 4.3 Protecting groups manipulation. Reagents and conditions: (a) KOH, MeOH/DCM, r.t., 2h; (b) 
Benzoyl chloride, DMAP, pyridine, 0° C to r.t., 24h 
 
The use of 2.2 eq. of TIPS-OTf allowed the simultaneous silylation of C3 hydroxyl and 
the generation of the silyl enol ether that was isolated and reacted with trihydrate HFA 
in presence of trimethylsilyl trifluoromethanesulfonate (TMS-OTf) as Lewis acid. The 
reaction led to the formation of an undesired product, whose structure could not be 
attributed unequivocally by NMR and MS. All these unsuccessful outcomes forced us 
to reconsider the use of hydrate HFA in the aldol reaction. We therefore investigated 
the possibility of generating in situ gaseous HFA. The lack of literature about a 
productive dehydration technique for HFA with a common laboratory set-up was 
partially filled by industrial patents reporting the dehydration of HFA exerted by 
strong acids, such as concentrated HCl or HF. The generation of gaseous HFA was 
accomplished by dropping trihydrate HFA in concentrated sulfuric acid warmed at 50° 
C: we observed the saturation of the flask by a white mist, allegedly the HFA gas. This 
could be delivered directly, with the aid of a stream of nitrogen, into the reaction 
vessel containing the enolate partner. With this technique in hands, we could optimize 
the choice of conditions for the aldol reaction. We firstly replaced the acetate ester-
protecting group on the C3 hydroxyl with a benzoate (50) to avoid the potential double 
enolization of the starting material. The lithium enolate of compound 50 was generated 
by treatment with butyl lithium in presence of diisopropyl amine, to generate LDA 
(lithium diisopropylamide) in anhydrous THF at -78°C (Table 4.1 - entry 5). After the 
enolate was formed, we delivered through a cannula the generated gaseous HFA to 
the enolate solution. The set up of the reaction is depicted in Figure 4.4. 
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Figure 4.4 Schematic set up for the aldol reaction with in situ generation of gaseous HFA 
 
This optimized procedure allowed the isolation of the desired product in modest yield 
(20%). The main drawback of this protocol was the presence of an impurity consistent 
with 2,2,2-trifluoro-N,N-diisopropylacetamide derived from the attack of LDA on 
HFA. The purification of desired product resulted to be troublesome; we decided 
therefore to change the reaction conditions. We envisioned the use of potassium 
bis(trimethylsilyl)amide (KHMDS) (Table 4.1 - entry 6), to shut down the 
nucleophilicity of the spent base. Conversion of the starting material, evaluated by 
TLC analysis, was appreciable but not complete; after working-up the reaction with a 
satured aqueous solution of ammonium chloride, a second spot appeared. Analysis by 
means of NMR and MS of the isolated side-product showed it to be the dehydrated 
aldol product (α-β unsaturated ketone). The desired molecule could nevertheless be 
isolated with a relieving yield of 30%.  
We speculated the dehydrated product to arise from the basic conditions employed 
during the work up. Switching to a 5% aqueous solution of ammonium chloride 
reduced the dehydration of the product and the yield of the process increased to 47% 
(Table 4.1 - entry 7). The best result was finally obtained with a 5% solution of acetic 
acid in water. The yield of the process was assessed to be a satisfactory 67% (Table 4.1 
- entry 8). At this point, with a robust synthesis in hands, we could tackle the reduction 
of the carbonyl function to the corresponding alcohol. This was straightforwardly 
accomplished by treatment of compound 51 with NaBH4 in a mixture of methanol and 
THF. Eventually, the reduced molecule was obtained by direct saponification of the 
benzoate ester to liberate the C3 hydroxyl group. The synthetic pathway for the 
Δ
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synthesis of compound 53, tagged as UPR1357 is summarized in Scheme 4.4. The 
molecule synthesized was then tested in vitro to evaluate its inhibitory activity. 
 
  
Scheme 4.4 Synthetic pathway for molecule 53 (UPR1357). Reagents and conditions: (a) KHMDS, dry THF,  
-78° C, 30 min; (b) H2SO4, 50° C; (c) NaBH4, MeOH/THF, r.t., 2h; (d) MeONa, MeOH/THF, r.t., 1 h. 
 
 
A B  
Figure 4.5 (A) In vitro anti-proliferative effect on KMS11 human multiple myeloma cells treated with 
increasing doses of NSC172285 (red) and UPR1357 (black) compounds. No relevant inhibitory effect was 
observed when UPR1357 compound was tested. (B) Induction of cell death was assessed in KMS11 cells 
treated with increasing concentrations of NSC172285 (red) and UPR1357 (black). 
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Surprisingly, as shown in Figure 4.5, no relevant inhibitory effects were observed 
when UPR1357 was tested. Puzzled by these findings, we speculated the two 
molecules being different diastereoisomers and decided to make a deep investigation 
on the structure of the two molecules. ESI-MS spectra of both compounds was 
recorded and showed the same mass peak (m/z = 483.3 [M+H]+) and the same 
molecular fragmentations (Figure 4.6A,B). Co-injection of the two compounds in 
HPLC-MS revealed two different peaks with different retention times, thereby 
confirming that the molecule synthesized UPR1357 was not chemically equivalent to 
NCS172285.  
 
A  B !
C !
Figure 4.6 Mass spectra for compounds NSC172285 (A) and UPR1357 (B) revealed the same molecular 
fragmentation. (C) Co-injection in HPLC-MS of a mixture of compounds NSC172285 (peak 1) and UPR1357 
(peak 2) 
 
1H-NMR spectra displayed subtle, but remarkable differences between the 
compounds: as shown in Figure 4.7, from the superposition of the spectra was clearly 
identifiable a different shift for the singlet signals belonging to H18, a different pattern 
of the aliphatic resonance peaks (1.0-2.1 ppm) and a slight shift of the triplet signal 
corresponding to H20. We came to the conclusion that UPR1357 and NSC172285 were 
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two different chemical species and we speculated they could be epimers at C20. This 
hypothesis was consistent with the structural evidences recorded (same mass 
spectrum, different NMR spectra). Indeed, the absolute configuration of C20 was not 
univocally defined in the structure of NCS172285, and we concluded that being the 
only new stereogenic center generated during the synthesis, the diastereomeric nature of 
the two compounds could only derive from an epimeric relationship at C20. 
 
!
Figure 4.7 Superposition of NCS172285 (blue) and UPR1357 (red) 1H-NMR spectra. 
 
To test our hypothesis we reviewed our synthetic procedure in order to establish a 
protocol for the reduction of ketone 51 that could generate the C20 epimer of 
compound 52. The results of this screening effort are outlined in Table 4.2.  
Employing aluminum-based reducing agents such as lithium aluminium hydride 
(LiAlH4) (Table 4.2 – entry 2) and the hindered diisobutylaluminium hydride (DIBAL-
H) (Table 4.2 – entry 3) led to the exclusive formation of the C20 epimer 52 as already 
obtained with the precedent protocol (Table 4.2 – entry 1). The first encouraging 
results were obtained using sodium triacetoxyborohydride (Table 4.2 – entry 4). 
Owing to the steric and electronic effects of the acetoxy groups, sodium 
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triacetoxyborohydride is a milder reducing agent than sodium borohydride or even 
sodium cyanoborohydride and it is especially suitable for reductive aminations of 
aldehydes and ketones18. 
 
Table 4.2 Screening results for the reduction of compound 51 generating C20 epimers 52 (major)  
or 54 (minor)a 
 
Entry Reducing agent Solvent Temperature 
drb 
major:minor 
1 NaBH4 MeOH/THF r.t. >99:1c 
2 LiAlH4 THF 0° C >99:1c 
3 DIBAL-H THF 0° C >99:1c 
4 Na(AcO)3BHd,e THF 0° C to r.t. 87:13 
5 NaBH4/CeCl3.7H2O MeOH/THF r.t. >99:1c 
6 BMS/D-prolinole THF r.t. 93:7 
7 BMS/L-prolinole THF r.t. >99:1c 
a reaction conditions: 1.0 eq. (0.03 mmol) of 51, 1.2/1.3 eq. of reducing agent 
b determined by 1H-NMR analysis of the crude reaction mixture 
c exclusively formation of major C20 epimer was observed 
d 6.0 eq. of Na(OAc)3BH were used  
e conversion of the starting material not complete 
 
 
Evans and coworkers deeply investigated the use of Na(ACO)3BH in reduction of β-
hydroxy ketones 19 . These reductions proceed by an apparent rate-determining 
exchange of the substrate hydroxyl group for an acetate of the triacetoxyborohydride 
which precedes the reduction step, which proceeds by intramolecular hydride 
delivery. This led us to assume that the intramolecular hydride transfer, opposite to 
the classical intermolecular reduction, might result in a reverse stereochemical course 
of the process, leading to the formation of minor C20 epimer. The reaction of substrate 
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51 with Na(ACO)3BH was indeed very slow and a large excess of reductant was 
necessary to obtain an appreciable conversion of the starting material. The 
diastereomeric ratio (dr), determined by means of 1H-NMR spectroscopy on crude 
reaction mixture, was 87:13 in favor of major 52 epimer. Reduction of a series of keto 
steroids, including pregnenolone, under Luche’s conditions (NaBH4/CeCl3.7H2O) was 
investigated by Št’astná and coworkers20. They reported, for pregnenolone, an increase 
of the minor 20S alcohol when the reduction was performed with sodium borohydride 
in presence of cerium (III) chloride heptahydrate. Application of Luche’s reduction 
conditions to our substrate 51 didn’t provide the desired effect: exclusive formation of 
the major C20 epimer was again observed (Table 4.2 – entry 5). Borane reductions with 
chiral ligands were reported for pregnenolone. Göndös et al.21 demonstrated that the 
use of borane methyl sulfide (BMS) in presence of prolinol-based chiral ligands 
reversed the stereochemistry affording the 20S alcohol as major product. The protocol 
developed by Göndös and colleagues was applied to our starting material 51. The use 
of D-prolinol in combination with BMS afforded a mixture of major 52 and minor 54 
products with a dr of 93:7 while L-prolinol afforded exclusively diol 52.  
 
  
Scheme 4.5 Synthetic pathway for compound 55 (UPR1358). Reagents and conditions: (a) Na(AcO)3BH, THF, 
0° C to r.t., 6h; (b) MeONa, MeOH/THF, r.t., 1 h. 
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Among the screened procedures the best results were obtained with Na(AcO)3BH as 
reducing agents. The reduction using sodium triacetoxyborohydride was repeated on a 
larger scale in order to obtain, after a troublesome chromatographic separation 
performed with the aid of an automated medium pressure column chromatography, 
compound 54 in sufficient amount. The benzoate ester group was removed by trans-
esterification with catalytic MeONa in MeOH to afford product 55 tagged as UPR1358. 
The synthesis of this compound is summarized in Scheme 4.5.  
We performed 1H-NMR and 13C-NMR analysis on UPR1358 55 to verify its chemical 
identity with NSC172285. The perfect superposition of 1H-NMR spectra revealed the 
correctness of the epimeric assumption for the two compounds (Figure 4.8). As 
expected, by testing in vitro UPR1358 and NSC172285, the two compounds showed the 
same antiproliferative and cytotoxic profile (Figure 4.9). 
 
 
 
Figure 4.8 Superposition of NCS172285 (red) and UPR1358 (55) (blue) 1H-NMR spectra.  
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 A B  
Figure 4.9 (A) In vitro anti-proliferative effect on KMS11 human multiple myeloma cells treated with 
increasing doses of NSC172285 (red) and UPR1358 (black) compounds. (B) Induction of cell death (reported 
as percent of PI+ cells) was assessed in KMS11 cells treated with increasing concentrations of NSC172285 
(red) and UPR1358 (black). 
 
 
4.3.2 Stereochemistry attribution 
After having accomplished the design and the synthesis of the two diastereoisomers 
UPR1357 53 and UPR1358 55, a complete characterization of this novel compounds 
was required. We finally had to face the elusive question that we postponed for a later 
moment at the beginning of our synthesis, about the absolute configuration at C20. The 
challenge resided in the univocal attribution of the absolute stereochemistry of the 
newly generated stereocenter of the reduction step by means of NMR spectroscopy. As 
previously said (see paragraph 4.1), literature evidences let us to speculate that the 
major and minor products of the reduction step (compound 52 and compound 54), were 
the 20R the 20S respectively, and therefore corresponding final products 53 and 55 
would have the same absolute configuration.  
Interpretation of the NMR spectra started from the observation of the peculiar 
multiplicity of the resonance peak corresponding to H20. In both compounds 53 and 55 
the signal observed for H20 is a triplet with identical coupling constants (J) of 10.3 Hz. 
As shown in Figure 4.10, H20 possesses 3 vicinal protons (H17, H21a, H21b) and its 
signal could, in principle, be split into up to eight lines: a doublets of doublets of 
doublets (ddd).  
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Figure 4.10 H20 proton (blue labeled) is coupled with vicinal protons H17, H21a and H21b (red labeled) 
 
The unexpected H20 low multiplicity can be attributed to two reasons: 1) two coupling 
constants are equal and 2) the magnitude of coupling with one of the vicinal proton is 
null. 1H-TOCSY experiment with selective band center irradiation on the H20 signal 
allowed isolating, from the crowded aliphatic portion of the spectra, the signals 
belonging to the same spin system (Figure 4.11).  
 
 
Figure 4.11 1H-TOCSY spectra for compounds 53 (on top) and 54 (on bottom) 
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The peaks corresponding to H21a and H21b, directly coupled with H20, could be 
easily identified, as they posses the highest intensity. The doublet at 1.98 ppm for 
compound 53 and at 2.18 ppm for compound 55 was assigned to the hydrogen marked 
as H21a; in both molecules this proton has only one geminal (2J) coupling with H21b (J 
= 15.0 and 15.1 Hz, respectively). The signal at 1.91 ppm for compound 53 and at 1.88 
ppm for compound 55 was assigned to the hydrogen marked as H21b. The multiplicity 
of this proton is poorly resolved: the overlapping of a doublet of doublets resonance 
lines generate a triplet-like signal in which is possible, however, to identify two 
coupling constants. H21b have one geminal (2J1) coupling with H21a (J1 = 15.0 and 15.1 
Hz for compounds 53 and 55, respectively) and a vicinal (3J2) coupling with H20 (J2 = 
11.1 and 11.3 Hz for compounds 53 and 55,respectively). Thus, H21a was found to 
have null coupling with H20. According to Karplus’ equation, the dihedral angle 
between these protons should be close to 90°. Moreover the value of the coupling 
constants between H17-H20 and H20-H21b is consistent with a diaxial 3J coupling 
suggesting an anti-conformation. We speculated a conformationally locked, six-
membered arrangement induced by an intramolecular hydrogen-bond involving the 
hydroxyls of the 1,3 diol portion. (Figure 4.12A). 
 
A  
B  
Figure 4.12 (A) Preferential conformations for compounds 53 and 55.  
(B) Geometries of compounds 53 and 55.  See experimental section for details. 
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With the minimum-energy geometries represented in Figure 4.12B, the coupling 
constants calculated by the software Schrodinger Maestro 9.7 for H20 were consistent 
with the observed triplets. In particular, the calculated values for H20-H17, H20-H21b 
and H20-H21a were 9.9, 11.0 and 1.0 Hz for 53 and 9.7, 11.3 and 1.5 for 55, respectively. 
From the minimized geometries of the final compounds with 20R and 20S 
stereochemistry (tentatively assigned for 53 and 55, respectively) it is possible to see 
the enantiomorphic arrangement of the diol motif (Figure 4.12B), where a remarkable 
difference in the distance between the C18 methyl group and the C21 methylene 
suggested the use of Nuclear Overhauser Enhancement (NOE) monodimensional 
NMR experiments to discriminate the two epimers. In particular for compound 55, 20S 
diastereoisomer, the proximity of H21a to H18, in the conformer of minimum energy, 
is sufficient to result in a NOE contact. Reversely for diastereoisomer 53, 20R alcohol, 
the distance between H21a and H18, when adopting the same conformation, is not 
sufficient for a nuclear transfer spin polarization between the nuclei.  
 
Figure 4.13 1D NOE-NMR spectra of compounds 53 (on top) and 55 (on bottom) with selective band center 
irradiation on H18 
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The results of 1D NOE experiment with selective band center irradiation on the H18 
protons of the methyl group are reported in Figure 4.13. The NOE-NMR spectra of 
both compounds show a clear NOE contact between H18 and H20, indicating an 
identical relative distance, as well as for the relative intensity of H18 and H19 (proton 
on –CH3 C19). While compound 55 shows NOEs between H18 and a proton at 2.18 
ppm that is unequivocally assigned to H21a, compound 53 shows significant NOEs 
with protons at 2.05, 1.50 and 1.15 ppm; these signals, however, could not be 
unequivocally identified by the use of 2D-COSY and HSQC-NMR experiments. In 
particular, the NOE contact at 2.05 is close to the signal attributed to H21a (1.98 ppm) 
and the lack of an unambiguous attribution for this signal did not allow drawing final 
conclusions. Additionally, the poor signal/noise ratio proved detrimental to the 
success of these NOE experiments.  
We thus decided to functionalize final products blocking the diol conformation by 
engaging the C20 and C22 hydroxyls in a 6-membered ring. At the same time, we 
looked for a functionalization that could shift some of the critical signals at lower 
magnetic fields, to avoid overlapping and simplify the attribution of the key peaks. We 
accomplished these purposes by synthesizing the corresponding cyclic carbonate 
derivatives 56 and 57 by treatment of benzoylated precursors 52 and 54, respectively, 
with triphosgene (Scheme 4.6): the electrophilic properties of the carbonyl moiety 
clarified the spectra of the aliphatic portion by altering the chemical shift of several 
protons.  
 
 
Scheme 4.6 Synthesis of compounds 56 and 57. Reagents and conditions: (a) triphosgene, pyridine, DCM, -50° 
C to r.t., 2h. 
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In particular critical H21a, that assumes a (pseudo-) equatorial arrangement in the 6-
membered ring (H21eq), resonates at 2.42 ppm for compound 56 and at 2.55 ppm for 
compound 57, in a region of the spectra free of other resonance peaks.  
The energy-minimized geometries (Figure 4.14) allowed the calculation of the distance 
between H21eq and H18, found to be 4.33 and 2.46 Å for compounds 56 and 57, 
respectively. As previously described for compounds 53, the distance between H18 
and H21eq of compound 56, is not sufficient for a significant NOE contact while the 
distance of 2.46 Å between H18 and H21eq in compound 57 can result in a NOE 
contact, analogously to the parent compound 55. 
 
Figure 4.14 Geometries of compounds 56 and 57 
 
The results of NOE investigations are outlined in Figure 4.15. H18 of compound 56 
shows NOE contacts with H19 (d = 2.95 Å), H16 (d = 2.43 Å), H11ax (d = 2.18 Å), H8 (d 
= 2.17 Å), H12eq (d = 2.53 Å) and H20 (d = 2.35 Å); the unequivocal assignment of 
these signals was accomplished by 2D-COSY and HSQC-NMR experiments and these 
results are consistent with the proposed conformation (see Figure 4.14). As expected, 
no contact was observed between H21eq (2.42 ppm) and H18 of compound 56. On the 
contrary, H18 of 57 shows NOE contacts with H19 (d = 2.96 Å), H8 (d = 2.17 Å), H21eq 
(d = 2.46 Å) and H20 (d = 2.41 Å).  
The results collected were sufficient to confirm the initial hypothesis of the 
stereochemistry of the compounds: the NOE contact between H18 and H12eq of 
compound 57 is consistent with a 20S absolute configuration while the absence of this 
contact in compound 56 reveal a R configuration for C20. The complete structures of 
the final compounds 53 (UPR1357) and 55 (UPR1358) with explicit absolute 
configuration of C20 are reported in Figure 4.16. 
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Figure 4.15 1D NOE-NMR spectra of compounds 56 (on top) and 57 (on bottom) with selective band center 
irradiation on H18 
 
 
 
Figure 4.16 Structure of final compounds 53 (UPR1357) and 55 (UPR1358) 
 
 
HO
H
HH
53 
UPR1357
HO
CF3
CF3
HO
HO
H
HH
HO
CF3
CF3
HO
R S
54 
UPR1358
 
Chapter 4 - Synthesis NSC172285: a stereochemistry issue 
 
  
 
 119 
4.4 Conclusions 
In this Chapter the synthesis of NSC172285 is reported. The major challenge associated 
was the necessity of planning the synthesis on the base of a poorly described structure. 
A synthetic pathway for NSC172285, not reported in the literature before, was setup 
and an efficient method for using HFA trihydrate as electrophilic partner in an aldol 
reaction, with standard laboratory equipment was developed. The hurdle of the 
reduction step relied in the formation of one or two products, with the minor 20S 
compound 55 (UPR1358 – NCS172285) possessing the highest inhibitory potency on 
FGF2-FGFR interaction. In the stereochemistry of C20 resides the first SAR evidence 
for this class of compounds. 
Eventually, the unequivocal attribution of the stereochemistry at C20 was carried out 
through a simple derivatization, leading to a compound that could be thoroughly 
analyzed by means of NOE experiments, confirming the preliminary observations 
made on final compounds 53 and 55. 
Future directions point to the investigation of SAR starting from the C20 as crucial site 
for biological activity. 
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Chapter 
5 
 
 
 
 
Experimental section 
 
 
5.1 Chapter 3 
5.1.1 Chemistry 
All chemicals were used as received unless stated otherwise. All reactions were performed under a steady 
overpressure of nitrogen delivered through a balloon. Tetrahydrofuran was distilled over 
sodium/benzophenone prior to use. Anhydrous solvents such as dichloromethane, N,N-
dimethylformamide, toluene and acetonitrile were directly purchased from an appropriate vendor, and were 
supplied stored over 3 Å molecular sieves and packed under Ar. They were subsequently manipulated by 
syringe under a steady pressure of nitrogen. Column chromatography was performed on silica gel 60 (0.040-
0.063 mm) under forced flow of the appropriate solvent mixtures. TLC analysis was conducted on HPTLC 
aluminum sheets (Sigma-Aldrich, silica gel 60, F254), compounds were visualized by UV absorption (245 nm) 
and/or by dipping in a solution of (NH4)6Mo7O24·4 H2O 25 g/l and (NH4)4Ce(SO4)4·2 H2O 10 g/l, in 1 L of 
10% aqueous H2SO4. Microwave reactions were conducted using a CEM Discover synthesis unit (CEM 
Corp., Matthews, NC). Melting points were not corrected and were determined with a Gallenkamp melting 
point apparatus. 1H- and 13C-NMR spectra were recorded with a Bruker AV 300, 400. Chemical shifts (δ 
scale) are reported in parts per million (ppm) relative to the central peak of the solvent. 1H-NMR spectra are 
reported in the following order: multiplicity, number of protons and approximate coupling constant (J 
value) in hertz (Hz); signals were characterized as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), 
dt (doublet of triplets), q (quartet), m (multiplet), bs (broad siglet). Mass Spectra were recorded on a Applied 
Biosystem API-150 EX system spectrometer with an ESI or an APCI interface. Final compound 2 was 
purchased from Sigma-Aldrich whereas compound 1 was synthesized according to literature methods1. 
Purity of final compounds were analyzed on ThermoQuest (Italia) FlashEA1112 Elemental Analyzer for C, 
H, and N (analyses were within 0.4% of theoretical values) or by HPLC with UV detection at λ = 254 or 220. 
Purity of compounds was determined by analytical high performance liquid chromatography (HPLC) 
employing a Shimadzu HPLC gradient system (Shimadzu Corp., Kyoto, Japan) equipped with two LC-10AD 
solvent delivery modules, a Rheodyne 7125 sample injector and a SPD-10A UV-VIS detector. Prior to 
analysis, samples were prepared in MeOH at a final concentration of 0.1 mg/mL. Chromatographic 
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separation occurred on a Supelco Discovery C18 column (150 X 4.6 mm, 5 mm particle size) by gradient 
elution. Flow rate was 1 mL/min and injected volume was 10 mL. Solvent A was methanol and Solvent B 
was water both additioned of 0.1% v/v formic acid. Gradient conditions A were employed for all BTZs 
compounds: t(0 min): 55% A: 45% B; t(15 min): 95% A: 5% B; t(17 min): 95% A: 5% B; returning to initial 
conditions after 1 min. Isocratic conditions B were employed for all triterpenes compounds: 90% A: 10% B 
t(13 min). Purity results are presented as tR (min) and relative chemical purity (%). All tested compounds 
were >95% pure. 
 
2-Methylbenzo[d]isothiazol-3(2H)-one 3: To a RT stirring solution of benzo[d]isothiazol-3(2H)-one 2 (61 mg, 
0.393 mmol) in MeCN (2 ml) anhydrous K2CO3 (54 mg, 0.393 mmol) and KI (88 mg, 166.00 mmol) is added. 
The resulting white suspension is refluxed for 30 min and then cooled back to r.t.. Iodomethane (25 µl, 0.393 
mmol) is added and the reaction mixture stirred at r.t. for 20h under nitrogen atmosphere. The solvent is 
evaporated under reduced pressure and the crude is purified by FC (SiO2, DCM100% then DCM/Et2O 95:5) 
furnishing 287 mg of pure 2-methylbenzo[d]isothiazol-3(2H)-one 3 as white waxy solid (65%); 1H-NMR (300 
MHz, CDCl3) δ: 8.00 (d, 1H, J= 7.11 Hz); 7.59-7.49 (m, 2H); 7.36 (m,1H); 3.41 (s, 3H). MS-APCI: Calc. for 
C8H7NOS: 166.0, Found: 165.8 [M+H+]. Anal. Calc. for C15H12N2O3S: C, 58.15; H, 4.27; N, 8.48; Found: 58.43; 
H, 4.35; N, 8.19. Melting point = 54° C. 
 
2-(6-Chlorohexyl)benzo[d]isothiazol-3(2H)-one 4: To a RT stirring solution of benzo[d]isothiazol-3(2H)-one 
2 (100 mg 0.66 mmol) in MeCN (2 ml), K2CO3 (91.41 mg, 0.66 mmol) is added and the resulting suspension is 
stirred for 10 min under nitrogen atmosphere. 1-chloro-6-iodohexane (1.0 ml, 6.6 mmol) is dropwise added 
over 5 min and the resulting mixture is stirred for 18 h and then refluxed for 1h. The solvent is removed by 
distillation under reduced pressure and the crude is purified by FC (SiO2, EtOAc/Hex 50:50) to give 66 mg 
of the expected product 4 a as colorless oil (37%). 1H-NMR (300 MHz, CDCl3) δ: 8.03 (d, 1H, J= 7.9 Hz); 7.63-
7.54 (m, 12H); 7.40 (td, 1H, J = 8.0, 1.3 Hz); 3.90 (t, 2H, J = 7.1 Hz); 3.52 (t, 2H, J = 6.6 Hz); 1.78 (m, 4H); 1.51 
(m, 4H). 
 
2-(6-(Piperidin-1-yl)hexyl)benzo[d]isothiazol-3(2H)-one 5: Piperidine (29 µl, 0.29 mmol) is dropwise added 
to a r.t. stirring solution of K2CO3 (169.0 mg, 1.22 mmol), KI (8.13 mg, 0.049 mmol) and 2-(6-
chlorohexyl)benzo[d]isothiazol-3(2H)-one 4 (66 mg, 0.25 mmol) in dry DMF (1 ml). The resulting suspension 
is heated to 60° C and stirred under nitrogen atmosphere. After 18h the reaction further piperidine (29 µl, 
0.29 mmol) and DMF (1 ml) are added and the reaction is carried out by microwave irradiation (Power = 200 
W, Temperature = 110° C, Pressure = 100 psi, Time = 5 min). DMF is removed by distillation under reduced 
pressure and EtOAc is added. After filtration, the crude is purified by FC (SiO2, DCM/MeOH 95:5) giving 33 
mg of expected product as colorless oil (yield = 41%); 1H-NMR (300 MHz, CDCl3) δ: 8.00 (d, 1H, J = 7.9 Hz); 
7.61-7-52 (m, 2H); 7.38 (m, 1H); 3.87 (t, 2H, J = 7.3 Hz); 2.35 (bs, 4H); 2.27 (t, 2H, J = 7.8 Hz); 1.75 (quintet, 2H, 
J = 7.1 Hz); 1.61-1.32 (m, 12H). MS-APCI: Calc. for C18H26N2OS: 319.2, Found: 319.5 [M+H+]. Anal. Calc. for 
C18H26N2OS x 1/2 H2O: C, 66.01; H, 8.31; N, 8.55; Found: C, 66.33; H, 8.15; N, 8.42. 
 
2,2'-Disulfanediyldibenzoyl chloride 7: A r.t. stirring suspension of 2,2’-Dithiosalicylic acid 6 (600 mg 1.96 
mmol) in SOCl2 (19.6 ml, 268.4 mmol) is refluxed until it became a solution and then for further 3h. The 
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solution is cooled to RT and exceeding SOCl2 is distilled away under reduced pressure. The obtained dark-
red residue is stripped with anhydrous toluol (twice) and used, without any further purification. 
 
2-(Chlorocarbonyl)phenyl hypochlorothioite 8: The crude 2,2'-disulfanediyldibenzoyl chloride is 
suspended in dry CCl4 at r.t. and an anhydrous flux of Cl2 is bubbled through the suspension until the 
suspended solid residue is completely dissolved. The reaction vessel was tightly closed and the bubbling is 
stopped so to leave the reaction mixture under a Cl2 saturated atmosphere for an additional 1 h. The reaction 
mixture is rapidly filtered and the solvent is distilled away under reduced pressure giving a yellow oil used 
without any further purification. 
 
General method A: cyclization. To a 0° C stirring suspension of the proper amine (1.5 eq.) and dry TEA (4.8 
eq.) in dry DCM, a solution of 2-(chlorocarbonyl)phenyl hypochlorothioite 8 in dry DCM is dropwise added 
over 2 min. The reaction mixture is stirred at r.t. under nitrogen atmosphere for 16 h. The solvent is distilled 
away under reduced pressure from the reaction mixture, the residue is taken up with EtOAc and the 
resulting mixture is washed with Na2CO3 saturated aqueous solution, 0.1M HCl aqueous solution and brine. 
The organic phase is dried over Na2SO4 and the solvent removed under reduced pressure affording the 
crude product that is subjected to flash column chromatography with an appropriate eluent mixture and to 
crystallization to furnish the purified product. 
 
2-Phenethylbenzo[d]isothiazol-3(2H)-one 9: Starting from a 0.392M solution (1.0 ml, 0.39 mmol) of 2-
(chlorocarbonyl)phenyl hypochlorothioite 8 according to method A, after purification by FC (SiO2 
Hex/EtOAc 70:30) and crystallization from n-hexane, final product (16 mg, 11%) is obtained as pale yellow 
crystals. 1H-NMR (300 MHz, CDCl3) δ: 8.04 (dd, 1H, J = 7.9, 0.7 Hz); 7.60 (td, 1H, J = 8.2, 1.2 Hz); 7.53 (d, 1H, J 
= 7.4 Hz); 7.40 (td, J = 7.9, 1.0 Hz); 7.24-7.35 (m, 5H); 4.15 (d, 2H, J = 7.4 Hz); 3.09 (t, 2H, J = 7.7 Hz). MS-APCI: 
Calc. for C15H13NOS: 256.1, Found: 256.2 [M+H+]. Anal. Calc. for C15H13NOS: C, 70.56; H, 5.13; N, 5.49; 
Found: C, 70.58; H, 5.10; N, 5.39. Melting point = 90-92° C. 
 
2-(2-(Naphthalen-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one 10: Starting from a 0.392M solution (2.6 ml, 1.02 
mmol) of 2-(chlorocarbonyl)phenyl hypochlorothioite 8 according to method A, after purification by FC 
(SiO2 DCM 100%) and crystallization from n-hexane, final product (25 mg, 14%) is obtained as pale yellow 
crystals. 1H-NMR (300 MHz, CDCl3) δ: 8.25 (d, 1H, J = 8.4 Hz); 8.07 (d, 1H, J = 7.8 Hz); 7.88 (d, 1H, J = 7.8 
Hz); 7.78 (t 1H, J = 4.5 Hz); 7.63-7.39 (m, 7H); 4.22 (t, 2H, J = 7.8 Hz); 3.54 (t, 2H, J=7.8 Hz). MS-APCI: Calc. for 
C19H15NOS: 306.1, Found: 306.2 [M+H+]. Anal. Calc. for C19H15NOS: C, 74.72; H, 4.95; N, 4.59. Found: C, 
74.66; H, 4.98; N, 4.61. Melting point = 101-102 °C. 
 
2-(2-(Naphthalen-2-yl)ethyl)benzo[d]isothiazol-3(2H)-one 11: Starting from a 0.392M solution (2.6 ml, 1.02 
mmol) of 2-(chlorocarbonyl)phenyl hypochlorothioite 8 according to method A, after purification by FC 
(SiO2 DCM 100%) and crystallization from n-hexane, final product (28 mg, 15%) is obtained as yellow 
crystals. 1H-NMR (300 MHz, CDCl3) δ: 1H-NMR (300 MHz, CDCl3) δ: 8.04 (d, 1H, J = 7.8 Hz); 7.76-7.83 (m, 
3H); 7.71 (s, 1H); 7.58 (td, 1H, J = 8.2, 1.2 Hz); 7.36-7.50 (m, 5H); 4.23 (t, 2H, J= 7.2 Hz); 3.24 (t, 2H, J = 7.5Hz). 
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MS-APCI: Calc. for C19H15NOS: 306.1, Found: 306.3 [M+H+]. Anal. Calc. for C19H15NOS * 1/10 H2O: C, 74.28; 
H, 4.99; N, 4.56; Found: C, 74.21; H, 4.97; N, 4.58. Melting point = 114-115° C. 
 
Cyclohexylbenzo[d]isothiazol-3(2H)-one 12: Starting from a 0.22M solution (11.90 ml, 2.62 mmol) of 2-
(chlorocarbonyl)phenyl hypochlorothioite 8 according to method A, after purification by FC (SiO2 Hex/Et20 
65:35) and vacuum distillation, final product (312 mg, 30%) is obtained as a white solid. 1H-NMR (300 MHz, 
CDCl3) δ: 8.05 (d, 1H, J = 7.89 Hz); 7.63-7.55 (m, 2H); 7.39 (m, 1H); 4.65-4.58 (m, 1H); 2.06 (d, 2H, J = 10.32 Hz); 
1.89 (d, 2H, J = 11.97 Hz); 1.74 (bd, 1H, J = 13.08 Hz); 1.60-1.42 (m, 4H); 1.30-1.20 (m, 1H). MS-APCI: Calc. for 
C15H17NOS: 234.1, Found: 234.0 [M+H+]. Anal. Calc. for C15H17NOS: C, 66.92; H, 6.48; N, 6.00; Found: C, 
66.68; H, 6.58; N, 5.82. Melting point = 84-85° C. 
 
3,3'-Dithiopropionyl chloride 14: A stirring suspension of 3,3’- Dithiopropionic acid 13 (1200 mg 5.7 mmol) 
in SOCl2 (6 ml) is refluxed until complete dissolution of the solid starting material (30 min). The solvent is 
evaporated under reduced pressure giving a brown oil used without any further purifications. 
 
3,3'-Disulfanediylbis(N-phenethylpropanamide) 15: To a 0° C stirring solution of 2-phenylethanamine 
(1370 µl, 10.88 mmol) and dry TEA (987 µl, 7.04 mmol) in dry 1,2-dichloroethane (17 ml) a 1.18 M solution 
(2.7 ml, 3.2 mmol) of 2,2'-dithiopropionyl chloride 14 in dry DCM is dropwise added over 2 min maintaining 
the temperature of reaction mixture below 15° C. The resulting suspension is allowed to reach r.t. and was 
stirred for 2 h. The crude is diluted with DCM (30 ml), washed with pH = 4.75 acetate buffer (10 ml, 2 times) 
and water (10 ml, 1 time). The organic layer is dried over anhydrous Na2SO4, filtered and the solvent is 
evaporated under reduced pressure giving 2.020 g of pale yellow solid. The obtained solid is washed with 
Et2O giving 1.389 g of desired product as a white solid (85%). 1H-NMR (300 MHz, CDCl3) δ: 7.35-7.21 (m, 
10H); 5.93 (bs, 2H); 3.55 (q, 4H, J = 6.87 Hz); 2.95 (t, 4H, J = 7.01 Hz) 2.84 (t, 4H, J = 7.02 Hz); 2.53 (t, 4H, J = 
6.99 Hz). 
 
2-Phenethylisothiazol-3(2H)-one 16: A 0.75M solution of SO2Cl2 in dry 1,2-dichloroethane (4,8 ml, 3.6 mmol) 
is dropwise added to a 0° C stirring suspension of 3,3'-disulfanediylbis(N-phenethylpropanamide) 15 (500 
mg, 1.2 mmol) in dry 1,2-dichloroethane (7 ml) over 2h. The solvent is evaporated under reduced pressure 
and the yellow oily residue is taken up with DCM. The resulting mixture is washed with H2O (10 ml, 2 
times), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure giving 697 mg of 
yellow oil. The crude is purified by FC (SiO2, DCM/Et2O 98:2 then 90:10) and crystalized from n-hexane 
giving 194 mg of desired product as a pale yellow powder (39%). 1H NMR (300 MHz, CDCl3) δ: 8.00 (d, 1H, J 
= 6.24 Hz); 7.35-7.22 (m, 5H); 6.27 (d, 1H, J = 6.24 Hz); 4.05 (t, 2H, J = 7.14 Hz); 3.04 (t, 2H, J = 7.44 Hz). MS-
APCI: Calc. for C11H11NOS: 206.1, Found: 206.2 [M+H+]. Anal. Calc. for C11H11NOS: C, 64.36; H, 5.40; N, 6.82; 
Found: C, 64.48; H, 5.42; N, 684. Melting point = 78-79° C. 
 
General method B: synthesis of intermediates 18a-b. To a stirring suspension of the corresponding 2-
hydroxynitrobenzoic acid in super-dry MeOH is added conc. H2SO4 (0.3 eq.) and the resulting mixture is 
refluxed for 96 hours. The solution is cooled to r.t. and MeOH is removed under reduced pressure. The 
residue is dissolved in EtOAc and washed twice with water. The organic phase is dried over Na2SO4 and the 
 
Chapter 5 – Experimental section 
 
  
 
 126 
solvent removed under reduced pressure to afford the desired product used without any further 
purification. 
 
Methyl 2-hydroxy-5-nitrobenzoate (18a): Starting from 2-hydroxy-5-nitrobenzoic acid 17a (2 g, 10.92 mmol) 
the desired product is obtained as a light yellow powder (2.90g, yield 97%), according to method B. 1H-NMR 
(300 MHz, CDCl3) δ: 8.78 (d, 1H, J = 2.8 Hz); 8.32 (dd, 1H, J = 9.2, 2.8 Hz); 7.06 (d, 1H, J = 9.2 Hz); 4.01 (s, 3H) 
 
Methyl 2-hydroxy-4-nitrobenzoate (18b): Starting from 2-hydroxy-4-nitrobenzoic acid 17b (2 g, 10.92 mmol) 
the desired product is obtained as a light yellow powder (1,73 g, yield 81%), according to method B. 1H-
NMR (300 MHz, MeOD) δ: 8.12 (d, 1H, J = 8.7 Hz); 7.78 (m, 2H); 4.04 (s, 3H) 
 
General method C: synthesis of intermediates 19a-e. To a solution of intermediate 18a-e and DABCO or 
NaH (from 1.2 to 2.2 eq.) in dry DMF is quickly added under N2 atmosphere, N,N-dithiocarbamoylchloride 
(1.5 eq.). The reaction is stirred at different temperatures until completion (see below for details). DMF is 
remover under reduced pressure and the residue is dissolved in EtOAc and washed twice with H2O, HCl 1% 
and NaHCO3. The organic phases are collected, dried over Na2SO4 and the solvent removed under reduced 
pressure. The crude product is subjected to flash column chromatography with an appropriate eluent 
mixture to furnish the purified product. 
 
Methyl 2-((dimethylcarbamothioyl)oxy)-5-nitrobenzoate 19a: Starting from methyl 2-hydroxy-5-
nitrobenzoate 18a (500 mg, 2.536 mmol) and DABCO (341 mg, 3.04 mmol), reaction is stirred at r.t. for 1.5 
hours. The residue is purified by FC (SiO2 Hex/EtOAc 80:20) giving 500 mg of desired product as a yellow 
powder (yield = 68%), according to method C. 1H-NMR (300 MHz, CDCl3) δ: 8.86 (d, 1H, J = 2.8 Hz); 8.41 (d, 
1H, J = 8.9, 2.9 Hz); 7.29 (d, 1H, J = 8.9 Hz); 3.90 (s, 3H); 3,46 (s, 3H); 3.42 (s, 3H). 
 
Methyl 2-((dimethylcarbamothioyl)oxy)-4-nitrobenzoate 19b: Starting from methyl 2-hydroxy-4-
nitrobenzoate 18b (600 mg, 3.05 mmol) and DABCO (681 mg, 6.09 mmol), reaction is stirred at r.t. for 16 
hours. The residue is purified by FC (SiO2 Hex/EtOAc 75:25) giving 396 mg of desired product as a yellow 
powder (yield = 40%), according to method C. 1H-NMR (300 MHz, CDCl3) δ: 8.15 (m, 2H); 8.00 (s, 1H); 3.90 
(s, 3H); 3,47 (s, 3H); 3.43 (s, 3H). 
 
Methyl 2-((dimethylcarbamothioyl)oxy)-5-methoxybenzoate 19c: Starting from methyl 2-hydroxy-5-
methoxybenzoate 18c (2.0 g, 10.9 mmol) and NaH (526 mg, 13.2 mmol) reaction is stirred at r.t. for 16 hours. 
The residue is triturated in DEE giving 1.83 g of desired product as a white powder (yield = 65%), according 
to method C. 1H-NMR (400 MHz, CDCl3) δ: 7.51 (d, 1H, J = 3.0 Hz); 7.11 (dd, 1H, J = 8.8, 3.0 Hz); 7.05 (d, 1H, J 
= 8.8 Hz); 3.86 (s, 6H); 3.49 (s, 3H); 3.41 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ: 188.1; 164.7; 157.0; 147.4; 125.9; 
124.3; 119.5; 115.5; 55.8; 52.3; 43.4; 38.9. 
 
Methyl 2-((dimethylcarbamothioyl)oxy)-4-methoxybenzoate 19d: Starting from methyl 2-hydroxy-4-
methoxybenzoate 18d (2.0 g, 10.9 mmol) and NaH (526 mg, 13.2 mmol) reaction is stirred at r.t. for 16 hours 
and additional 6 hours at 50° C. The residue is triturated in DEE giving 1.7 g of desired product as a white 
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powder (yield = 60%), according to method C. 1H-NMR (300 MHz, CDCl3) δ: 7.96 (d, 1H, J = 8.8 Hz); 6.82 
(dd, 1H, J = 8.8, 2.6 Hz); 6.62 (d, 1H, J = 2.5 Hz); 3.85 (s, 3H); 3.80 (s, 3H); 3.47 (s, 3H); 3.39 (s, 3H). 13C-NMR 
(75 MHz, CDCl3) δ: 187.3; 164.6; 163.7; 155.5; 133.0; 116.2; 111.9; 110.5; 55.8; 51.9; 43.4; 39.0. 
 
Methyl 2-((dimethylcarbamothioyl)oxy)-3-methylbenzoate 19e: Starting from methyl 2-hydroxy-3-
methylbenzoate 18d (2.0 g, 10.9 mmol) and NaH (526 mg, 13.2 mmol) reaction is stirred for 16 hours at 50° C. 
The residue is purified by FC (SiO2 Hex/EtOAc 90:10) giving 711 mg of desired product as a yellow powder 
(yield = 55%), according to method C. 1H-NMR (300 MHz, CDCl3) δ: 7.80 (dd, 1H, J = 7.8, 1.3 Hz); 7.38 (dd, 
1H, J = 6.9, 1.0); 7.16 (t, 1H, J = 7.7) 3.78 (s, 3H); 3.42 (s, 3H); 3.35 (s, 3H); 2.21 (s, 3H). 
 
General method D: synthesis of intermediates 20a-e. Corresponding intermediate 19a-e is suspended in 
diphenylether and the reaction is performed in a microwave reactor: 300W, 250°C, 0 PSI (open vessel) for 
different times (see below for details). When the starting material disappeared the solvent was removed by 
filtration on silica pad and the crude product is subjected to flash column chromatography with an 
appropriate eluent mixture to furnish the purified product. 
 
Methyl 2-((dimethylcarbamoyl)thio)-5-nitrobenzoate 20a: Compound 19a (640 mg, 2.25 mmol) is reacted 
for 1 min and purified by FC (SiO2 Hex/EtOAc 60:40) giving 500 mg of desired product as a yellow solid 
(yield = 78%), according to method D. 1H-NMR (300 MHz, CDCl3) δ: 8.73 (d, 1H, J = 2.6 Hz); 8.28 (dd, 1H, J = 
8.7, 2.6 Hz); 7.84 (d, 1H, J = 8.7 Hz); 3.95 (s, 3H); 3,15 (bs, 3H); 3.05 (bs, 3H). 
 
Methyl 2-((dimethylcarbamoyl)thio)-4-nitrobenzoate 20b: Compound 19b (396 mg, 1.39 mmol) is reacted 
for 20 min and purified by FC (SiO2 Hex/EtOAc 70:30) giving 319 mg of desired product as a yellow solid 
(yield = 80%), according to method D. 1H-NMR (300 MHz, CDCl3) δ: 8.46 (d, 1Η, J = 2.1 Hz); 8.23 (dd, 1H, J = 
8.6, 2.2 Hz); 8.00 (d, 1H, J = 8.6 Hz) 3.93 (s, 3H); 3,15 (s, 3H); 3.04 (s, 3H). 
 
Methyl 2-((dimethylcarbamoyl)thio)-5-methoxybenzoate 20c: Compound 19c (200 mg, 0.7 mmol) is reacted 
for 20 min and purified by FC (SiO2 Hex/EtOAc 60:40) giving 190 mg of desired product as a yellow oil 
(yield = 95%), according to method D. 1H-NMR (300 MHz, CDCl3) δ: 7.40 (d, 1H, J = 8.6  Hz); 7.32 (d, 1H, J = 
2.9 Hz); 6.93 (dd, 1H,  J = 8.8, 2.9 Hz); 3.79 (s, 3H); 3.74 (s, 3H); 2.96 (bs, 6H). 13C-NMR (75 MHz, CDCl3) δ: 
166.6; 166.5; 159.8; 138.9; 136.4; 119.7; 117.1; 115.8; 55.3; 52.1; 36.7.  
 
Methyl 2-((dimethylcarbamoyl)thio)-4-methoxybenzoate 20d: Compound 19d (200 mg, 0.7 mmol) is 
reacted for 10 min and purified by FC (SiO2 Hex/EtOAc 80:20) giving 190 mg of desired product as a yellow 
oil (yield = 95%), according to method D. 1H-NMR (400 MHz, CDCl3) δ: 7.78 (d, 1H, J = 8.7 Hz); 7.03 (d, 1H, J 
= 2.5 Hz); 6.76 (dd, 1H, J = 8.7, 2.5 Hz); 3.69 (s, 3H); 3.66 (s, 3H); 2.94 (bs, 3H); 3.87(bs, 3H).13C-NMR (100 
MHz, CDCl3) δ: 165.8; 165.5; 161.2; 132.3; 131.8; 125.8; 122.2; 113.6; 55.1; 51.5; 36.5.  
 
Methyl 2-((dimethylcarbamoyl)thio)-3-methylbenzoate 20e: Compound 19e (825 mg, 3.2 mmol) is reacted 
for 30 min and purified by FC (SiO2 Hex/EtOAc 80:20) giving 735 mg of desired product as a yellow oil 
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(yield = 89%), according to method D. 1H-NMR: (300 MHz, CDCl3) δ: 7.54 (dd, 1Η, J = 7.5, 1.6 Hz); 8.28 (dd, 
1H J = 7.6, 1.1 Hz); 7.29 (d, 1H, J = 7.6 Hz) 3.83 (s, 3H); 3,09 (bs, 3H); 2.97 (bs, 3H); 2.43 (s, 3H). 
  
General method E: synthesis of intermediates 21a-e. The intermediate 20a-e is suspended in a 2:1 
MeOH/H2O mixture, NaOH is added and the reaction is refluxed for 16 hours. MeOH is removed under 
reduced pressure and the mixture is cooled by adding ice water (temperature below 15°C). To the solution is 
added 1% HCl until a white precipitate appeared. The precipitate is filtered off and dried to afford the 
desired compound used without any further purification. 
 
2-Mercapto-5-nitrobenzoic acid 21a: Starting from methyl 2-((dimethylcarbamoyl)thio)-5-nitrobenzoate 20a 
(500 mg, 1.75 mmol), the desired product (255 mg, 73%) is obtained as a yellow powder, according to 
method E. 1H-NMR (300 MHz, DMSO) δ: 8.69 (s, 1H); 8.34 (m, 1H); 8.13 (m, 1H). 
 
2-Mercapto-4-nitrobenzoic acid 21b: Starting from methyl 2-((dimethylcarbamoyl)thio)-4-nitrobenzoate 20b 
(319 mg, 1.12 mmol), the desired product (172 mg, 77%) is obtained as a yellow powder, according to 
method E. 1H-NMR (300 MHz, MeOD) δ: 8.57 (s, 1H); 8.34 (d, 1H, J = 8.5 Hz); 8.13 (d, 1H, J = 8.6 Hz). 
 
2-Mercapto-5-methoxybenzoic acid 21c: Starting from methyl 2-((dimethylcarbamoyl)thio)-5-
methoxybenzoate 20c (1.7 g, 6.5 mmol), the desired product (600 mg, 50%) is obtained as a white powder, 
according to method E.  
 
2-Mercapto-4-methoxybenzoic acid 21d: Starting from methyl 2-((dimethylcarbamoyl)thio)-4-
methoxybenzoate 20d (1.6 g, 6.1 mmol), the desired product (1.4 g, 92%) is obtained as a white powder, 
according to method E.  
 
2-((Dimethylcarbamoyl)thio)-3-methylbenzoic acid 21e: Starting from methyl 2-((dimethylcarbamoyl)thio)-
3-methylbenzoate 20e (735 mg, 2.9 mmol), product 21e (293 mg, 60%) is obtained as a white powder, 
according to method E. 1H-NMR (300 MHz, D2O) δ: 7.38 (m, 3H); 3.04 (bs, 3H); 3.04 (bs, 3H); 2.84 (bs, 3H); 
2.28 (s, 3H). 
 
General method F: synthesis of intermediates 22a-e. Compound 21a-e is suspended in SOCl2 (50-100 eq.) 
and refluxed for 6h. The reaction turned to a deep brown color and became clear. SOCl2 is removed under 
reduced pressure and the residue is stripped twice with dry toluene. The brown oil (quantitative yield) 
obtained is dried, stored under nitrogen and used for the next step without any further purification.  
 
General method G: oxidative cyclization using iodine. In a dried, two-neck flask the proper amine (1.25 
eq.) is dissolved in dry THF under nitrogen atmosphere at 0°C. Dry TEA (3 eq.) is added to the mixture 
before a solution of preformed acyl chloride (1 eq.), dissolved in dry THF, is added. The reaction is gently 
warmed to r.t. and stirred for 16 hours. A solution of I2 (1.25 eq.) dissolved in dry THF is then added and the 
resulting mixture is stirred for further 4 h. The solvent is removed under reduced pressure and the residue is 
dissolved in EtOAc and washed twice with a PH=7 buffer phosphate. The organic phase is dried over 
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Na2SO4 and the solvent removed under reduced pressure affording the crude product that is subjected to 
flash column chromatography with an appropriate eluent mixture and/or to crystallization to furnish the 
purified product. 
 
5-Nitro-2-phenethylbenzo[d]isothiazol-3(2H)-one 23: Starting from compound 22a (280 mg, 1.29 mmol) and 
2-phenethylamine, the desired product is obtained, according to method G, as yellow crystals (230 mg, 60%) 
after purification by FC (SiO2 Hex/EtOAc 80:20) and crystallization from DCM/n-hexane. 1H-NMR (300 
MHz, CDCl3) δ: 8.86 (d, 1H, J = 2.1 Hz); 8.41 (dd, 1H, J = 8.8, 2.3 Hz); 7.62 (d, 1H, J = 8.8 Hz); 7.25 (m 4H); 4.15 
(t, 2H, J = 7.1 Hz); 3.07 (t, 2H, J = 7.3 Hz). MS-APCI: Calc. for C15H12N2O3S: 301.1, Found: 301.3 [M+H+]. 13C-
NMR (75 MHz, CDCl3) δ: 164.0; 146.3; 146.2; 137.3; 128.9; 128.8; 127.2; 126.2; 125.2; 122.7; 121.3; 45.9; 35.6. 
HPLC purity: tR 8.45 min - 99.2%. Melting point = 140° C. 
 
6-Nitro-2-phenethylbenzo[d]isothiazol-3(2H)-one 24: Starting from compound 22b (163 mg, 0.75 mmol) and 
2-phenethylamine, the desired product is obtained, according to method G, as yellow crystals (19 mg, 30%), 
after purification by FC (SiO2 Hex/EtOAc 65:35) and crystallization from DCM/n-hexane. 1H-NMR (300 
MHz, CDCl3) δ: 8.45 (d, 1H, J = 1.38 Hz); 8.23 (dd, 1H, J = 8.61, 1.77 Hz); 8.18 (d, 1 H, J = 8.58 Hz); 7.31 (m 
4H); 4.20 (t, 2H, J = 7.14, Hz); 3.11 (t, 2H,  J = 7.32 Hz). MS-APCI: Calc. for C15H12N2O3S: 301.1, Found: 301.1 
[M+H+]. Anal. Calc. for C15H12N2O3S: C, 59.99; H, 4.03; N, 9.33; Found: C, 59.94; H, 3.94; N, 9.06. 
 
5-Methoxy-2-phenethylbenzo[d]isothiazol-3(2H)-one 25: Starting from compound 22c (668 mg, 3.3 mmol) 
and 2-phenethylamine, the desired product is obtained, according to method G, as brown crystals (500 mg, 
55%), after purification by FC (SiO2 Hex/EtOAc 80:20) and crystallization from DCM/n-hexane. 1H-NMR 
(300 MHz, CDCl3) δ: 7.45 (d, 1H, J = 2.5 Hz); 7.35 (d, 1H, J = 8.8 Hz); 7.30-7.16 (m, 6H); 4.09 (t, 2H, J = 7.3 Hz,); 
3.84 (s, 3H); 3.03 (t, 2H J = 7.7 Hz). 13C-NMR (75 MHz, CDCl3) δ: 165.4; 158.4; 137.9; 132.1; 129.0; 128.7; 126.9; 
125.7; 122.5; 121.3; 107.8; 55.8; 45.6; 35.7. MS-APCI: Calc. for C15H12N2O3S: 286.1, Found: 286.2 [M+H+]. HPLC 
purity: tR 13.03 min - 98.5% 
 
6-Methoxy-2-phenethylbenzo[d]isothiazol-3(2H)-one 26: Starting from compound 22d (1.2 g, 5.7 mmol) and 
2-phenethylamine, the desired product is obtained, according to method G, as brown crystals (678 mg, 42%), 
after purification by FC (SiO2 Hex/EtOAc 70:30) and crystallization from DCM/n-hexane. 1H-NMR (400 
MHz, CDCl3) δ: 7.93 (d, 1H, J = 8.6  Hz); 7.32-7.26 (m, 5H); 6.98-6-94 (m, 2H); 4.11 (t, 2H, J = 7.3 Hz); 3.90 (s, 
3H); 3.07 (t, 2H, J = 7.3 Hz). 13C-NMR (100 MHz, CDCl3) δ: 165.2; 162.9; 142.5; 138.0; 129.0; 128.7; 127.8; 126.8; 
117.9; 114.7; 103.1; 55.8; 45.4; 35.8. MS-APCI: Calc. for C15H12N2O3S: 286.1, Found: 286.1 [M+H+]. HPLC 
purity: tR 9.1 min - 99.9% 
 
7-Methyl-2-phenethylbenzo[d]isothiazol-3(2H)-one 27: Starting from compound 22e (309 mg, 1.2 mmol) 
and 2-phenethylamine, the desired product is obtained, according to method G, as a brown solid (40 mg, 
19%), after purification by FC (SiO2 Hex/EtOAc 70:30 and Hex/EtOAc 50:50). 1H-NMR (300 MHz, CDCl3) δ: 
7.88 (dd, 1H, J = 7.1, 1.0 Hz); 7.37-7.22 (m, 8H); 4.15 (t, 2H, J = 7.5 Hz); 3.09 (t, 2H, J = 7,29 Hz); 2.34 (s, 3H). 
13C-NMR: (75 MHz, CDCl3) δ: 165.9; 140.4; 137.8; 131.9; 129.9; 128.9; 128.7; 126.8; 126.0; 124.5; 124.1; 45.5; 36.8; 
18.7. MS-ESI: Calc. for C16H15NOS: 270.1, Found: 270.2 [M+H+]. HPLC purity: tR 11.2 min - 97.8% 
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General method H: synthesis of final product 28-29. Compound 25-26 is dissolved under nitrogen 
atmosphere in dry benzene at 0°C. BBr3 (2.1 eq.) is dropwise carefully added and the reaction turned deep 
brown. The mixture is warmed to r.t. and refluxed for 1 hour; finally is cooled to r.t. and stirred for an 
additional hour. The reaction is quenched with water and EtOAc is added. The organic and the aqueous 
phases are separated, the organic layer is washed with water and the aqueous layer is washed several times 
with EtOAc. The organic phases are collected, dried over Na2SO4 and the solvent is removed under reduced 
pressure. The crude product is subjected to flash column chromatography with an appropriate eluent 
mixture and to crystallization to furnish the purified product. 
 
5-Hydroxy-2-phenethylbenzo[d]isothiazol-3(2H)-one 28: Starting from 5-methoxy-2-
phenethylbenzo[d]isothiazol-3(2H)-one 25 (99 mg, 0.35 mmol) after purification by FC (SiO2 Hex/EtOAc 
50:50) and crystallization from EtOH/H2O final product (33 mg, 35%) is obtained as a light yellow powder, 
according to method H. 1H-NMR (300 MHz, CDCl3) δ: 7.70 (d, 1H, J = 2.37 Hz); 7.40 (d, 1H, J = 8.67, Hz); 7.28 
(m, 6H); 4.14 (t, 2H, J = 7.35 Hz); 3.08 (t, 2H, J = 7.68 Hz). MS-APCI: Calc. for C15H13NO2S: 272.1, Found: 272.3 
[M+H+]. Anal. Calc. for C15H13NO2S: C, 66.40; H, 4.83; N, 5.16; Found: C, 66.70; H, 4.97; N, 4.94. 
 
6-Hydroxy-2-phenethylbenzo[d]isothiazol-3(2H)-one 29: Starting from 6-methoxy-2-
phenethylbenzo[d]isothiazol-3(2H)-one 26 (200 mg, 0.70 mmol) after purification by FC (SiO2 Hex/EtOAc 
50:50) final product (47 mg, 25%) is obtained as a light yellow powder, according to method H. 1H-NMR (300 
MHz, MeOD) δ: 7.74 (d, 1H, J = 8.64 Hz); 7.26-7.18 (m, 5H); 7.02 (d, 1H, J = 2.01 Hz); 6.87 (dd, 1H, J = 2.01, 
8.64 Hz); 4.07 (t, 2H, J = 7.35 Hz); 3.03 (t, 2H, J = 7.68 Hz). MS-APCI: Calc. for C15H13NO2S: 272.1, Found: 
272.3 [M+H+]. HPLC purity: tR 7.0 min - 99.3%. Melting point = 172°C. 
 
6-Ethoxy-2-phenethylbenzo[d]isothiazol-3(2H)-one 30: To a 0°C suspension of compound 29 (125 mg, 0.52 
mmol) in dry MeCN (7ml), K2CO3 (71 mg, 0.62 mmol) is slowly added. After few minutes to the solution is 
added EtBr (40 µl, 0.62 mmol). The mixture is gradually warmed to 30°C and stirred overnight. Once the 
reaction is complete the solvent is removed under reduced pressure. The residue is portioned between water 
and DCM (15 ml) and the organic phase is washed with water (3 * 15 ml), dried over Na2SO4, filtered and the 
solvent evaporated under reduced pressure affording 135mg of a brown oil. The residue is purified by FC 
(SiO2 Hex/EtOAc 70:30) to give 114 mg of pure product (yield = 74%). The product was crystalized from n-
hexane giving 77 mg of white crystals (yield after crystallization = 50%). 1H-NMR (300 MHz, CDCl3) δ: 7.92 
(d, 1H, J = 8.64 Hz); 7.30 (m, 5H); 6.94 (m, 5H); 4.15 (m, 4H); 3.06 (t, 2H, J = 7.68 Hz); 1,47 (t, 3H, J = 6.96 Hz). 
MS-APCI: Calc. for C17H17NO2S: 300.1, Found: 300.2 [M+H+]. HPLC purity: tR 11.1 min – 96.0%. Melting 
point = 107°C. 
 
Tert-butyl (3-oxobenzo[d]isothiazol-2(3H)-yl)carbamate 31: Starting from tert-butyl hydrazinecarboxylate 
and 2,2'-disulfanediyldibenzoyl chloride 7 (620 mg, 1.80 mmol), according to method G, the desired product 
is obtained after purification by FC (SiO2 Hex/EtOAc 60:40) as a pale yellow solid  (865 mg, 90%). 1H-NMR 
(300 MHz, CDCl3) δ: 8.07 (d, 1H, J = 7.9 Hz), 7.67 (t, 1H, J = 8.2 Hz); 7.51 (d, 1H, J = 8.1 Hz); 7.41 (t, 1H, J = 7.3 
Hz); 7.06 (bs, 1H); 1.51 (s, 9H); Melting point = 170° C 
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General method I: Synthesis of intermediates 32-d, 37a-b To a 0°C solution of compound 31 in dry DMF is 
portionwise added KHMDS (1.2 eq.). The reaction is stirred under nitrogen atmosphere for 10 minutes 
before a solution of the corresponding alkyl halide in dry DMF is added. The solution is gradually warmed 
to r.t. and stirred for 16 hours. The solvent is removed under reduced pressure and to the residue is added a 
PH 7 phosphate buffer and extracted 3 times with EtOAc. The organic phase is dried over Na2SO4, filtered 
and the solvent evaporated under reduced pressure affording the crude product that is subjected to flash 
column chromatography with an appropriate eluent mixture to furnish the purified product. 
 
Tert-butyl benzyl(3-oxobenzo[d]isothiazol-2(3H)-yl)carbamate 32a: Starting from compound 31 (700 mg, 
2.62 mmol) and benzylbromide (0.38 ml, 3.15 mmol) product 32a (586 mg, 62%) is obtained as a white solid 
after purification by FC (SiO2 Hex/EtOAc 80:20), according to method I. 1H-NMR (300 MHz, CDCl3) δ: 8.04 
(d, 1H, J = 8.5 Hz); 7.57 (d, 1H, J = 8.3 Hz); 7.27 (m, 7H); 5.28 (d, 1H, J = 14.7 Hz); 4.49 (d, 1H, J = 14.8 Hz); 1.41 
(bs, 9H). 
 
Methyl 4-(((tert-butoxycarbonyl)(3-oxobenzo[d]isothiazol-2(3H)-yl)amino)methyl)benzoate 32b: Starting 
from compound 31 (213 mg, 0.80 mmol) and methyl 4-(bromomethyl)benzoate after purification by FC (SiO2 
Hex/EtOAc 80:20), product 32b (237 mg, 71%) is obtained as a yellow oil, according to method I, 1H-NMR 
(400 MHz, CDCl3) δ: 8.01 (m, 3H), 7.58 (t, 1H, J = 7.2 Hz); 7.43 (d, 2H, J = 8.0 Hz); 7.34 (m, 2H); 5.25 (bd, 1H, J 
= 17.5 Hz); 4.56 (bd, 1H, J = 15.0 Hz); 3.89 (s, 3H); 1.41 (bs, 9H). 13C-NMR (100 MHz, CDCl3) δ: 166.8; 141.0; 
140.8, 132.9, 130.0, 129.9; 129.8; 128.8; 127.3; 125.5; 121.8; 120.5; 51.2; 28.1. 
 
Tert-butyl 4-(((tert-butoxycarbonyl)(3-oxobenzo[d]isothiazol-2(3H)-yl)amino)methyl)benzoate 32c: 
Starting from compound 31 (163 mg, 0.6 mmol) and tert-butyl 4-(bromomethyl)benzoate after purification by 
FC (SiO2 Hex/EtOAc 90:10), product 32c (150 mg, 54%) is obtained as a yellow oil, according to method I. 1H-
NMR (300 MHz, CDCl3) δ: 8.01 (d, 1H, J = 7.8 Hz); 8.94 (d, 2H, J = 8.2 Hz); 7.57 (t, 1H, J = 7.3 Hz); 7.41-7.31 
(m, 4H); 5.25 (bd, 1H, J = 14.0 Hz); 4.55 (bd, 1H, J = 15.0 Hz); 1.56 (s, 9H); 1.40 (bs, 9H). 
 
Tert-butyl ([1,1'-biphenyl]-4-ylmethyl)(3-oxobenzo[d]isothiazol-2(3H)-yl)carbamate 32d: Starting from 
compound 31 (179 mg, 0.7 mmol) and 4-(bromomethyl)-1,1'-biphenyl after purification by FC (SiO2 
Hex/EtOAc 90:10), product 32d (220 mg, 76%) is obtained as a white solid, according to method I.  1H-NMR 
(300 MHz, CDCl3) δ: 8.04 (d, 1H, J = 7.4); 7.60-7.55 (m, 5H); 7.45-7.25 (m, 7H); 5.30 (bd, 1H, J = 16.1 Hz); 4.53 
(bd, 1H, J = 14.9); 1.45 (bs, 9H). 
 
Di-tert-butyl pentane-1,5-diylbis((3-oxobenzo[d]isothiazol-2(3H)-yl)carbamate) 37a: Starting from 
compound 31 (500 mg, 1.9 mmol) and 1,5-diiodopentane (167 µl, 1.1 mmol) after purification by FC (SiO2 
Hex/EtOAc 70:30), product 37a (294 mg, 52%) is obtained as a light yellow solid, according to method I. 1H-
NMR (400 MHz, CDCl3) δ: 8.00 (d, 2H, J = 7.8 Hz); 7.60 (t, 2H, J = 7.6 Hz); 7.44 (d, 2H, J = 8.1 Hz); 7.34 (t, 2H, J 
= 7.5 Hz); 3.75-3.60 (m, 4H); 1.69-1.35 (m, 24H). 
 
Di-tert-butyl exane-1,5-diylbis((3-oxobenzo[d]isothiazol-2(3H)-yl)carbamate) 37b: Starting from compound 
31 (500 mg, 1.9 mmol) and 1,6-diiodoexane after purification by FC (SiO2 Hex/EtOAc 80:20), product 37b 
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(327 mg, 57%) is obtained as a white sponge, according to method I. 1H-NMR (400 MHz, CDCl3) δ: 8.00 (d, 
2H, J = 7.8 Hz); 7.60 (t, 2H, J = 7.3 Hz); 7.44 (d, 2H, J = 8.1 Hz); 7.34 (t, 2H, J = 7.6 Hz); 3.72 (q, 2H, J = 7.4 Hz); 
3.57 (q, 2H, J = 7.4 Hz); 1.66-1.36 (m, 26H). 
 
General method J: synthesis of final compounds 33-36, 38-39. To a solution of the corresponding precursor 
32a-d, 37a-b in DCM is dropwise added TFA (25 eq.) at 0°C. The reaction is gently warmed to r.t. and stirred 
for four hours. The solvent is removed under reduced pressure and the residue is dissolved in EtOAc and 
washed twice with NaHCO3 aqueous satured solution and once with brine. The organic phase is dried over 
Na2SO4, filtered and the solvent evaporated under reduced pressure affording the crude product that is 
subjected to flash column chromatography with an appropriate eluent mixture to furnish the purified 
product. 
 
2-(Benzylamino)benzo[d]isothiazol-3(2H)-one 33: Starting from intermediate 32a (400 mg, 1.12 mmol) after 
purification by FC (SiO2 DCM/EtOAc 97:3) and crystallization from n-hexane final product (200 mg, 70%) is 
obtained as white crystals, according to method J. 1H-NMR (300 MHz, DMSO) δ: 7.83 (t, 2H, J = 8.5 Hz); 7.64 
(t, 1H, J = 7.2 Hz); 7.32 (m, 6H); 6.76 (t, 1H, J = 4.1 Hz); 4.19 (d, 2H, J = 4.0 Hz). 13C-NMR (75 MHz, DMSO) δ: 
168.8; 144.9; 142.8; 137.3; 134.0; 133.4; 132.6; 130.8; 130.5; 128.8; 127.0; 59.2. MS-APCI: Calc. for C14H12N2OS: 
257.3, Found: 257.2 [M+H+]. Anal. Calc. for C14H12N2OS: C, 65.60; H, 4.72; N, 10.93; Found: C, 65.47; H, 4.71; 
N, 10.79. Melting point = 110°C. 
 
Methyl 4-(((3-oxobenzo[d]isothiazol-2(3H)-yl)amino)methyl)benzoate 34: Starting from intermediate 32b 
(237 mg, 0.57 mmol) after purification by FC (SiO2 Hex/EtOAc 70:30) and crystallization from DCM/Hex 
final product (90 mg, 50%) is obtained as white crystals, according to method J. 1H-NMR (300 MHz, CDCl3) 
δ: 8.00 (m, 3H); 7.60 (t, 1H, J = 7.3 Hz); 7.50 (d, 2H, J = 8.2 Hz); 7.38 (m, 2H); 5.41 (bs, 1H); 4.36 (s, 1H); 3.90 (s, 
3H). 13C-NMR (75 MHz, CDCl3) δ: 167.0; 164.9; 141.6; 139.7; 132.3; 129.9; 129.9; 129.2; 126.6; 125.5; 123.3; 120.4; 
55.0; 52.2. MS-ESI: Calc. for C16H14N2O3S: 315.3, Found: 315.2 [M+H+]. HPLC-UV tR purity: 6.6 min – 98.9%. 
Melting point = 174 - 176° C. 
 
4-(((3-Oxobenzo[d]isothiazol-2(3H)-yl)amino)methyl)benzoic acid 35: Starting from intermediate 32c (150 
mg, 0.3 mmol) after purification by FC (SiO2 Hex/EtOAc 40:60) final product (60 mg, 61%) is obtained as a 
white powder, according to method J. 1H-NMR (300 MHz, CD3COOD) δ: 8.04 (d, 3H, J = 8.2 Hz); 7.61 (m, 
4H); 7.44 (dt, 1H, J = 8.0, 1.8 Hz); 4.40 (s, 2H). 13C-NMR (75 MHz, CD3COOD) δ: 172.7; 167.2; 144.6; 141.6; 
134.2; 131.8; 130.8; 130.5; 120.0; 127.3; 124.6; 122.1; 55.8. MS-ESI: Calc. for C15H12N2O3S: 301.1, Found: 301.3 
[M+H+]. HPLC-UV purity: tR 7.1 min - 96% 
 
2-(([1,1'-Biphenyl]-4-ylmethyl)amino)benzo[d]isothiazol-3(2H)-one 36: Starting from intermediate 32d 
(220mg, 0.5 mmol) after purification by FC (SiO2 Hex/EtOAc 70:30) final product (98 mg, 60%) is obtained as 
a white powder, according to method J.  1H-NMR (300 MHz, CDCl3) δ: 8.03 (d, 1H, J = 7.9 Hz); 7.60-7.33 (m, 
12H); 5.02 (bs, 1H); 4.35 (s, 2H). 13C-NMR (75 MHz, CDCl3) δ: 164.8; 140.9; 140.8; 139.7; 135.4; 132.2; 129.7; 
128.8, 127.6; 127.5; 127.2; 126.6; 125.5; 120.4; 55.2; MS-APCI: Calc. for C20H16N2OS: 333.4, Found: 333.3 
[M+H+]. HPLC-UV purity: tR 14.9 min – 99.9% 
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2,2'-(Pentane-1,5-diylbis(azanediyl))bis(benzo[d]isothiazol-3(2H)-one) 38: Starting from intermediate 37a 
(294 mg, 0.5 mmol) after purification by FC (SiO2 Hex/EtOAc 30:70) final product (146 mg, 75%) is obtained 
as a white solid, according to method J.  1H-NMR (300 MHz, CDCl3) δ: 8.00 (d, 2H, J = 7.8 Hz,); 7.60 (t, 2H, J = 
7.6 Hz); 7.47 (d, 1H J = 8.0 Hz); 7.37 (t, 2H, J = 7.5 Hz); 4.58 (bs, 2H); 3.15 (t, 4H, J = 6.6 Hz); 1.64-1.48 (m, 
6H).13C-NMR (75 MHz, CDCl3) δ: 164.6; 139.4; 132.1; 126.6; 125.5; 123.7; 120.4; 51.4; 27.4; 24.3. MS-ESI: Calc. 
for C19H20N4O2S2: 401.1, Found: 401.5 [M+H+]. HPLC purity: tR 5.6 min - 98.8% 
 
2,2'-(Exane-1,5-diylbis(azanediyl))bis(benzo[d]isothiazol-3(2H)-one) 39: Starting from intermediate 37b 
(327 mg, 0.5 mmol) after purification by FC (SiO2 Hex/EtOAc 20:80) final product (103mg, 48%) is obtained 
as a white solid, according to method J.  1H-NMR (400 MHz, CDCl3) δ: 8.03 (d, 2H, J = 7.9 Hz); 7.62 (t, 2H, J = 
7.6 Hz); 7.51 (d, 2H, J = 8.0 Hz); 7.40 (t, 2H, J = 7.5 Hz); 4.15 (bs, 2H); 3.17 (t, 2H, J = 6.6 Hz); 1.62-1.44 (m, 8H). 
13C-NMR (100 MHz, CDCl3) δ: 164.6; 139.5; 132.1; 126.6; 125.5; 123.7; 120.5; 51.5; 27.5; 26.8. MS-ESI: Calc. for 
C20H22N4O2S2: 415.1, Found: 415.4 [M+H+]. HPLC purity: tR 7.2 min - 99.1% 
 
2-(Benzyl(methyl)amino)benzo[d]isothiazol-3(2H)-one 40: To a solution of 33 (58 mg, 0.23 mmol) in MeI 
(0.7 ml, 11.18 mmol), imidazole (16 mg, 0.24 mmol) is added in one portion. The solvent is evaporated under 
reduced pressure and the residue is purified by FC (SiO2 DCM/MeOH 99:1) affording 39 mg (yield = 64%) 
of product as a pale yellow waxy solid.  1H-NMR (300 MHz, CDCl3) δ: 8.00 (d, 1H, J = 7.9 Hz); 7.58 (td, 1H, J 
= 8.0, 1.2 Hz); 7.44 (d, 1H, J = 8.0 Hz); 7.25-7.35 (m, 4H); 4.24 (s, 2H); 2.95 (s, 3H). MS-APCI: Calc. for 
C15H14N2OS: 271.1, Found: 271.3 [M+H+]. Anal. Calc. for C15H14N2OS: C, 66.64; H, 5.22; N, 10.36; Found: C, 
66.87; H, 5.46; N, 9.84. Melting point = 142°C. 
 
(2R,4aS,6aS,12bR,14aS,14bR)-methyl 10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-
1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate 42: 
Commercially available compound 41 (celastrol) (80 mg, 0.2 mmol) is dissolved in dry DMF at 0°C under 
nitrogen atmosphere. NaHCO3 (44 mg, 0.5 mmol) and MeI (56 µl, 0.9 mmol) are added and the mixture 
stirred overnight under nitrogen and protected from light. To the reaction are added DEE (10 ml) and 
Ammonium chloride satured solution (10 ml) and aqueous phase is washed 5 times with DEE. Organic 
phases are collected and washed with water (20 ml) and brine (20 ml). The organic phase is dried over 
Na2SO4 and the solvent evaporated under reduced pressure affording 102 mg of a orange oil. The residue 
was purified by FC (SiO2 Hex/EtOAc 85:15) giving 61 mg of an orange solid (yield = 74%). 1H-NMR (400 
MHz, CDCl3) δ: 7.00 (d, 1H, J = 7.0 Hz); 6.52 (s, 1H); 6.33 (d, 1H, J = 7.2 Hz); 3.54 (s, 3H); 2.40 (d, 1H, J = 15.7 
Hz); 2.23 (s, 3H); 2.19-2.00 (m, 6H); 1.89-1.32 (m, 13H); 1.25 (s, 3H); 1.16 (s, 3H); 1.08 (s, 3H); 0.95 (d, 1H, J = 14 
Hz); 0.52 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ: 178.8, 178.3, 170.3, 164.9, 146.1, 134.2, 127.5, 126.7, 119.6, 118.2, 
117.3, 51.6, 45.1, 44.4, 43.0, 40.7, 40.5, 39.5, 38.3, 36.5, 34.9, 33.6, 32.8, 31.7, 30.8, 31.0, 30.6, 30.0, 29.7, 28.7, 21.7, 
18.4, 10.3. APCI-MS Calc. for C30H40NO4: 465.3, Found: 465.4 [M+H+]. HPLC-UV purity: tR 6.03 min – 99.9%. 
 
2R,4aS,6aS,12bR,14aS,14bR)-phenethyl 10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-
1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate 45: 
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Commercially available compound 41 (celastrol) (50 mg, 0.1 mmol) is dissolved in dry DMF under nitrogen 
atmosphere. NaHCO3 (28 mg, 0.3 mmol) and phenethylbromide (75 µl, 0.6 mmol) are added and the mixture 
stirred overnight under nitrogen and protected from light. To the reaction are added DEE (10 ml) and 
Ammonium chloride satured solution (10 ml) and aqueous phase is washed 5 times with DEE. Organic 
phases are collected and washed with water (20 ml) and brine (20 ml). The organic phase is dried over 
Na2SO4 and the solvent evaporated under reduced pressure affording 200 mg of an orange oil. The residue 
was purified by FC (SiO2 Hex/EtOAc 90:10) giving 54 mg of an orange solid (yield = 88%). 1H-NMR (400 
MHz, CDCl3) δ: 7.33-7.20 (m, 5H); 7.04 (d, 1H, J = 7.1 Hz); 6.54 (s, 1H); 6.34 (d, 1H, J = 7.1 Hz); 4.25 (dt, 1H, J = 
10.9, 6.7 Hz); 4.03 (dt, 1H, J = 11.0, 6.6 Hz); 2.90 (t, 2H, J = 6.6 Hz); 2.36 (d, 1H, J = 15.9 Hz); 2.23 (s, 3H); 2.20-
1.83 (m, 5H); 1.71-1.25 (m, 14H); 1.15 (s, 3H); 1.10 (s, 3H); 0.94 (d, 1H, J = 13.9 Hz); 0.43 (s, 3H). 13C-NMR: (75 
MHz, CDCl3): 178.4, 170.4, 164.9, 146.1, 138.2, 134.3, 129.0, 128.6, 127.5, 126.7, 119.7, 118.2, 117.3, 65.2, 45.1, 
44.4, 43.1, 40.5, 39.5, 38.4, 36.5, 34.9, 33.7, 32.8, 31.7, 30.9, 30.5, 29.9, 29.6, 28.7, 21.7, 18.5, 10.4. APCI-MS Calc. 
for C37H46NO4: 555.3, Found: 555.4 [M+H+]. HPLC-UV purity: tR 5.27 min – 99.9% 
 
(2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-N,2,4a,6a,9,12b,14a-heptamethyl-11-oxo-
1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxamide 46: 
Commercially available compound 41 (celastrol) (50 mg, 0.1 mmol) is dissolved in dry DMF at 0°C under 
nitrogen atmosphere. DIPEA (38 µl, 0.2 mmol) and HATU (42 mg, 0.1 mmol) are added and the mixture 
stirred for 15 min. Methylamine solution 2.0M in THF (111 µl, 0.2 mmol) is added and the reaction is stirred 
overnight under nitrogen and protected from light. To the reaction are added DEE (10 ml) and ammonium 
chloride satured solution (10 ml) and aqueous phase is washed 5 times with DEE. Organic phases are 
collected and washed with water (20 ml) and brine (20 ml). The organic phase is dried over Na2SO4 and the 
solvent evaporated under reduced pressure affording 75 mg of a orange oil. The residue was purified by FC 
(SiO2 Hex/EtOAc 30:70) giving 34 mg of an orange solid (yield = 66%). 1H-NMR: (400 MHz, CDCl3) δ: 7.01 
(dd, 1H, J = 1.2, 7.1 Hz); 6.54 (d, 1H, J = 1.2 Hz); 6.34 (d, 1H, J = 7.2 Hz); 5.75 (d, 1H, J = 4.1 Hz); 2.67 (d, 3H, J 
= 4.6 Hz); 2.44 (d, 1H, J = 14.1 Hz); 2.20 (s, 3H); 2.16-1.48 (m, 13H); 1.43 (s, 3H); 1.25 (s, 3H); 1.14 (s, 3H); 1.12 
(s, 3H); 1.01 (d, 1H, J = 14.0 Hz); 0.61 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ: 178.5, 178.2, 164.9, 146.1, 134.4, 
127.5, 119.6, 118.2, 117.4, 45.2, 44.5, 43.2, 40.4, 39.5, 38.3, 36.5, 35.1, 33.7, 33.6, 31.7, 31.7, 31.4, 31.0, 30.2, 29.6, 
28.8, 26.5, 21.8, 18.2, 10.4. APCI-MS Calc. for C30 H41NO3: 464.3, Found: 464.4 [M+H+]. HPLC-UV purity: tR 
3.4 min – 97.3%. 
 
(2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-N-phenethyl-
1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxamide 47: 
Commercially available compound 41 (celastrol) (50 mg, 0.1 mmol) is dissolved in dry DMF at 0°C under 
nitrogen atmosphere. DIPEA (38 µl, 0.2 mmol) and HATU (42 mg, 0.1 mmol) are added and the mixture 
stirred for 15 min. Phenethylamine (27 µl, 0.2 mmol) is added and the reaction is stirred overnight under 
nitrogen and protected from light. To the reaction are added DEE (10 ml) and Ammonium chloride satured 
solution (10 ml) and aqueous phase is washed 5 times with DEE. Organic phases are collected and washed 
with water (20 ml) and brine (20 ml). The organic phase is dried over Na2SO4 and the solvent evaporated 
under reduced pressure affording 60 mg of a orange oil. The residue was purified by FC (SiO2 Hex/EtOAc 
65:45) giving 46 mg of an orange solid (yield = 78%). 1H-NMR (400 MHz, CDCl3) δ: 7.30 (m, 2H); 7.23 (m, 
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1H); 7.16 (d, 2H, J = 7.0 Hz); 7.04 (d, 1H, J = 7.0 Hz); 6.56 (s, 1H); 6.35 (d, 1H, J = 7.2 Hz); 5.71 (t, 1H, J = 4.1 
Hz); 3.39 (q, 2H, J = 6.7 Hz); 2.76 (t, 2H, J = 6.8 Hz); 2.40 (d, 1H, J = 14.5 Hz); 2.23 (s, 3H); 2.12 (dd, 1H, J = 3.9, 
13.9 Hz); 1.90-1.78 (m, 5H); 1.66-1.44 (m, 10H); 1.30-1.25 (m, 4H); 1.20 (s, 3H); 1.10 (s, 3H); 0.92 (d, 1H, J = 7.1 
Hz); 0.55 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ: 178.3, 177.7, 170.6, 164.9, 146.1, 139.0, 134.2, 128.8, 128.8, 127.5, 
126.7, 119.6, 118.1, 117.2, 45.1, 44.4, 43.1, 40.7, 40.4, 39.4, 38.2, 36.4, 35.3, 35.0, 33.8, 33.6 31.7, 31.1, 30.8, 30.2, 
29.5, 28.7, 21.8, 18.4, 10.4. APCI-MS Calc. for C37H47NO3: 554.3, Found: 554.3 [M+H+]. HPLC-UV purity: tR 4.7 
min – 97.6%. 
 
 
5.1.2 Pharmacology 
Collected biological data were from experimentations carried out by Prof. Piomelli’s research group (Departments of 
Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California Irvine 
Irvine, CA, USA)  
 
MGL Cloning. Rat MGL cDNA was cloned out of the pBluescript-SK vector using the following primers: 5'- 
CGCGGCAGCCATATGCTGAGGCAAGTTCACC (forward primer) and 5'- 
AGCAGCCGGATCCTCTCAGGGTAGACACCTAG (reverse primer). These primers introduced a BamHI 
and an NdeI endonuclease restriction site at the 5' and 3' end of the cDNA, respectively. Platinum Pfx DNA 
polymerase (Invitrogen, Carlsbad, CA) was used to run the polymerase chain reaction (PCR), followed by 
BamHI/NdeI double digest of the PCR product and the pET15b vector (Novagen, La Jolla, CA) containing 
an n-terminal histidine tag. The vector and the PCR product were ligated using T4 DNA ligase (Promega, 
Madison, WI) following the dephosphorylation of the pET15b vector DNA. The ligation setup was 
transformed into DH5α E.coli cells and plated on a Luria Broth agar plate containing 50 µg/ml ampicillin. 
Ten colonies were selected and their plasmid DNAs were purified according to the QIAGEN plasmid DNA 
miniprep Kit protocol (QIAGEN, Valencia, CA). Restriction digest analysis resulted in four positive clones, 
which were subjected to DNA sequencing, confirming the correct sequence.  
MGL Expression and Purification. Clone 2 was expressed in Rosetta 2(DE3)pLysS E. coli cells (Novagen) at 
37°C using 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG). This clone was used for all subsequent 
protein expression experiments. 4 L of LB + 50 µg/ml ampicillin were inoculated with 40 ml of overnight 
culture of Rosetta 2(DE3)pLysS cells transformed with pET15b/MGL grown in LB + 50 µg/ml ampicillin. 
Cells were grown at 37°C until the optical density (OD) at 600 nm reached 0.8. At this point, addition of 
IPTG to a final concentration of 1 mM induced MGL overexpression. After 4 h, the cells were harvested by 
centrifugation at 6,000g for 15 min and the bacterial pellet was resuspended in 100 ml of lysis buffer (50 mM 
HEPES pH 7.4, 300 mM NaCl, 10 mM MgCl2,10 µM E-64 and 10 µg/ml aprotinin). The cells were lysed using 
a French press and the cell lysate centrifuged at 3,000g for 1 h at 4°C to separate the membrane fraction from 
the cell debris. The supernatant (membrane fraction) was then subjected to another centrifugation at 35,000g 
for 1 h at 4°C. The pellet was resuspended in 50 mM HEPES pH 7.4., 300 mM NaCl, 3 mM β- 
mercaptoethanol, 1% Triton X-100, stirred for about 30 min, and centrifuged again at 5,000g for 1 h at 4°C. 
The supernatant was loaded onto a TALON column (Clontech, Mountain View, CA) equilibrated with 50 
mM HEPES pH 7.4, 300 mM NaCl, 3 mM β-mercaptoethanol, 0.1% Triton X-100 (buffer A). The column was 
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washed with 5 volumes of buffer A, and the protein subsequently eluted from the column using a step 
gradient of imidazole ranging from 10 to 200 mM imidazole in buffer A (5 column volumes each). The 
protein eluted at about 75 mM imidazole.  
MGL assay. Either 10 ng of purified MGL or 2.5–50 µg of protein from MGL-transfected HeLa cell lysates 
were preincubated with inhibitors for 10 min at 37°C in assay buffer (50 mM Tris-HCL, pH 8.0, 0.5 mg·mL-1 
bovine serum albumin, fatty acid-free). Following preincubation, 2-oleoylglycerol (2-OG) substrate (10 µM 
final) was added, and samples were incubated for an additional 10 min at 37°C. Reactions were stopped with 
chloroform : methanol (2:1, vol : vol), containing heptadecanoic acid (5 nmol) as an internal standard. In 
some experiments with cell lysates, 1(3)heptadecanoylglycerol (1-HG) and heptadecenoic acid were used as 
substrate and internal standard respectively. Samples were subjected to centrifugation at 2000 × g at 4°C for 
10 min, and the organic layers were collected and dried under a stream of N2. The residues were suspended 
in chloroform : methanol (1:3, vol : vol) and analysed by liquid chromatography/mass spectrometry 
(LC/MS). 
LC/MS analysis. We used a reversed-phase Eclipse C18 column (30 × 2.1 mm i.d., 1.8 µM, Agilent 
Technologies, Wilmington, DE, USA) eluted with 95% of solvent A and 5% solvent B for 0.6 min at a flow 
rate of 0.6 mL.min-1 with column temperature set at 50°C. Solvent A consisted of methanol containing 0.25% 
acetic acid and 5 mM ammonium acetate. Solvent B consisted of water containing 0.25% acetic acid and 5 
mM ammonium acetate. Under these conditions, analytes eluted from the column at the following retention 
times: oleic acid, 0.34 min; heptadecanoic acid, 0.37 min; heptadecenoic acid, 0.29 min. Electrospray 
ionization was in the negative mode, capillary voltage was set at 4 Kv, and fragmentor voltage was 100 V. N2 
was used as drying gas at a flow rate of 13 L.min-1 and a temperature of 350°C. Nebulizer pressure was set at 
60 psi. For quantification purposes, we monitored the [M-H]- ions of m/z = 281.3 for oleic acid, m/z = 269 for 
heptadecanoic acid, and m/z = 267 for heptadecenoic acid. 
Rapid dilution assay. Samples containing of purified MGL (100-fold concentrated compared with standard 
assays) were preincubated with 10-fold the IC50-equivalent concentration of octhilinone, MAFP or vehicle 
(dimethylsulphoxide, DMSO, final concentration 2%) for 20 min at 37°C. Samples were then diluted 100-fold 
with assay buffer containing substrate to initiate reactions, and the time course of product formation was 
measured by LC/MS. 
Site direct mutagenesis. A full-length rat MGL cDNA was subcloned into the pEF6/V5-His vector 
(Invitrogen, San Diego, CA, USA). The MGL gene was modified by using the QwikChange II XL Site-
Directed Mutagenesis Kit (Strategene, La Jolla, CA, USA) following the manufacturer’s instructions. Primers 
were commercially synthesized (Invitrogen). Following DNA sequencing, positive clones were identified 
and transfected into HeLa cells by using the Superfect transfectant reagent (Qiagen, Valencia, CA, USA), 
following standard protocol. Cells were resuspended in ice-cold Tris-HCL (50 mM, pH 8.0) containing 0.32 
M sucrose and harvested by using a cell scraper. Lysates were sonicated on ice for 1 min followed by three 
rounds of freeze thawing. Samples were subjected to centrifugation at 100 000 × g at 4°C for 30 min to 
separate membrane (pellet) and cytosolic (supernatant) fractions. 
Protein analysis. Protein concentrations were measured by using the BCA Protein Assay kit (Pierce, 
Rockford, IL, USA). Samples (5 µg) were electrophoresed on a 4–20% SDS-polyacrylamide gel (Invitrogen) 
and transferred to a polyvinylidene difluoride membrane (Amersham, Piscataway, NJ, USA). Membranes 
were blocked in 10% milk and incubated in the presence of anti-V5 monoclonal antibody (1:3000, 12 h; 
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Invitrogen). Immunoreactive bands were visualized by using the ECL-Plus kit (Amersham), exposed to high 
performance chemiluminescence film (Amersham) and developed with a Mini-Medical film processor (AFP 
Imaging, Elmsford, NY, USA). As a loading control, membranes were stripped for 15 min at room 
temperature and probed again by using an anti-actin monoclonal antibody (1:10 000, 12 h; Calbiochem, La 
Jolla, CA, USA). 
Statistical analyses. All results are expressed as mean SEM. Non-linear regression analyses were performed 
by using Prism (GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was assessed by the 
Student’s t-test. 
 
 
5.1.3 Computational studies 
Molecular Modeling. Molecular Modeling studies were performed using the Schrödinger software suite. 
Ligand molecules were built in Maestro 9.22 and prepared with Ligprep 2.53; the protein structure was 
refined using the Protein Preparation Wizard tool4. Covalent docking studies were performed using Prime 
3.05, while docking studies were carried out with Glide 5.76,7. 
Protein Preparation. The crystal structure of human MGL (PDB 3HJU, chain A) was used as model structure 
for docking studies. The hydrogen atoms were added, and the hydrogen bonding network was optimized by 
sampling the conformation of histidine, asparagine and glutamine side chains; the orientations of thiol and 
hydroxyl group were optimized and the protonation state of ionizable residues were adjusted to be 
consistent with physiological pH. The resulting structure was subjected to a restrained minimization with 
the OPLS2005 force field in which only hydrogen atoms were free to move. A second minimization was 
performed by restraining the heavy atoms until a RMSD value of 0.3 Å. 
Covalent Docking Studies. The Prime Covalent Docking facility was used to perform covalent docking 
studies. In order to allow the accommodation of the ligands, both the attachment residue (CYS201) and 
residues within 8 Å of CYS201 were allowed to adjust in the loop sampling procedure. Ligands 9, 33, 34, 35 
and 40 were initially prepared using Ligprep 2.5, and then minimized with Macromodel 9.98, applying the 
OPLS2005 force field9 to an energy gradient of 0.05 kJ mol-1 Å-1. 20 poses were collected for each covalent 
docking run and ranked according to the Prime Energy values. The top ranked poses were selected and 
subjected to energy minimization to an energy gradient of 0.05 kJ mol-1 Å-1. 
Docking studies. Docking studies were performed to evaluate the binding modes of compounds 38 and 39. 
The Induced Fit Docking protocol was applied in order to account for both ligands and protein flexibility 
during the ligand docking procedure. As a first step, a softened-potential docking was performed by 
applying van der Waals radii scaling factors of 0.6 and 0.5 on the non polar-atoms of the protein and the 
ligands, respectively. Energy grids for this first docking run were centered on Cys201 and Cys208, with the 
enclosing box length in X and in Y set to 10 Å and the box length in Z set to 16 Å. Ligands 38 and 39, which 
were previously prepared with Ligprep 2.5 were then flexibly docked in the standard precision mode. The 
resulting complexes were then subjected to the protein refinement step. In this stage residues within a 
distance of 6 Å from any ligand pose were refined through a side-chain conformational search and finally 
minimized. The final step of the IFD procedure involved a further docking run of the ligands in the protein 
structures generated in the previous step. The complexes were evaluated according to their IFD score and 
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finally minimized with Macromodel 9.9, applying the OPLS2005 force field to an energy gradient of 0.05 kJ 
mol-1 Å-1. 
Metadynamics studies. The Protein Data Bank code used for human MGL is 3HJU10, and the used sequence 
comprises residues P7-A297 of the chain A. Models of MGL with C201 and C208 oxidized to sulfenic acid 
and of MGL with a covalent adduct of UPR1218 at C201 were built from 3HJU using Maestro 9.62. Well-
tempered Metadynamics11 simulations were performed using Desmond 3.412. Each system comprises a 
portion of POPC membrane bilayer, using the coordinates provided by the Orientation of Protein in 
Membranes (OPM) database13. The protein membrane systems are solvated with spc water molecules, in a 
simulation box including approximately 95000 atoms. The OPLS2005 force field was used to model the 
system. The system was relaxed using a modified version of a membrane relaxation protocol implemented 
in the Desmond package. The equilibration phase was then followed by 100ns well-tempered metadynamics 
performed in the NPT ensemble at 300K and 1 atm, using the Langevin coupling system. Bond lengths to 
hydrogens were constrained using M-SHAKE; short-range electrostatic interactions were cut off at 9 Å, 
while long-range electrostatic interactions were calculated using the Smooth Particle Mesh Ewald method. A 
RESPA integrator was used with a time-step of 2 fs, and long-range electrostatics were computed every 6 fs. 
The Metadynamics method allows the enhanced sampling of the conformational space by adding to the total 
energy of the system an external history-dependent potential, which is a function of few degrees of freedom 
called Collective Variables (CVs). In this work the distances between the center of mass of carbons α (CA) of 
specific residues on the lid domain of MGL were used as CVs. Specifically, CV1 corresponds to the distance 
between the centers of mass of residues 176-179 and residues 150-157 CA, while CV2 corresponds to the 
distance between the centers of mass of residues 176-179 and residues 158-164 CA. The width of the 
Gaussians was set at 0.05 Å; the time interval between consecutive depositions was 0.09 ps. The well-
tempered implementation involves adjusting the height of the Gaussians added; in this work the initial 
height was set to 0.03 kcal/mol, and the potential was adjusted by using a kT of 2.4. 
The convergence of the simulations performed was evaluated by analyzing the free energy difference at 5 ns 
intervals. Once the free energy profile stopped changing, the simulations were considered as converged. 
Each simulation was run for 100ns and analyzed upon convergence. 
 
 
5.1.4 Reactivity studies with glutathione  
Stock solutions of all reagents were purged with argon and all reactions took place under argon atmosphere 
removing aliquots for analysis by syringe under positive argon pressure. Reactions were initiated by 
injection of a 10 mM DMSO stock solution of benzisothiazolone (final concentration: 100 µM) into a 
temperature equilibrated (37.0°C) vial containing a buffered reaction solution with a 2-fold molar excess of 
glutathione (GSH) over benzisothiazolinone (final GSH concentration: 200 µM). Final concentration of 
DMSO was 1% v/v in 10 mM phosphate buffered saline (PBS) pH 7.4. The disappearance of reacting BTZ 
and the formation of corresponding reaction species was monitored by HPLC/UV using a gradient elution. 
Column used was a Supelco Discovery C18 column 150x4.6 mm i.d., 5 µm particle size (Supelco, Bellefonte, 
PA, USA). Eluent A: water additioned of 0.05% v/v trifluoroacetic acid (TFA); eluent B: methanol additioned 
of 0.05% v/v TFA. Gradient was as follows: t(0 min): 95% A:5% B; t(6 min): 95% A:5% B; t(26 min): 5% A:95% 
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B; t(28 min): 5% A:95% B returning to initial conditions in 0.5 min. Total gradient time was 30 min. 
Absorbance was monitored at the two wavelengths of 210 and 254 nm. Flow rate was 1 mL/min. Injected 
volume: 10 µL. 
A Shimadzu HPLC gradient system (Shimadzu Corp., Kyoto, Japan) fitted with two LC-10AD Shimadzu 
pumps and a Shimadzu SPD-10 variable wavelength detector was employed for analysis. Standard curves 
for quantification of GSH and oxidized glutathione (GSSG) were prepared in PBS buffer and showed good 
linearity in the 5-500 µM concentration range. The limit of quantification (LOQ) was 5 µM, monitoring 
absorbance at λ = 210 nm. Standard curves for quantification of concentrations of BTZ were prepared by 
spiking PBS buffer with stock solutions of test compounds in the 100 nM-100 µM concentration range. The 
limit of quantification (LOQ) was 100 nM, monitoring absorbance at λ = 254 nm. The coefficients of 
correlation (r2) were > 0.99 for all curves. 
Identity of reaction species was confirmed by HPLC-ESI-MS/MS analysis. Column used was a Phenomenex 
Sinergy Fusion (100 x 2.0mm i.d., 4 µm particle size (Phenomenex, Bologna, Italy). Eluent A: water 
additioned of 0.1% v/v formic acid (FA); eluent B: methanol additioned of 0.1% v/v FA. Chosen gradient 
was as follows: t(0 min): 95% A:5% B; t(1 min): 95% A:5% B; t(6 min): 5% A:95% B; t(9 min): 5% A:95% B 
returning to initial conditions in 0.5 min. Total gradient time was 13 min. Flow rate was 350 µL/min. Injected 
volume: 10 µL. A Thermo Accela UHPLC gradient system (Thermo Italia, Milan, Italy) coupled to a Thermo 
TSQ Quantum triple quadrupole mass spectrometer with heated electrospray ionization (H-ESI) ion source 
was used for compound detection and analysis. Mass spectrometric analyses were done in positive ion mode 
and in full scan mode in the 150-750 amu range. H-ESI interface parameters were set as follows: probe 
middle (D) position; capillary temperature 270 °C; spray voltage 3.0 kV. Nitrogen was used as nebulizing gas 
at the following pressure: sheath gas 35 psi; auxiliary gas 15 arbitrary units (a.u.). Argon was used as the 
collision gas at a pressure of approximately 1.5 mtorr (1 torr = 133.3 Pa). The software Xcalibur, version 1.3, 
(Thermo Italia, Milan, Italy) was employed for data acquisition and processing. 
 
 
5.1.5 Kinetic studies by NMR spectroscopy 
NMR spectra of compounds 2, 9, 33, 23 and 29 were recorded on a Bruker AV 400 MHz spectrometer at 298 
K. Equimolar concentration (80 mM) of BTZ and NAC were separately dissolved in deuterated methanol 
and mixed together. 1H-NMR spectra were measured at 4 minutes and then every 2 minutes until reaction 
was complete. 1H chemical shifts were given on the δ scale and were calibrated to the residual solvent signal 
of MeOD at δ 3.31. 
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5.2 Chapter 4 
5.2.1 Chemistry 
All chemicals were used as received unless stated otherwise. All reactions were performed under a steady 
overpressure of nitrogen delivered through a balloon. Tetrahydrofuran was distilled over 
sodium/benzophenone prior to use. Anhydrous solvents such as dichloromethane, N,N-
dimethylformamide, pyridine were directly purchased from an appropriate vendor, and were supplied 
stored over 3 Å molecular sieves and packed under Ar. They were subsequently manipulated by syringe 
under a steady pressure of nitrogen. Column chromatography was performed on silica gel 60 (0.040-0.063 
mm) under forced flow of the appropriate solvent mixtures. TLC analysis was conducted on HPTLC 
aluminum sheets (Sigma-Aldrich, silica gel 60, F254), compounds were visualized by UV absorption (245 nm) 
and/or by dipping in a solution of (NH4)6Mo7O24·4 H2O 25 g/l and (NH4)4Ce(SO4)4·2 H2O 10 g/l, in 1 L of 
10% aqueous H2SO4. 1H- and 13C-NMR spectra were recorded with a Bruker AV 300, 400 and with a Varian 
600. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak of the 
solvent. 1H-NMR spectra are reported in the following order: multiplicity, number of protons and 
approximate coupling constant (J value) in hertz (Hz); signals were characterized as s (singlet), d (doublet), 
dd (doublet of doublets), t (triplet), dt (doublet of triplets), q (quartet), m (multiplet), bs (broad signal). Mass 
Spectra were recorded on a Applied Biosystem API-150 EX system spectrometer with an ESI or an APCI 
interface. Purity of final compounds were analyzed by HPLC with UV detection at λ = 220. Purity of 
compounds was determined by analytical high performance liquid chromatography (HPLC) employing a 
Shimadzu HPLC gradient system (Shimadzu Corp., Kyoto, Japan) equipped with two LC-10AD solvent 
delivery modules, a Rheodyne 7125 sample injector and a SPD-10A UV-VIS detector. Prior to analysis, 
samples were prepared in MeOH at a final concentration of 0.1 mg/mL. Chromatographic separation 
occurred on a Supelco Discovery C18 column (150 X 4.6 mm, 5 mm particle size) by gradient elution. Flow 
rate was 1 mL/min and injected volume was 10 mL. Solvent A was MeCN and Solvent B was water both 
additioned of 0.1% v/v formic acid. Isocratic conditions were employed for all final compounds: 75% A: 25% 
B. Purity results are presented as tR (min) and relative chemical purity (%). All tested compounds were 
>95% pure. 
 
1-((3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-
1H-cyclopenta[a]phenanthren-17-yl)ethanone 49:  
Commercially available pregnenolone acetate 48 (2.0 g, 5.6 mmol) is dissolved in a mixture of MeOH/DCM 
1:3 (60 ml), a solution of KOH (3.1 g, 56 mmol) in MeOH (20 ml) is added at r.t. and the reaction is stirred for 
two hours. Reaction mixture is neutralized with a 1M HCl solution, additioned of EtOAc (50 ml) and washed 
with 3 times with brine (30 ml). The organic phase is dried over Na2SO4 and the solvent evaporated under 
reduced pressure affording 1.7 g of a white powder used without any further purification (yield = 98%). 1H-
NMR (300 MHz, CDCl3) δ: 5.33 (bd, 1H, J = 5.2 Hz); 3.50 (m, 1H); 2.51 (t, 1H, J = 9.0 Hz); 2.32-2.15 (m, 3H); 
2.11 (s, 3H); 2.05-1.97 (m, 2H); 1.88-1.81 (m, 2H); 1.71-1.37 (m, 9H); 1.29-0.93 (m, 7H); 0.62 (s, 3H). 13C-NMR 
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(100 MHz, CDCl3) δ: 209.7; 140.9; 121.4; 71.6; 63.7; 56.9; 50.0; 44.1; 42.3; 38.9; 37.3; 36.6; 31.9; 31.8; 31.6; 24.5; 
22.8; 21.1; 19.4; 13.3. ESI-MS Calc. for C21H32O2: 317.2, Found: 317.1 [M+H+]. 
 
(3S,8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-yl benzoate 50: 
Pregnenolone 49 (2.5 g, 8.0 mmol) is dissolved in pyridine (30 ml) at 0° C. Benzoyl chloride (1.2 ml, 10.3 
mmol) and DMAP (96 mg, 0.8 mmol) are added and the reaction mixture is stirred at r.t. for 24 h. 1M HCl 
solution is added and the mixture is diluted with DCM (50 ml). Organic phase is washed with brine (20 ml) 
and HCl 1M (20 ml), dried over Na2SO4 and the solvent is evaporated under reduced pressure. The crude 
product is triturated in EtOAc affording 2.7 g of desired product as a white solid (yield = 81%). 1H-NMR (300 
MHz, CDCl3) δ: 8.05 (d, 2H, J = 7.1 Hz); 7.57 (t, 1H, J = 7.4 Hz);  7.45 (t, 1H, J = 7.7 Hz); 5.44 (bd, 1H, J = 4.3 
Hz); 4.87 (m, 1H); 2.57 (t, 1H, J = 9.1 Hz); 2.50 (d, 2H, J = 7.8 Hz); 2.26-1.92 (m, 8H); 1.83-1.48 (m, 8H); 1.30-
1.19 (m, 3H); 1.14-1.05 (m, 4H); 0.66 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ: 209.7; 166.1; 139.8, 132.9; 130.9; 
129.6; 128.4; 122.6; 74.5; 63.8; 56.9; 50.0; 44.1; 38.9; 38.2; 37.1; 36.8; 31.9; 31.9; 31.7; 27.9; 24.6; 22.9; 21.2; 19.5; 
13.3. ESI-MS Calc. for C28H36O2: 413.3, Found: 413.1 [M+Na+]. 
 
(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-(4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanoyl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate 51: 
In a two neck flask, compound 50 (150 mg, 0.4 mmol) is dissolved in dry THF under nitrogen atmosphere at 
-78° C. A solution of KHMDS (99 mg, 0.5 mmol) in dry THF is added and the reaction mixture is stirred at -
78° C for 30 min. In a separate two neck flask conc. H2SO4 (10 ml) is warmed to 50° C and linked through a 
cannula with the enolate flask. Trihydrate HFA (large excess ≈ 3 ml) is dropped inside the H2SO4 and a 
colorless gas formation is observed. Through a positive nitrogen pressure, gaseous HFA is bubbled inside 
the enolate solution. The reaction mixture is then warmed to r.t.. A 5% aqueous solution of acetic acid is 
added and the reaction is stirred for 15 min before being diluted with EtOAc. The organic phase is then 
washed with H2O (10 ml) and brine (10 ml), dried over Na2SO4 and the solvent is evaporated under reduced 
pressure affording a yellow oil (370 mg). The residue is purified by FC (SiO2 Hex/DCM 50:50) giving 140 mg 
of a white solid (yield = 67%). 1H-NMR (400 MHz, CDCl3) δ: 8.04 (d, 2H, J = 7.1 Hz); 7.55 (t, 1H, J = 7.4 Hz); 
7.43 (t, 1H, J = 7.8 Hz); 7.08 (s, 1H); 5.41 (bd, 1H, J = 4.7 Hz); 4.86 (m, 1H); 2.94 (d, 1H, J = 17.2 Hz); 2.80 (d, 
1H, J = 17.2 Hz); 2.61 (t, 1H, J = 9.0 Hz); 2.47 (bd, 2H, J = 7.0 Hz); 2.18 (q, 1H, J = 9.3 Hz); 2.04-1.90 (m, 4H); 
1.79-1.49 (m, 8H); 1.30-1.20 (m, 3H); 1.09-1.04 (m, 4H); 0.69 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ: 212.1; 166.1; 
139.8; 132.9; 130.8; 129.6; 128.4; (127.0; 123.9; 121.1; 118.4 (CF3)2); 122.3; (76.8; 76.5; 76.2; 75.9 (COH(CF3)2); 74.4; 
64.9; 57.0; 49.9; 45.3; 38.7; 38.3; 37.8; 37.1; 36.7; 32.0; 31.8; 27.9; 24.4; 22.9; 21.1; 19.5; 13.3. ESI-MS Calc. for 
C31H36F6O3: 387.3, Found: 387.2 [M+H+]. 
 
(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((R)-4,4,4-trifluoro-1,3-dihydroxy-3-(trifluoromethyl)butyl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate 52: 
Compound 51 (140 mg, 0.2 mmol) is dissolved in a MeOH/THF 1:1 mixture before NaBH4 (12 mg, 0.3 mmol) 
is added at r.t.. Reaction is stirred 2 hours before a 1M HCl solution (5 ml) is added and stirring is continued 
for 15 min. Then reaction is diluted with a 2M NaOH solution and stirred for additional 2 hours. Organic 
phase, after addition of EtOAc (10 ml) is washed with brine (10 ml) dried over Na2SO4 and the solvent is 
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evaporated under reduced pressure affording a white solid (120 mg). The residue is purified by FC (SiO2 
Hex/DCM 30:70) giving 100 mg of a white powder (yield = 72%). 1H-NMR (400 MHz, CDCl3) δ: 8.03 (d, 2H, J 
= 7.1 Hz); 7.56 (t, 1H, J = 7.4 Hz); 7.44 (t, 1H, J = 7.8 Hz); 6.77 (s, 1H); 5.42 (bd, 1H, J = 4.8 Hz); 4.88 (m, 1H); 
4.21 (q, 1H, 9.3 Hz); 2.98 (d, 1H, J = 7.7 Hz); 2.48 (m, 2H); 2.18 (q, 1H, J = 9.3 Hz); 2.09-1.92 (m, 6H); 1.81-1.35 
(m, 9H); 1.26-1.15 (m, 3H); 1.09-1.040 (m, 4H); 0.84 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ: 166.7; 139.8; 133.2; 
130.4; 129.7; 128.4; (128.0; 127.3; 125.1; 124.4; 122.3; 121.5; 119.2; 118.4; (CF3)2); 122.6; (77.1; 76.8; 76.5; 76.2 
(COH(CF3)2); 56.9; 56.1; 50.0; 42.6; 39.9; 38.2; 37.2; 36.8; 33.7; 31.9; 31.7; 28.3; 27.8; 25.4; 24.5; 21.0; 19.5; 12.6. 
ESI-MS Calc. for C31H38F6O4: 587.3, Found: 587.2 [M-H-]. 
 
(R)-4,4,4-trifluoro-1-((3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-3-
(trifluoromethyl)butane-1,3-diol 53 (UPR1357): 
Compound 52 (100 mg, 0.2 mmol) is dissolved in a MeOH/THF 2:1 mixture before Na (5 mg, 0.2 mmol) is 
added and the reaction stirred for 1 hour. After neutralization with a 1M HCl solution, the mixture is diluted 
with EtOAc and the organic phase is washed with brine (5 ml) dried over Na2SO4 and the solvent is 
evaporated under reduced pressure affording a white solid (95 mg). The residue is purified by FC (SiO2 
Hex/EtOAc 70:30) giving 76 mg of a white powder (yield = 93%). 1H-NMR (600 MHz, MeOD) δ: 5.34 (bd, 
1H, J = 2.8 Hz); 4.06 (t, 1H, J = 10.3 Hz); 3.39 (heptuplet, 1H, J = 4.9 Hz); 2.21 (m, 2H); 2.10 (dt, 1H, J = 3.5, 
12.8); 2.02-1.92 (m, 3H); 1.85 (dt, 1H, J = 3.54, 13.4); 1.78 (m, 1H); 1.69 (m, 2H); 1.57-1.45 (m, 6H); 1.29-1.14 (m, 
4H); 1.09-1.02 (m, 4H); 0.96 (td, 1H, J = 5.2, 6.2); 0.81 (s, 3H). 13C NMR (100 MHz, MeOD) δ: 141.0; (128.2; 
127.5; 125.4; 124.6; 122.5; 121.8; 119.7; 119.0; (CF3)2); 121.0; (76.9; 76.8; 76.4 (COH(CF3)2); 71.1; 70.9; 56.7; 56.3; 
50.5; 42.4; 41.7; 39.2; 37.3; 36.4; 33.5; 31.8; 31.7; 31.0; 25.1; 24.2; 20.7; 18.6; 11.2. ESI-MS Calc. for C24H34F6O3: 
483.2, Found: 483.3 [M-H-]. HPLC-UV purity: tR 6.6 min - 96%. 
 
(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((S)-4,4,4-trifluoro-1,3-dihydroxy-3-(trifluoromethyl)butyl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate 54: 
Compound 51 (90 mg, 0.2 mmol) is dissolved in THF before Na(OAc)3BH (190 mg, 0.9 mmol) is added at 0° 
C. Reaction is warmed to r.t. and stirred for 6 hours. A 1M HCl solution (5 ml) is added and stirring is 
continued for 15 min. Then reaction is diluted with a 2M NaOH solution and stirred for additional 2 hours. 
Organic phase, after addition of EtOAc (10 ml) is washed with brine (10 ml) dried over Na2SO4 and the 
solvent is evaporated under reduced pressure affording a white solid (120 mg). The residue is purified by FC 
(SiO2 Hex/EtOAc 80:20) and by means of Biotage (gradient t(0): Hex/EtOAc 98:2; t(20) Hex/EtOAc 80:20) 
giving 22 mg of a white powder (yield = 24%). 1H-NMR (300 MHz, CDCl3) δ: 8.03 (d, 2H, J = 7.2 Hz); 7.55 (t, 
1H, J = 7.4 Hz);  7.43 (t, 1H, J = 7.7 Hz); 6.42 (bs, 1H); 5.42 (bd, 1H, J = 4.4 Hz); 4.85 (m, 1H); 4.21 (t, 1H, 9.6 
Hz); 2.47 (d, 2H, J = 7.8 Hz); 2.23 (d, 1H, J = 15.2 Hz); 2.04-1.43 (m, 13H); 1.35-1.07 (m, 8H); 0.85 (m, 1H); 0.72 
(s, 3H). ESI-MS Calc. for C31H38F6O4: 587.3, Found: 587.2 [M-H-]. 
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(S)-4,4,4-trifluoro-1-((3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-3-
(trifluoromethyl)butane-1,3-diol 55 (UPR1358): 
Compound 54 (70 mg, 0.1 mmol) is dissolved in a MeOH/THF 2:1 mixture before Na (3 mg, 0.2 mmol) is 
added and the reaction stirred for 1 hour. After neutralization with a 1M HCl solution, the mixture is diluted 
with EtOAc and the organic phase is washed with brine (5 ml) dried over Na2SO4 and the solvent is 
evaporated under reduced pressure affording a white solid (66 mg). The residue is purified by FC (SiO2 
Hex/EtOAc 80:20) giving 55 mg of a white powder (yield = 96%). 1H-NMR (600 MHz, MeOD) δ: 5.35 (bd, 
1H, J = 5.5 Hz); 4.05 (t, 1H, J = 10.3 Hz); 3.39 (heptuplet, 1H, J = 4.6 Hz); 2.24-2.19 (m, 3H); 1.98 (m, 1H); 1.94-
1.86 (m, 2H); 1.80 (m, 2H); 1.72-1.43 (m, 8H); 1.28-1.04 (m, 5H); 1.02 (s, 3H); 0.96 (td, 1H, J = 11.4, 4.7); 0.72 (s, 
3H). 13C-NMR (100 MHz, MeOD) δ: 142.4; (129.6; 128.7; 126.8; 126.0; 124.0; 123.2; (CF3)2); 122.4; (76.9; 76.8; 
76.4 (COH(CF3)2); 72.6; 71.8; 59.1; 58.1; 51.7; 43.1; 42.8; 40.6; 38.6; 37.8; 35.0; 33.0; 32.9; 32.4; 31.0; 26.6; 25.0; 
22.1; 20.0; 12.9. ESI-MS Calc. for C24H34F6O3: 483.2, Found: 483.3 [M-H-]. HPLC-UV purity: tR 5.2 min - 98%. 
 
(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((R)-2-oxo-6,6-bis(trifluoromethyl)-1,3-dioxan-4-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate 56: 
Compound 52 (50 mg, 0.08 mmol) is dissolved in dry DCM (5ml) under nitrogen atmosphere before pyridine 
(70 µl, 0.8 mmol) is added. The mixture is cooled to -50°C and thiphosgene (25mg, 0.08 mmol) is added and 
stirred for 2h. Once warmed to r.t. the mixture is added of a satured aqueous solution of NH4Cl and a 1M 
HCl solution. The mixture is then diluted with EtOAc and the organic phase is washed with brine (5 ml) 
dried over Na2SO4 and the solvent is evaporated under reduced pressure affording a white solid (55 mg). 
The residue is purified by FC (SiO2 Hex/DCM 50:50) giving 40 mg of a white powder (yield = 77%). 1H-NMR 
(400 MHz, MeOD) δ: 8.03 (m, 2H); 7.54 (m, 1H);  7.42 (t, 1H, J = 7.7 Hz); 5.40 (bd, 1H, J = 3.9 Hz); 4.86 (m, 1H); 
4.44 (t, 1H, 10.9 Hz); 2.47-2.38 (m, 3H); 2.21 (m, 2H); 2.19 (m, 3H); 2.17-1.45 (m, 9H); 1.28-1.03 (m, 8H); 0.78 (s, 
3H). 
 
 (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((R)-2-oxo-6,6-bis(trifluoromethyl)-1,3-dioxan-4-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl benzoate 57: 
Compound 54 (70 mg, 0.1 mmol) is dissolved in dry DCM (5ml) under nitrogen atmosphere before pyridine 
(70 µl, 1.2 mmol) is added. The mixture is cooled to -50°C and thiphosgene (42mg, 0.1 mmol) is added and 
stirred for 2h. Once warmed to r.t. the mixture is added of a satured aqueous solution of NH4Cl and a 1M 
HCl solution. The mixture is then diluted with EtOAc and the organic phase is washed with brine (5 ml) 
dried over Na2SO4 and the solvent is evaporated under reduced pressure affording a white solid (65 mg). 
The residue is purified by FC (SiO2 Hex/EtOAc 95:5) giving 50 mg of a white powder (yield = 68%). 1H-NMR 
(400 MHz, MeOD) δ: 8.03 (m, 2H); 7.54 (m, 1H);  7.43 (t, 1H, J = 7.8 Hz); 5.42 (bd, 1H, J = 4.9 Hz); 4.86 (m, 1H); 
4.21 (t, 1H, 9.1 Hz); 2.54 (dd, 1H, J = 15.2, 2.0 Hz); 2.47 (m, 1H); 2.21 (dd, 1H, J = 12.2, 13.8 Hz); 2.10-1.99 (m, 
3H); 1.91 (dt, 1H, J = 3.44, 13.28); 1.82.-1.43 (m, 10H); 1.34-1.01 (m, 7H); 0.72 (s, 3H). 
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5.2.2 Pharmacology 
Collected biological data were from experimentations carried out by Prof. Presta’s research group (Department of 
Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Brescia, Italy). 
 
Viable cell counting. Cells were cultured under appropriate conditions for 48 hours in the presence of 
increasing doses of different compounds. Propidium iodide staining (Immunostep, Salamanca, SP, EU) was 
used to detect PI- viable cells by flow cytometry. Absolute cell counts were obtained by the counting function 
of the MACSQuant® Analyzer (Miltenyi Biotec).  
 
 
5.2.3 Computational studies 
Geometries. Geometries of compounds 53, 55-57 were optimized with OPLS2005 Force Field in combination 
with an implicit solvent model (water) using a convergence criteria for energy minimization of 0.05 Kcal 
mol-1 Å-1. 
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